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ABSTRACT
A number of conditions related to X-linked intellectual disabilities (XLID) are in
part due to microduplications that are not visible cytogenetically. With the focus on Rho,
Ras and Rab genes, a family of genes known to be associated with intellectual
disabilities, were screened for dosage aberrations (Leeuwen, F. N. 1997), (Ng, E. L.
2008), (Gissen, P. 2007), (Gurkan, C. 2005). Cohorts of intellectually disabled ID
individuals were explored with new technologies. These new technologies include
comparative genomic hybridization (CGH), multiplex ligation dependent probe
amplification (MLPA) and quantitative PCR (qPCR) (Madrigal, I. 2007), (Hermsen, M.
A. 2005), (Morey, J. S. 2006).
The first screening was of two groups of individuals, one group with hypotonia
and varying degrees of ID and the other of individuals with nonsyndromic ID and a
suspected X-linked etiology. These cohorts were screened using the Mental Retardation
on the X chromosome (MRX) kit, which focuses on genes that cause intellectual
disability and are located on the X chromosome. The second screening consisted of the
two former groups and 5 additional cohorts totaling 1152 patients, using a synthetic probe
kit that was designed to target primarily Ras, Rab and Rho X-linked genes that were not
covered by the MRX kit. The 5 additional cohorts were individuals that had normal
sequencing results for one of the following X-linked genes XNP, L1CAM, UBE3A,
FGD1, and STK9.
The MRX screening produced a GDI1 duplication, deletion in FACL4 and an
FMR2 missense mutation (c.474C>T). The synthetic MLPA screening found a partial
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XNP duplication (248kb), a 1p36 duplication/deletion complex rearrangement and a
greater than 3Mb 1p36 deletion. It has been concluded from this study that duplications
in these genes are rare, appearing in less than 1% in these chosen populations.
Another section of this project is the characterization of a 275kb Xq25 duplication
found during routine MLPA testing for MECP2. An Xq25 control peak on the MRC
Holland MECP2 MLPA revealed a duplication in a female that presented with a MECP2
phenotype (Chahrour, M. 2007). This duplication spanned four genes (AIF, ELF4,
BCORL1 and RAB33A) and of these four, two were over-expressed (AIF and RAB33A).
Using qPCR to look for the link that may cause the similar phenotype to Rett syndrome
in this patient, 26 Ras, Rab and Rho genes were tested in patients with Rett syndrome,
Fragile X syndrome, ID with unknown etiology and the Xq25 patient. A similar pattern
of expression was seen in this small cohort with ID. The CREB1 gene, the co-activator of
MECP2, part of the transcription factor complex for 21 of the 26 genes screened, plays a
role in all of these conditions and may be the linking factor in producing these patterns.
The over expression of the AIF gene seemed to play a role in the mis-regulation of many
genes, but with uncertainty on how it led to any affect on the phenotype.
In this study duplications that play a role in the causation of ID were found using
MLPA technology. As array CGH becomes more refined, with higher coverage and
better software, the finding of microduplications that cause ID will increase.
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CHAPTER ONE
INTRODUCTION
The focus of this study is to determine the frequency of X-linked duplications in
specific cohorts of individuals with intellectual disability (ID). The groups to be studied
will consist predominately of male and a small number of female patients that have
been subsequently subdivided based on other clinical features and exhibit varying
degrees of intellectual disability. One group will consist of males with intellectual
disabilities that appear to be X-linked due to family history. The study will focus but
not be restricted to the X chromosome. A synthetic multiplex ligation-dependent probe
amplification (MLPA) probe set will also be used to analyze several groups of patients
that exhibit a classical phenotype for an X-linked clinical disorder, but are normal
based on sequence-based testing.
A genetic screen of multiple patient cohorts will determine the frequency of
duplications that are disease causing and have been missed by other diagnostic
methods. MLPA technology, a relatively new testing method for gene dosage will be
used to determine if there are mechanisms other than missense and nonsense mutations
causing these conditions. MLPA can target specific regions simultaneously for dosage
aberrations (Schouten, J. P. 2002). MLPA has been used to reveal the genetic causation
of specific cancers, syndromal and nonsyndromal disease, X-linked and otherwise. The
primary screening method used in this study is two MLPA probe sets:
•

MRX MLPA Kit from MRC Holland (Commercially available)
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•

A custom synthetic MLPA kit developed as a part of this project to target Xlinked and autosomal genes of interest.
The first screening was of two groups of individuals, one group with hypotonia and
varying degrees of ID and the other of individuals with nonsyndromic ID and suspected
X-linked etiology. In the hypotonia and X-linked cohorts, which totaled 300 patients,
the MRX MLPA found three patients that warranted further study. The genes that
appeared to be affected were, GDI1 and PQBP1 duplication in one patient, a FACL4
deletion in one patient and an unusual drop in signal in FMR2 in another.
A second screening used the synthetic MLPA probe set included the two former
groups and 5 additional cohorts totaling 1152 patients. The 5 additional cohorts were
individuals that had normal sequencing results for one of the X-linked genes XNP,
L1CAM, UBE3A, FGD1, and STK9. From these screening six individuals warranted
further study. The regions or genes that appeared to be affected are, XNP duplication in
one patient, L1CAM and NEMO duplication in one patient and four individuals with
1p36 deletions and/or duplications.
Further investigation by quantitative polymerase chain reaction (qPCR) of the three
MRX individuals led to the confirmation of the GDI1 duplication, but not the PQBP1
duplication. In later experimentation the PQBP1 probes proved to be unreliable and
these MRX MLPA results were taken as a false positive. The FACL4 deletion was
confirmed and this data was used to help in determining the region of the breakpoint by
sequencing.
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The FMR2 unusually low result was caused by a point mutation (c.474C>T) within
the MLPA probe hybridization region. Further investigation found the mother and
maternal grandmother to be carriers of this change. A group of normal controls were
screened for this mutation and it appears not to be in the normal population.
This screening with the synthetic MLPA probe set was performed one cohort at
a time. The screening of the hypotonia cohort identified a partial XNP duplication. The
clinical phenotype of the proband was clearly consistent with ATRX but with sequence
testing was found to be normal. The obligate carrier females had 100% skewed X
inactivation, which is also consistent with the diagnosis of ATRX. The duplication end
point regions were determined using qPCR and this XNP duplication is 244kb and
spans from exon 2 through exon 31. Northern blot analysis demonstrated that no fulllength transcript existed, suggesting the duplication disrupted normal transcription of
the gene and the cause of disease was the loss of gene product. During qPCR primer
development and using NCBI BLAST function to validate the specificity of the
primers, there appears to be multiple Alu sequences in these regions, giving nonhomologous recombination as the probable cause of the duplication event. (Woodward,
K. J. 2005), (Van Esch, H. 2005), (Bailey, J. A. 2003), (Vissers, L. E. 2003), (Lin, Y.
1999), (Lundin, C. 2002).
The L1CAM/NEMO duplication was found to span from NEMO to SLC6A8.
This region includes the MECP2 gene and there were ongoing studies at the
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Greenwood Genetic Center of MECP2 duplications in males. This sample was
transferred to these studies for further evaluation.
Four individuals had results consistent with 1p36 duplication and/or deletion. Of
these four, two were regarded as false positives with further investigation. The two
remaining individuals, one with a 1p36 duplication/deletion complex rearrangement
(56560) and one with a 1p36 deletion (60175) confirmed multiple times on many
different testing platforms. The phenotypes in both of these individual were similar to
X-linked conditions and this explains why they were included in these cohorts.
The second part of this study is of a female with an Xq25 duplication, born to
normal parents, that has a similar phenotype routinely seen in females with Rett
syndrome and MECP2 loss of function mutation (Jordan, C. 2007), (LaSalle, J. M.
2007), (Nikitina, T. 2007). The Xq25 duplication spans 255kb and encompasses four
known genes and three unknown genes. Characterization of this novel duplication and
exploration of some of the possible mechanisms causing this abnormal phenotype was
accomplished. Duplications may increase or disrupt gene expression depending on the
nature and span of the change (Mazzarella, R. 1998) Duplications that span over areas
that include more than one gene may cause over- expression of those genes (Van Esch,
H. 2005). By using real time PCR, expression levels of the genes that are duplicated
were determined. The four known genes, BCORL1, ELF4, AIF and RAB33A were all
tested and the results demonstrated that only two of the genes (AIF and RAB33A)
displayed over-expression. The main question asked is what similarities are there
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between a loss of MECP2 and over-expression of AIF and RAB33A and how is it
possible they cause a similar phenotype.

5

CHAPTER TWO
BACKGROUND
Intellectual disability (ID) affects 2-3% of the population. ID is a developmental
disability that exhibits global deficiency in cognitive abilities and is the impairment of
learning, and processing of complex information (Levitt, P. 2004), (Johnston, M.V.
2003). Intellectual disabilities are considered to be syndromic when associated with
other congenital abnormalities, such as body and brain malformations that include
neurological, neuroendocrine, psychiatric symptoms and metabolic defects. Intellectual
disability can also stand-alone and not be associated with other functional or anatomical
abnormalities, which is considered nonsyndromal ID (Ramakers, G. J. 2002). Severe
intellectual disabilities may be associated with brain malformations, such as,
microcephaly, lissencephaly, and a deficiency in neuronal development and migration.
There is an association of ID with abnormal dentritic spine morphology in the
pyramidal neurons in the cerebral cortex and hippocampus of patients with Trisomy 21,
Rett and fragile X syndromes, which appears, in part, to be due to abnormal
development of neuronal connectivity (Ramakers, G. J. 200).
Families of developmental genes regulating neuronal growth, which are
associated with actin polymerization, affect the neuronal growth cone, a specialized
structure at the distal end of a developing neurite. Constant extension and retraction of
filopodia and lamellipodia guide the extending neurite toward its target in a developing
nervous system. The growth cone receives a variety of signals from molecules on the
surface of other cells, the extracellular matrix and diffusible chemoattractants and
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chemorepellants. These environmental cues direct the developing neurite to extend in
the correct direction by the reorganization of the internal actin cytoskeleton (Kozma, R.
1997). Using the mouse model, the most studied genes that are regulators of actin are
RhoA, Rac1 and Cdc42. These genes play a large part in mammalian neuronal
development and ID. Overall, Rho proteins are highly conserved regulators of the actin
cytoskeleton, cell adhesion and migration, cytokinesis and gene expression. In human,
three X-linked genes that participate directly in cellular signaling through Rho GTPases
are oligophrenin 1 (OPHIN1), PAK3, and αPIX (ARHGEF6). Oligophrenin acts as a
Rho-GAP (GTPase-activating protein) and stimulates the GTPase activity of RHOA,
RAC1 and CDC42. PAK3 is a serine/threonine protein kinase that mediates effects of
downstream RAC1 and CDC42 on the actin cytoskeleton and gene expression. αPIX
are a guanine nucleotide exchange factor for RAC1 and CDC42. It is noted that Rholinked nonspecific X-linked intellectual disability (XLID) proteins interact with Rho
GTPases at different locations in the regulatory pathway. Other Rho genes associated
with nonsyndromic ID are FMR2, GDI1, IL1RAPL, TM4SF2 (Ramakers, G. J. 2002).
Rho proteins play a part in the formation of dendrites, and abnormalities in
these structures will impair information processing at the cellular and processing
network level. Dendrite spine and function are closely linked with observed
abnormalities in shape and abundance. Observed abnormalities are likely to impair
synaptic transmission and plasticity. RHO and RAC1 maintain a strict balance as
antagonistic regulators in the formation of neurite outgrowth. The activation of RHO
reduces neurite formation, growth cone motility and dendrite branching. The activation
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of RAC1 induces the density and length of spine necks and neurite formation. The
dendrite spine morphology in the cerebral cortex of the normal human infant exhibits
many short, thick spines, while the ID dendrite morphology exhibit long thin spines
with a mushroom cap. These long, capped spines disappear as the child matures and the
denrite has a smooth appearance (Ramakers, G. J. 2002), (Leeuwen, F. N. 1997).
Another pathway known to be associated with ID is the mitogen activated
protein kinase (MAPK) signaling cascade. The downstream activation of the MAPK
cascade stimulates phosphorylation of the transcription factor CREB and may also
stimulate CREB-Binding protein (CBP), which has histone acetyltransferase activity
that can lead to weakening of the DNA/histone interaction. This results in an open
chromatin structure that promotes transcription. CREB and MECP2 are known to be coactivators and combined they activate a large number of genes that appear to be
involved with ID (Chahrour, M. 2008). The Ribosomal S6 Kinase-2 (RSK2) gene is
associated with Coffin-Lowry syndrome in humans and is a protein kinase that
activates CREB through phosphorylation. RSK2 is activated by phosphorylation by
several membrane receptor-coupled signaling cascades, adenylate cyclase, Ras-MAPK,
Protein Kinase C (PKC) and Ca2+/Calmodulin-dependent protein Kinase II (CaMKii)
pathways. MAPKs cause cognitive disorders with defects in the signaling pathways
that facilitate Rab function including Ras effectors that serve as guanine nucleotide
exchange factors (GEF’s) and activators of Ras family proteins, in the following
diseases; Coffin-Lowry syndrome, Rubinstein-Taybi syndrome, Neurofibromatosis 1,
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Tuberous sclerosis 2, X-linked α thalassemia, and Faciogenital dysplasia (Johnston,
M.V. 2003), (Mitin, N. 2005).
This research takes a closer look into the dosage of genes involved in regulating
actin cytoskeleton, a representative number of the Rab, Ras and Rho genes and their
counterparts that traffic proteins in a tightly linked fashion, and a known group of genes
that are implicated in causing intellectual disability. There are Rab, Ras and Rho genes
expressed primarily in the brain and may be candidate genes associated with ID.
We are primarily focusing on Rab genes. It is important to focus on these genes
because, Rab proteins comprise the largest group within the Ras superfamily. There are
over 60 Rab proteins identified in humans. Individual Rab subtypes characteristically
associate with specific membrane compartments (Gurkan, C. 2005). Ras proteins on the
other hand function as signaling hubs that are activated by convergent signaling
pathways. Activated Ras regulates a diversity of downstream cytoplasmic signaling
cascades. Recent observations have established a complex signaling interplay between
Ras and other members of the family (Mitin, N. 2005).
Understanding the regulation and organization of the exocytic and endocytic
membrane trafficking pathways is a large undertaking. There are housekeeping Rabs,
specialized Rabs and tissue-specific Rabs. In this study we have an Xq25 duplication
that has been shown to cause over-expression of the RAB33A gene.

Twenty-six

specific genes that interact with RAB33A will have their background discussed within
the Xq25 section. The RAB33A protein is thought to facilitate endosome to Golgi
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transport. Interestingly, expression profiles show the RAB33A gene has prominent
expression in the brain and co-regulates other Rab genes (Zheng, J.Y. 1998),
(Stenmark, H. 2001). Rabs have close interactions, play a role in each other’s inhibition
and activation, and are found to cluster. One such Cluster contains RAB3A, RAB26,
RAB33A and RAB40B, which sometimes are joined by RAB4B and RAB11B. This
cluster is up-regulated in the brain tissue and co-cluster with the RAB3A-regulated hub.
RAB3A is one of the most notable and best characterized of the specialized Rabs, which
is active in the regulated secretory pathway in the neuron. RAB3A has been extensively
studied in the neurotransmitter release given its high abundance in the brain and
presence in synaptic vesicles. RAB3A is believed to play an important role in tethering
and docking of synaptic vesicles in preparation for fusion. Rabs can also be regulators.
Up-regulation of RAB40B is confined to brain tissue with an expression profile almost
identical to RAB3A. It is possible that RAB40B may be found to be a Rab-regulated hub
modulating a linked step in the RAB3A-dependent synaptic vesicle cycle in the brain.
RAB33A in brain tissue may direct an unanticipated strong link between
RAB3A/RAB40B/RAB26 function and endosome-Golgi recycling pathways (Gurkan, C.
2005). RAB3A co-clusters with the RAB3A-interacting proteins calmodulin, GDI1,
RIM2, RIM3, Rabphiolin-3A and synapsin. Rabs can also be effectors and can interact
with multiple other effectors to regulate the spatiotemporal function of organelles in
membrane traffic. These Rabs direct vesicle tethering, docking, and fusion and can
direct dynein motors that move along the cytoskeleton. The main point to be taken, Rab
gene family members do not function alone, cluster members appear to co-regulate one
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another and there are still many undiscovered Rab pathways responsible for
development and coordination of brain activity (Gurkan, C. 2005), (Grosshans, B. L.
2006), (Sexton, T. 2007).
The exploration of gene dosage will consist of Rab, Ras and Rho genes and
their counterparts and how this dosage affects expression levels of other Rab and Ras
proteins in a tightly linked fashion (Mitin, N. 2005). First a group of known genes that
are implicated in the cause of intellectual disability will be tested using MLPA.
Secondly a group of genes not yet proven to be linked with ID will have expression
levels charted using qPCR in the Xq25 duplication patient with over-expression of
RAB33A and a small cohort of normal and affected individuals.
Duplications in other X-linked and autosomal genes are known to cause disease.
Some clinically significant duplications are mentioned in the following:
X-Linked
•

Mutations in MECP2 (methyl-CpG binding protein 2) gene causes Rett
syndrome, a severe neurological disorder usually thought to affect exclusively
females. Its prevalence is about 1 in 10,000 female births, and it is a prominent
cause of profound ID in females. These mutations were initially thought to be
lethal in males. However MECP2 mutations are now frequently identified in
mentally retarded male patients (Villard, L. 2007). Duplication of MECP2
causes over-expression in males. These males have severe mental retardation,
hypotonia, recurrent respiratory infections, and absence of speech development,
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seizures, and spasticity (Friez, M. J. 2006). In humans, not only impaired or
abolished gene function, but also increased MECP2 dosage causes a distinct
phenotype (Van Esch, H. 2005).
•

The X-linked PLP1 gene has been found to cause Pelizaeus-Merzbacher disease
(PMD). This gene is located at Xq22 and duplications have been found in 70%
of clinically diagnosed patients. Some of the patients exhibit more than three
copies, but copy number does not seem to play a role in the severity of the
disease (Wolf, N. I. 2005). PMD is a rare X-linked disorder affecting
myelination of the central nervous system. The PLP1 gene is dosage sensitive
and duplications and missense mutations both contribute to defective proteolipid
protein (PLP) dosage (Takanashi, J. 1999), (Woodward, K. J. 2005), (Wolf, N.
I. 2005), (Mazzarella, R. 1998).
Autosomal

•

3-6

MB

microduplications

at

chromosome

22q11.2

are

caused

by

misalignments of low copy repeats. Deletions in this area have been known to
cause DiGeorge/velocardiofacial syndrome (Levitt, P. 2004). DiGeorge
syndrome is characterized by neonatal hypocalcemia, which may present as
tetany or seizures, due to hypoplasia of the parathyroid glands, and
susceptibility to infection due to a deficit of T cells. A variety of cardiac
malformations are seen in particular affecting the outflow tract (Jawad, A. F.
2001), (Edelmann, L. 1999), (Moerman, P. 1980). Duplication in the same 3MB
region was described a 4-year-old girl. She presented with failure to thrive,

12

marked hypotonia, sleep apnea, and seizure-like episodes in infancy, later
showed delay of gross motor development with poor fine motor skills,
velopharyngeal insufficiency, and a significant delay in language skills. Her
facial features were mildly dysmorphic, with a narrow face and down-slanting
palpebral fissures. Hearing and vision were normal, and there were no
detectable cardiac abnormalities. FISH analysis identified a partial interstitial
duplication of chromosome 22q11. Duplication produces Cat Eye Syndrome in
the same 3-Mb region that is deleted in DiGeorge syndrome (Edelmann, L.
1999).
•

Charcot-Marie-Tooth disease type 1A (CMT1A) gene is located at 17p11.2-p12.
CMT1A disease is a hereditary neuropathy associated with duplications of the
1.5-Mb region on 17p11.2-p12. Deletions in this region cause Hereditary
Neuropathy with liability to pressure palsies (HNPP). These two rearrangements
are the reciprocal products of an unequal meiotic crossover between the two
chromosome 17 homologues, caused by the misalignment of the CMT1A repeat
sequences (CMT1A-REPs), the homologous sequences flanking the 1.5-Mb
CMT1A/HNPP monomer unit (Matise, T. C. 1994),

(Schiavon, F. 1994),

(Lopes, J. 1996).
•

Duplication in 16p13.11p13.3 causes a phenotype resembling that of X-linked α
thalassemia/mental retardation syndrome. The same clinical features including
severe ID, characteristic facies and behavior are exhibited. It is proposed that
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the HBA gene in this region may be a target of XNP (ATRX) gene regulation
(Akahoshi, K. 2005).
•

Duplication and triplication of APBA2 gene, located at 15q11-q13, is caused by
high homology that facilitates mispairing and unequal recombination events in
meiosis. Interstitial deletion of 15q11-q13 results in Prader Willi syndrome
when the deletion is paternally derived or Angelman syndrome when the
deletion is maternally derived. The interstitial duplication of the same region
has been found in cases of autism, and the data suggests a higher risk with
maternal compared to paternal duplications. Larger duplications are typically
associated with a more severe autistic phenotype as multiple genes may be
duplicated. APBA2 has also been called Mint2 for Munc-interacting protein 2,
which functions as a neuronal adapter protein and essential for synaptic vesicle
exocytosis (Sutcliffe, J. S. 2003).

A study where 5,380 patients were screened for dosage aberrations, with the most
common reasons for referral were; developmental delay (DD), and/or ID,
dysmorphic features (DF), multiple congenital anomalies (MCA), seizure disorders
(SD), and autistic, or other behavioral abnormalities. There were pathogenic
rearrangements found at subtelomeric regions in 236 patients (4.4%). Among these
patients, 103 had a deletion, 58 had a duplication, 44 had an unbalanced
translocation, and 31 had a complex rearrangement (Shao, L. 2008). With array
technology both oligonucleotide-based and bacterial artificial chromosome (BAC)based arrays, the finding of micro duplications and deletions is routine. One study
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identified 10 unique deletions and duplications ranging in size from 280 kb to 8.3
Mb. Analysis of parental DNA samples indicated that most of the imbalances had
occurred de novo. Moreover, seven of the 10 imbalances represented novel
disorders, adding to an increasing number of conditions caused by large-scale
deletions or duplications (Aradhya, S. 2007).
To discuss all the newly found duplications in the literature is beyond the scope
of this study. The duplications, deletions and mutations in this study will have the
appropriate background included in the relevant result sections.
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CHAPTER THREE
COLLABORATION
Experimentation regarding expression and functional studies were done under
the guidance of Karl J. Franek, Ph.D. staff scientist at the Center for Molecular Studies
in the J.C. Self Research Institute at the Greenwood Genetic Center. The proper
equipment is available to perform the needed procedures.
The first gene we explored was XNP. Using antibodies that target the Nterminus of the protein, were found available from Santa Cruz Biotechnology. Dr.
Franek has recommended that preliminary work consist of sequencing the cDNA from
the family with the identified XNP duplication. Due to the duplication being only
partial, a truncated transcript as well as a full transcript may be present. It needs to be
determined if there is more than one form of the transcript as this may give insight to
the cause of disease.
Collaboration with the lab of Dr. Barbara DuPont, Director of the cytogenetic
lab at the Greenwood Genetic Center concerning Fluorescent In Situ Hybridization
(FISH) studies will be under the direction of her staff. Array-CGH data will also be
confirmed using FISH as necessary.
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CHAPTER FOUR
RESEARCH DESIGN AND METHODS
Importance of Study
Duplications have been under diagnosed in the past due to limitations in
diagnostic methods. It is believed that a number of conditions related to X-linked
Intellectual Disabilities (XLID) are, in part, due to microduplications that are not
visible cytogenetically. With new technologies, such as: Multiplex Ligation-dependent
Probe Amplification (MLPA), comparative genomic hybridization (CGH) and
quantitative polymerase chain reaction (qPCR) duplications of varying sizes are now
more readily identified.
Duplications may or may not exhibit the same phenotype that might be
expected when the affected gene is distorted with mutations and other pathogenic
rearrangements. The MECP2 gene located at Xq28 is associated with Rett syndrome in
females, which is characterized in females by a period of normal development for the
first 6 to 18 months followed by progressive deterioration and degenerative mental
retardation. Duplications have now been found in males with syndromic mental
retardation. Previously, Rett syndrome was thought to be an X-dominant condition that
is typically lethal in hemizygous males (Van Esch, H. 2005), (Moog, U. 2005). Males
with duplications are quite different than the female Rett counterparts. They present
clinically with psychomotor and developmental delay very early in life. As patients
mature other common symptoms include: spasticity, predominantly of the lower limbs,
seizures as well as axial and facial hypotonia. Additionally, males often suffer from
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recurrent respiratory infections, which in many cases are severe enough to cause early
death. MECP2 duplications in males present a different phenotype than the typical
phenotype seen in females with missense and nonsense mutations and small deletions
that are associated with Rett syndrome (Van Esch, H. 2005). In the PLP gene, which
causes Pelizaeus-Merzbacher’s disease (PMD), duplications appear to be associated
with a specific sub phenotype called connatal PMD. This is due to over-expression of
the PLP gene, whereas, missense mutations are associated with classic PMD. Connatal
PMD causes progressive myelination while classical PMD is the lack of myelination in
the cerebral corticospinal tract (Takanashi, J. 1999). Unlike the PLP gene, XNP
duplication does not appear to have two different clinical presentations. To date there
is only one report consisting of two cases, and both were found to have partial
duplication of XNP. These partial duplications, unlike full duplications that cause twofold higher expression, disrupt gene transcription, causing a loss of gene product,
therefore, causing a classical ATRX phenotype (Thienpont, B. 2007). Depending on the
role duplication plays in the expression of a specific gene determines the nature of the
potential clinical manifestations. Therefore, this leads us to believe that we may find
duplications in other XLID genes. The phenotypes may be similar or vary from what is
seen with missense or nonsense mutations in that gene.
Probands that have presumed XLID and have normal sequencing results for
genes associated with specific clinical features of a known XLID entity are of particular
interest in this study. These affected individuals are good candidates for an X-linked
duplication that is small and not visible by routine cytogenetic analysis that may disrupt
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gene transcription. Probands with suspected X-linked etiology and non-specific clinical
findings might have larger duplications encompassing one or more genes. Contiguous
gene duplications may lead to phenotypes involving ID due to an over-expression of
one or more gene product.
Duplications have been the mechanism for large genomic changes through time.
Beginning with chromosomal evolution, it is thought to have occurred in a random
process of breakage and rearrangement. However, there appears to be an abundance of
primate specific segmental duplications at the breakpoints of syntenic blocks in the
human genome. Breakpoint regions are defined as the gaps between syntenic blocks.
Conservatively, 25% of all breakpoints contain 10 KB of duplicated sequence. This
association is highly significant (p< .0001), and supports the non-random model of
chromosomal evolution. These results indicate that segmental duplications are
associated with syntenic rearrangements. Segmental duplications are comprised of
genes or gene segments as well as common transposable elements. This implies specific
regions having been predisposed to both recurrent small-scale duplications and largescale evolutionary rearrangements within specific “fragile” regions of the mammalian
genome (Bailey, J. A. 2004).
The mechanisms that may play a role in the formation of duplications are; repair of
DNA damage (Bailey, J. A. 2003), (Read, L. R. 2004), homologous recombination
(Lin, Y. 1999), (Lundin, C. 2002), non-homologous recombination (Lundin, C. 2002),
transposition, Alu and Line mediated recombination (Bailey, J. A. 2003), low copy
repeats causing slippage, DNA cleavage, gross chromosomal rearrangement, repair and
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Topoisomerase 1 sites (Dai, Y. 2003). One study of 9,464 junctions within regions of
high quality finished sequence from a genome-wide set of 2,366 duplication alignments
observed 1Mb of Alu intervening sequence between segmental duplications.

Alu

retroposition activity initiated Alu-Alu mediated recombination events which caused
the expansion of gene rich segmental duplications 35-40 million years ago now have a
role in nonallelic homologous recombination. Alu is a primate-specific 300bp
retroposon and is the most abundant human repeat. Alu mediated rearrangement events
have long been recognized as a common source of local deletion and duplication events
associated with human disease (Bailey, J. A. 2003). Understanding the role of
segmental duplication in normal variation has just begun. Using a bacterial artificial
chromosome (BAC) microarray, consisting of 2,194 BACs assessing copy number
variation (CNV), identified genes or other relatively rare sequences that are duplicated,
either in tandem or at nearby locations. There were 199 regions of copy number
polymorphisms (CNP) identified in screening 47 normal individuals. Some clone
duplication signals overlapped, suggesting some copy number variations extend over
several hundred kilobases (Mazzarella, R. 1998). Some of the CNPs were in gene
clusters, such as the previously reported β-defensin at 8p21.1 (Hollox, E. J. 2003) and
the IGVH/SLC6A8/CDM pseudogene cluster at 15p11.2 (Barber, J. C. 1998), (Sharp,
A. J. 2005), (Bailey, J. A. 2004). CNPs were identified in 51 of the 130 rearrangement
hotspots that encompassed 108 genes and partially overlapped another 33 coding
regions. Of the 130 rearrangement hotspots there were no CNPs detected in 79 of them
in the normal population. This suggests these remaining hotspots may be associated
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with genomic disorders

(Sharp, A. J. 2005). There are known regions on the X

chromosome that have duplications that are clinically significant. Some of these are,
Xp22.3 causing ichthyosis (Weaving, L. S. 2004) the dosage sensitive sex reversal
candidate region in Xp21.3 (Portnoi, M. F. 2000), the Pelizaeus-Merzbacher region in
Xq22 (Wolf, N. I. 2005), (Takanashi, J. 1999), MECP2 in males at Xq28 (Friez, M. J.
2006), (Bauters, M. 2008), regions in the Xq24-q26 region in females causing
developmental delay and ID (Armstrong, L. 2003), the lymphoproliferative syndrome
in Xq23 (Garcia-Heras, J. 1997) and XNP at Xq13 (Thienpont, B. 2007).
Duplications have been a known evolutionary occurrence and source of normal
variation documented in the human genome. We now have a better appreciation that
duplications of various size cause disease by several mechanisms. By screening a
targeted set of cohorts we intend to determine the degree of ID that may be caused by
duplications in select X-linked genes. These genes are known to cause ID by other
mutational events, but have not had dosage aberrations identified as a recurrent cause of
disease. First, we intend to address if they exist, and if so, to work towards explaining
how they function in context to the diagnosis in those affected by the duplications.
Purpose of Study
The focus of this study is to determine the frequency of duplications, in
different X-linked genes involved with its ID-related conditions, which in some way
affect the normal function of a given gene and associated pathways. How duplications
disrupt normal gene function may be different in each case. Fluorescent in situ
hybridization (FISH) results are pending. This methodology can help in the
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determination of the duplicated gene location and orientation, such as, if the gene is
duplicated in tandem or on another chromosome, partially duplicated or part of a gross
chromosomal rearrangement. Genes known to be involved with XLID will be targeted
using MLPA, a new technology that is highly specific and capable of determining copy
number. This research examines gene dosage aberrations and then will determine if the
duplication is the cause of disease. To feel confident that the duplication is disease
causing the following must be addressed.
1

Clarify the expression level of the duplicated genes.

2

Determine if full length mRNA is fully transcribed.

3.

Determine if the mRNA is functional and translated.

4

Does the overexpression of one gene affect the expression of other genes?
Explanation of Research Design

The MRC Holland MLPA kit includes probes for 13 XLID genes. They include:
RSP6KA, ARX, IL1RAPL1, TM4SF2, PQBP1, OPHIN, FACL4, DCX, PAK3, AGTR2,
FMR2, SLC6A8 and GDI1. The commercial kit provides a starting point, but to look at
other genes of interest (Rho, Rab, Ras and MAPK genes) not included in this
commercial kit, led to the development of a custom synthetic MLPA probe set. The
synthetic probe set targeted X-linked genes (XNP, STK9, FGD1, NEMO, and L1CAM)
with SKI and UBE3A serving as autosomal controls and SRY as a sex marker gene. By
combining the data from both MLPA probe sets; multiple XLID genes are
simultaneously tested for duplications and deletions. This study will determine the
frequency of duplications in these genes in the XLID population.
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RSP6KA
ARX, STK9, IL1RAPL1

Autosomal Controls
• SKI located at 1p36
• UBE3A located at 15q11-q13

TM4SF2
PQBP1
FGD1
OPHN
XNP

Sex Marker
• SRY located on Y chromosome

FACL4

Figure 1. X chromosome gene
coverage.

DCX, PAK3
AGTR2

FMR2, GDI1, LICAM, NEMO

Genes in blue are offered on the
MRC Holland MRX MLPA.
Genes in red are located on the
synthetic MLPA probe set.

SLC6A8

Two cohorts were studied using the MRC Holland MRX MLPA kit and they
consisted of 95 males exhibiting hypotonia and varying degrees of intellectual disability
(ID) and a second cohort of 205 (194 males and 11 females) individuals with
nonsyndromic ID and suspected X-linked etiology.

The hypotonia and X-linked

cohorts totaling 300 patients, plus five additional cohorts totaling 552 patients with
normal sequencing results for one of the X-linked genes (XNP, L1CAM, UBE3A, FGD1
and STK9) were included in the synthetic MLPA study (Table 1).
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Table 1. Number of patients screened by test and cohort.
COHORT
Hypotonia
Suspected X-linked
XNP-sequence normal
L1CAM-sequence normal
UBE3A-sequence normal
FGD1-sequence normal
STK9-sequence normal

MRX
95
205

SYNTHETIC
95
205
29
177
130
182
34

Duplications in other XLID genes may cause syndromic ID with different
phenotypes other than what is considered the classic phenotype for abnormalities in that
gene. It now appears clearly evident that duplications and increased dosage of the
MECP2 gene product cause a distinct phenotype from Rett syndrome, which is
typically caused by point mutations and small deletions in MECP2. Loss of function
versus over-expression in any neurologically significant gene may cause profound ID
with phenotypes truly unique from one another (Van Esch, H. 2005). Xq28 duplications
involving MECP2 usually include at least several of the flanking genes and typically
range in size from 400 Kb to 800 Kb. Carrier females with MECP2 duplications are
nearly always asymptomatic and have highly skewed X inactivation. The two fold
increased dosage of MECP2 mRNA has been demonstrated using qPCR and is believed
to be the key genetic cause for the features seen in these males. L1CAM, SLC6A8 and
GDI1 are also commonly found duplicated along with MECP2, and are known to be
involved with ID and may contribute to some extent to the phenotype (Van Esch, H.
2005), (Wong, E. V. 1995).
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MLPA
The detection of duplications using MLPA opened a new means of screening
patients for dosage dependent mutations. To date, 232 different MLPA tests are
commercially available. MLPAs were first designed for the detection of deletions and
duplications in BRCA1, MSH2 and MLH1 genes. This was followed by applications
designed for the detection of trisomies and chromosomal aberrations in cell lines and
tumor samples as well as SNP/mutation detection (Schouten, J. P. 2002). An MLPA
(Figure 2A-C) consists of a group of probes each made a different length. Each probe
consists of two oligonucleotides, one left and one right with a ligation site designed to
join the two sub-probes. The probe hybridizes with genomic DNA and when each
probe half is in place ligation can occur.
Figure 2. MLPA Probe Design

A

B

C

Figure 2A. Hybridization of probe to DNA.
Figure 2B. Ligation of MLPA probes.
Figure 2C. Amplification of probe by universal primer pair. The
amplification product of each probe has a unique length (92- 480 bp).
(MRC Holland 2002)
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Figure 3.
MLPA of the BRCA1 gene.

3A

3B

Figure 3A. Normal BRCA1 MLPA. Each peak is the amplification product of
a specific probe.
Figure 3B. Difference in relative peak area indicates a copy number
change in the target sequence. Sample peak areas are normalized and
compared to the average of normalized control samples peak areas. In the
electropherogram 3B, exon 13 of BRCA1 has a lower height than the normal
sample 3A above, indicating a drop in gene dosage.

All the probes have identical M13 end sequences allowing concerted
amplification with one primer pair. Each probe is designed to produce an amplicon 46bp different than its neighbor, and is a part of a range of probes spanning from 90-480
bp. The ligated probe is the template for PCR amplification; therefore, the amount of
initial intact probe dictates the amount of end PCR product. The 3’ M13 primer is FAM
labeled and fragment analysis is accomplished using capillary electrophoresis. The
quantity of PCR product influences the peak height and area when electrophoresed and
analyzed on a fragment analysis program. Comparing the peak height and area of each
sample in an Excel spreadsheet is done by first normalizing all the samples, patients
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and controls. The samples are compared by dividing the patient sample by the average
of the normalized control samples, giving a numerical value of 1.0 as normal, 0.5 as
deleted and 1.5 and above for duplications (Schouten, J. P. 2002). One of the greatest
advantages that MLPA affords is that it can distinguish dosage exon by exon, which
allows highly specific analysis.
It has been noted using a combination of FISH, CGH and MLPA that
Subtelomere aberrations (duplications and deletions) account for approximately 5-7%
of genetic disease in the ID population (Varga, T. 2005), (Ahn, J. W. 2007). With that
in mind, a population of patients that have been mapped to the X-chromosome, and are
not genetically diagnosed, were screened using MLPA. We found duplications in a
fraction of patients that have been found to be normal by DNA sequence analysis for a
specific gene given the suspected clinical diagnosis. Sequencing will not find largescale duplications and we have a number of patients that exhibit the clinical criteria to a
mutation in a specified gene and have a normal sequencing result for the expected gene.
One of the first ID MLPA kits offered by MRC Holland was for MECP2 and this test
has increased the rate of diagnosis by finding the duplications and deletions not
detected by sequencing. The following genes are not included in commercially
available MLPA kits and have been deemed important candidates for determining
dosage in this study;
•

XNP (Xq13.3) causing alpha thalassemia mental retardation syndrome
(ATRX). The protein is 2492 amino acids (aa) with 3 zinc finger domains. A
nuclear localization signal is located at 1025-1050 aa, and a coil-coil motif is at

27

1326-1347 aa, with a central domain that is an ATPase helicase. It also has a
catalytic domain and a DNA binding region. This protein is involved with
regulation of gene expression, chromatin structure, and is found to bind to the
short arms of acrocentric chromosomes (Villard, L. 1997).
•

STK9 (Xp22) serine/threonine kinase 9 also known as CDKL5 (cyclindependent kinase like 5) is involved with an atypical presentation of Rett
syndrome. The protein is 1022 aa and has an activation motif of classic MAP
kinases. This protein has ATP binding activities and is involved in posttranslational phosphorylation (Tao, J. 2004), (Montini, E. 1998).

•

FGD1 (Xp11.21) mutations cause facial genital dysplasia, also known as
Aarskog syndrome. This protein is a guanine nucleotide exchange factor and
activates Rho GTPase 42. It is a regulatory and signaling protein and is
involved in embryonic development and the regulation of the osteoblast actin
cytoskeleton (Pasteris, N. G. 1994).

•

NEMO (Xq28)(IKBKG) inhibitor of kappa light polypeptide gene enhancer
in B-cells. This protein has 4 alpha helix a leucine zipper and in its c terminal
zinc finger motif. It is involved with B-cell survival and T cell development
(May, M. J. 2002).

•

L1CAM (Xq28) L1 cell adhesion molecule is 1256 aa in length and has 6
repeating immunoglobin domains, 5 repeating fibronetin type III domains on
the extracellular surface. L1CAM protein function is involved with cell-to-cell
adhesion and without the functioning protein hydrocephaly is the prominent
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clinical finding. It is a glycoprotein with two isoforms, one neuronal and one
leukocyte (Faranda, S. 1996).
Two autosomal genes, SKI and UBE3A were added to the synthetic probe set to
serve as autosomal controls. The UBE3A gene was chosen, as it is known to be
associated with ID. SKI is an autosomal gene more involved with cancer, but resides in
a region known to be unstable in chromosome 1. SRY was chosen to be the sex marker.
Working with duplications on the X, the sample must have proper gender assigned.
•

SKI (1p36) is a transforming growth factor-beta, which inhibits growth, is
involved in differentiation and the induction of apoptosis. It is 728 aa in length,
with DNA binding and repressor activities (Shapira, S. K. 1997).

•

UBE3A (15q12) is involved with short lived or abnormal proteins and neural
development. Two diseases come from this region. Instead of duplications, this
region is coordinately regulated by an imprinting center and it makes a
difference with which gene, paternal or maternal is being expressed. Lack of
functional paternal copy of 15q11-q13 causes Prader Willi syndrome while
lack of a functional maternal copy of UBE3A, a gene within this region, causes
Angelman syndrome (Horsthemke, B. 2008).

•

SRY (Yp11.3) Sex marker and control.

Probe sequences for the synthetic MLPA may be found in Appendix A
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Overview of Methodological Decisions
MLPA
MLPA is a methodology designed to measure the dosage of selected genomic
sequences. MLPA may target one gene (all exons) or multiple gene panels. The data is
normalized and the patient sample compared to at least four normalized control
samples. Autosomal deletions are expected to generate values approaching 0.5 while
duplications should be roughly 1.5 relative to control ratios. With X-linked data,
deletions in males are expected to be 0 and duplications at 2.0 whereas, in females,
deletions are 0.5 and duplications are at 1.5. The MLPA method is not capable of
detecting balanced translocations. The MLPA shows a decreased value if there is a base
change in the DNA that is near the probe ligation site. This phenomenon will happen if
there is a SNP within the DNA sequence where probe hybridization occurs, producing
false positive results consistent with a deletion.
DNA Isolation
DNA isolation was performed using Autopure and Flexigene DNA kits
(Qiagen: Hilden, Germany) following manufacturer’s recommendations. DNA samples
were

diluted

to

100ng/ul.

RNA

was

isolated

following

manufacturer’s

recommendations using the PAXgene Blood RNA Kit (Qiagen: Hilden, Germany)
Selected family members were tested diagnostically by using Superscript One Step RT
PCR with Platinum Taq
(Invitrogen: Carisbad, CA) combined with Big Dye chemistry and an ABI 3730
sequencer (Applied Biosystems, Foster City, California USA).
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Northern Blot
Northern Blot of 0.7% agarose gel was electrophoresed overnight with RNA
from 4 controls, proband “A”, and “B” and his obligate carrier mother. This was
transferred to a nylon membrane using a Turbo Blotter system (Whatman, GE
Healthcare, USA). An XNP probe (Appendix B) was hybridized overnight and two
room temperature washes with 2X SSC and four washes .05X SSC at 72°C was
performed. The RAB33A probe (Appendix B) was hybridized overnight and two room
temperature washes with 2X SSC and two washes at .05X SSC at 42°C and two washes
at 60°C was performed. The AIF probe (Appendix B) was hybridized overnight and
two room temperature washes with 2X SSC and two washes at .05X SSC at 55°C and
two washes at 65°C was performed. Autoradiography was performed with various
exposures.
FMR2 Sequencing
FMR2 primers were developed to alter the sequence to produce a restriction site for
Xba1 if the sample had the c.474 C>T change restriction took place making a double
band.
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FMR2 polymorphism screen
Primer sequence in red: Xba1 restriction recognition sequence (5’-TCTAGA)
G GAT AAT ACC CAT CCT TCA GCA CCA ATG CCT CCA CCT TCT GTT GTG
ATA CTG AAT TCA ACT CTA ATA CAC AGC AAC AGA AAA TCA AAA CCT
GAG TGG TCA CGT GAT AGT CAT AAC CCT AGC ACT GTA CTG GCA AGC
CA
c.474 C>T

Changed nucleotide (C>A)
in primer to create a
restriction site for XbaI
when the c.474C>T change
is present.

Array CGH

Array CGH was performed on two independent platforms. First, an X-specific
array from Nimblegen was utilized to validate the original MLPA and real-time data.
Secondly, a separate X-specific array (Oxford Gene Technologies) with multiple data
points in the region involving XNP was used to help clarify the breakpoints for a
selected family. Genomic DNA was isolated as previously described and subsequently
purified using the Zymo DNA Clean & Concentrator™ kit (ZymoResearch, Orange,
California). Reference DNA used in the comparative hybridization was obtained
commercially (Promega Madison, Wisconsin). DNA concentration and its purity were
determined using the 260/280 ratio with a ND-1000 Spectrophotometer (NanoDrop
Technologies, Wilmington, Delaware). Samples were purified with YM-30 Microcon
filters from Millipore (Bedford, Massachusetts). Hybridization and washes followed
Oxford Gene Technology’s (OGT) CytoSure™ Chromosome X exon specific array
protocol (Oxford, UK). Arrays were scanned with the GenePix 4000B scanner from
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Molecular Devices (Sunnyvale, California). Array feature extraction was performed
with GenePix Pro 6.1. Copy number analysis was performed with OGT’s CytoSure™
Viewer software package. Agilent Analysis: ImaGene 8.0 (Modified Circular Binary
Segmentation (CBS) algorithm).
RNA Isolation
Total RNA was extracted using the RNeasy Mini Kit (Qiagen Hilden, Germany)
via a PAX tube. Samples were reverse transcribed using Superscript III (Invitrogen
Carlsbad, California) using random primers. Each sample was Nanodrop quantified and
diluted to 30ng/ul for cDNA. Expression qPCR was performed for BCORL1, ELF4,
PDCD8, Rab33A genes using RNA specific primers, spanning exon boundaries and
compared to the housekeeping gene PGK1. The patient mRNA level was quantified by
the relative comparison of the mRNA level of PGK1, commonly known as the ∆∆ CT
method.
Quantitative PCR
Real Time PCR: Delta-delta CT (∆∆Ct) method was performed for all qPCR
assays. Primers used (Appendix C) for all quantitative experiments, were designed for
the gene of interest, primer efficiencies were calculated using a serial dilution across 5
different molarities and graphed. This serial dilution of DNA or cDNA ranging from
stock to 1/32 determined the best primer efficiency. The primer concentration with a
slope less than .1 was chosen and used for all subsequent gene quantification
experiments. All patient samples were run using the appropriate primer molarity. The
critical threshold (CT) values for the samples were subtracted from the CT value of the
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housekeeping gene and then compared logarithmically normal controls. All RNA
samples were DNAsed before being reverse transcribed by Invitrogen’s First Strand
Synthesis kit (Invitrogen Carlsbad, California). All sample DNA’s were diluted to 15
ng/ul and cDNA’s to 30 ng/ul.
X-Inactivation
X inactivation testing used methylation sensitive restriction enzyme HpaII. Mix;
2ul of DNA, 1ul 10X NEB buffer 1, 1ul of HpaII enzyme and 6ul of distilled water and
allow to digest overnight. The PCR reaction; mix 11ul of distilled water, 2.5ul of 10X
PCR buffer, 5ul of DNTPs, 1.0ul of FAM labeled-X-inactivation forward primer and
1.0 X-inactivation reverse primer, 0.5ul Taq polymerase, 1.5ul of DMSO and 2.5ul of
the digested sample DNA. PCR Conditions: 94˚C x 10.0’ initial denaturation, 94˚C x
30 sec, 62˚C x 30 sec, 30 cycles, 72˚C x 30 sec, 4 x ∞. The PCR reaction generates
FAM labeled fragments that are separated by capillary electrophoresis and analyzed by
GeneMapper, an ABI fragment analysis program. The PCR reaction can take place only
if the template remains intact. Therefore, the X chromosome with a strong PCR
amplification signal is the inactive X as the methylation has protected the template from
digestion.
PCR/Sequencing
Per sample, a standard PCR reaction stock was made of 30.5ul 6M Betaine, 5
ul of 10X Taq Gold buffer, 3ul of 25mM MgCl2, 8ul of .25mM dNTP, 1ul each of
100ng/ul forward and reverse primers, 1ul (2.5 units) of Taq Gold polymerase, and 1ul
of 100ng/ul DNA. PCR reaction product was purified using Qiaquick PCR purification
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kit (Qiagen Hilden, Germany). 2.75ul of 6M Betaine, 2ul of One Half Big Dye
(Genetix Limited Queensway, NH) and 2ul of Big Dye (Applied Biosystems, Foster
City, California), 1 ul of 100ng/ul forward primer and 2ul of purified PCR product was
set for the sequencing reaction by using 95°C for five minutes, the 27 cycles consisting
of 95°C for 10 seconds, 60°C for 2 minutes, the to 4°C hold. These products were put
through Dye Ex columns
(Qiagen Hilden Germany), dried, and resuspended in 15ul of formamide and run on an
ABI 3730 sequencer.
Synthetic MLPA
A Synthetic probe set was developed (Figure 4) based on guidelines from MRC
Holland (Amsterdam, The Netherlands). Briefly, to develop a synthetic probe, choose
2-4 exons in the gene of interest that will give a good representation of that gene. Find a
section of sequence of desired length that has no recorded polymorphisms, is not
repetitive and is 40-60% GC rich. Split the sequence roughly in half and have the 5’
side of the probe be considered the left side. The 3’ side of the probe will be labeled
right. The right probe needs to be phosphorylated during the manufacturing process for
the ligation reaction. These sequences are flanked on both ends by forward and reverse
M13 tails, respectively. The left and right sides, including the M13 sequence are equal
to one probe. The left universal M13 PCR primer is FAM labeled when manufactured.
Each length is added up and each probe needs to be at least 5 bp longer than the former
probe. All probes have been PAGE purified: to eliminate double peaking in some of the
probes and also allows the probes to run closer to their expected size. To make a longer
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probe set; a left, middle, and right probe are designed with 5’ phosphorylation on the 5’
end of the middle and right probe sequence set. Synthetic probe reliability testing is
done by: running probes from two genes sets only then mix different gene sets with
each other. Check that the probes don’t interfere with one another, and lastly, is to
remove one probe from the full set and make sure the correct peak is the one that has
been intentionally deleted (Figure 4).
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CHAPTER FIVE
RESULTS
Figure 4. The final synthetic MLPA probe set. 1,Control peak, 2 XNP, 3 UBE3A,
4 L1CAM, 5 ATRX, 6 UBE3A, 7 XNP, 8 NEMO, 9 L1CAM, 10 AARSKOG, 11 SRY,
12 STK9, 13 SKI, 14 SKI, 15 AARSKOG, 16 XNP.
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CHAPTER FIVE
RESULTS
MRX MLPA
Using the MRC Holland MRX kit that targets Rho and MAPK genes, a group of
100 male college student controls were screened for validation of the kit. This group of
intellectually normally individuals was then followed by a cohort of 206 undiagnosed
patients with a suspected X-linked etiology and 95 ID with hypotonia probands. Some
of the DNA samples were old and had traces of organics as contamination. This made
the older samples more difficult to get reliable results from, as good MLPA data is
DNA quality dependent. This led to numerous repeats as well as Qiagen column
cleanup on problematic samples. In the end, most samples did produce a result that was
reproducible. The net result was approximately a 1% were truly abnormal.
Approximately 3% of the results appeared to be false positives due to DNA quality and
all of these had to be resolved using qPCR.

The entire MRX MLPA screening

uncovered a small group of distinct aberrations. The patients with normal results will
require further testing to determine the causative agent of their disease. For gene dosage
studies, Array CGH may be a good candidate as it covers the entire genome, if
negative, it would be indicated that that missense and nonsense mutations are likely
more causative and new genes would need to be explored. The MLPA proved to be
fast, inexpensive and makes a good first-round screening test.
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All of the following were found in the cohort with possible X-linked causation.
The summary of the patient screening:
•

One patient with a GDI1 and PQBP1 duplication.

•

One patient with a FACL4 deletion.

•

A FMR2 point mutation was identified by a low value for the exon 4 FMR2
probe.
Each sample was repeated with MRX at least three times to ensure

reproducibility. Quantitative Real-time Polymerase Chain Reaction (qPCR) was used to
confirm dosage. For all quantitative experiments, quantitative PCR (qPCR) primers
were designed for the gene of interest, primer efficiencies were calculated using a serial
dilution and graphed. The primer concentration with a 90% efficiency or better was
used for all subsequent gene quantification experiments.

38

GDI1 and PQBP1 Duplication
In one patient a GDI1 duplication was identified by two probes with a
normalized peak area value of 1.43 and a PQBP1 duplication two probes having
normalized values of 1.36 and 1.67 was found using the MRX MLPA (Table 2).
Normalized MLPA data values with a change greater than .35 from 1.0 are considered
for further investigation. Also the OPHIN1 probe shows a high value of 1.87. This
probe appears randomly high and low in many samples and is not reproducible among
runs. Therefore, it was considered unreliable and taken out of consideration for further
study. The GDI1 and PQBP1 genes are on different arms of the X chromosome and
primers were designed to target the same regions as the MLPA probes in order to
confirm the duplication. The GDI1 and PQBP1 duplications in sample #13805, using
the delta-delta CT method, confirmed the GDI1 duplication with primers targeting
GDI1 exons 1 and 5. The qPCR data is set to males with one X chromosome to be
equal to 1.0. This data shows that the female with two X chromosomes available has a
value around 2.0. Indicating that the gene dosage is consistent within the normal
controls. The GDI1 sample has a value at 2.0, indicating double the dosage in this
region. The PQBP1 duplication did not confirm in either PQBP1 exon 1 or 4 with
values at 1.0 (Figure5). The normal control female is high and the samples were
compared to a normal male to give more rationale to the values observed.
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Table 2. MRX MLPA patient #13805

GENE

13805

synthetic
UTY
DBY
CNTRL
GDI1
FMR1
FACL4
FMR2
TM4SF2
FMR1
ARHGEF6
RPS6KA3
FACL4
ARX
ARHGEF6
DCX
ARX
IL1RAPL1
FMR2
FACL4
FMR2
TM4SF2
DCX
FMR2
IL1RAPL1
SLC6A8
PQBP1
DCX
IL1RAPL1
FMR2
ARHGEF6
AGTR2
RPS6KA3
OPHN1
GDI1
PAK3
PQBP1
PAK3
OPHN1
PAK3
IL1RAPL1
OPHN1
ARHGEF6
RPS6KA3
SLC6A8
OPHN1
PAK3

CHROM
OR
EXON
2q14
Y-.014.5
Y.014.0
Xq11.2
Xq28
Xq27.3
Xq22.3
Xq28
Xp11.4
Xq27.3
Xq26
Xp22.2
Xq22.3
Xp22.1
Xq26
Xq23
Xp22.1
Xp22.1
Xq28
Xq22.3
Xq28
Xp11.4
Xq23
Xq28
Xp22.1
Xq28.1
Xp11.23
Xq23
Xp22.1
Xq28
Xq26
Xq24
Xp22.2
Xq12
Xq28
Xq23
Xp11.23
Xq23
Xq12
Xq23
Xp22.1
Xq12
Xq26
Xp22.2
Xq28.1
Xq12
Xq23

CONTROL AVE
HEIGHT
0.0262
0.0108
0.0160
0.0198
0.0424
0.0275
0.0348
0.0263
0.0260
0.0385
0.0457
0.0441
0.0208
0.0279
0.0293
0.0371
0.0323
0.0236
0.0218
0.0109
0.0160
0.0251
0.0287
0.0145
0.0231
0.0205
0.0096
0.0166
0.0211
0.0173
0.0249
0.0200
0.0231
0.0183
0.0150
0.0130
0.0119
0.0101
0.0166
0.0097
0.0122
0.0064
0.0171
0.0118
0.0139
0.0127
0.0089

AREA
0.0255
0.0106
0.0165
0.0194
0.0408
0.0263
0.0336
0.0255
0.0250
0.0371
0.0441
0.0425
0.0202
0.0273
0.0286
0.0363
0.0316
0.0232
0.0216
0.0108
0.0158
0.0251
0.0288
0.0146
0.0234
0.0209
0.0098
0.0171
0.0216
0.0179
0.0258
0.0206
0.0240
0.0191
0.0156
0.0138
0.0125
0.0106
0.0177
0.0104
0.0130
0.0067
0.0184
0.0126
0.0149
0.0136
0.0095

HEIGHT

AREA

0.70
0.96
0.77
0.82
1.56
1.05
1.07
1.01
1.04
1.05
1.21
1.15
0.97
1.03
1.35
0.77
0.95
0.98
0.76
1.03
0.69
1.07
0.69
0.79
0.91
1.23
1.31
0.69
0.83
0.73
1.16
1.01
0.99
0.85
1.28
0.70
1.46
0.68
0.71
0.72
0.79
1.53
1.02
1.24
1.02
0.83
0.80

0.68
0.94
0.86
0.96
1.43
0.97
0.98
0.95
0.95
1.02
1.13
1.04
0.89
0.95
1.23
0.71
0.86
0.91
0.73
0.97
0.66
1.05
0.68
0.79
0.92
1.25
1.36
0.72
0.85
0.77
1.22
1.09
1.08
0.96
1.43
0.78
1.67
0.78
0.81
0.86
0.93
1.87
1.21
1.50
1.25
1.03
0.98
0.94
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Table 2.The red
arrows indicate the
GDI1 and PQBP1
data points in patient
13805.
OPHN1 probe was not
reliable through out the
testing and the data was
disregarded.

GDI1 and PQBP1 qPCR
Normal GDI1
3.50

46203

3.00

51553

2.50

52601

2.00

13805

1.50

Normal PQBP1

1.00

46203
51553

0.50

52601
0.00

13805

A

B

C

D

E

A

B

C

D

E

Figure 5. GDI1 and PQBP1 Duplication. The black arrows show
the patient and how the GDI1 duplication in exon 5 confirmed with
real time PCR, but the PQBP1 at corresponding exon 4 did not.
A. Data set to normal male, B. 46203 normal female C. 51553
normal male D. 52601 normal male, E.13805 patient.
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FACL4 Deletion
A FACL4 exon 15 deletion was found using the MRX MLPA (Table 3.). This
family has two males affected by a deletion in the COL4A5 and FACL4 genes. The first
child born to this family is case #11774 and his younger brother is #11775. Both were
being treated for Alport syndrome, which is consistent with a deletion in COL4A5 gene.
It was unknown how far the deletion went into the FACL4 gene. The FACL4 deletion
was known in this kindred but one breakpoint was unknown. The MLPA narrowed the
breakpoint region to be between exons 10 and 15. Sequencing later found the
breakpoint to be located in exon 12. Figure 6 below is the order and direction of the
genes in the FACL4 region. The deletion is shown in red.

Figure 6. Gene order and direction of expression in the FACL4 region.
5’

3’
> COL4A5

IRSA>

GUCY2F>

AMMECR1>

FACL4
3’

< FACL4
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5’

Table 3. MRX MLPA FACL4 Deletion
#

CMS-11774
synthetic
UTY
DBY
CNTRL
GDI1
FMR1
FACL4
FMR2
TM4SF2
FMR1
ARHGEF6
RPS6KA3
FACL4
ARX
ARHGEF6
DCX
ARX
IL1RAPL1
FMR2
FACL4
FMR2
TM4SF2
DCX
FMR2
IL1RAPL1
SLC6A8
PQBP1
DCX
IL1RAPL1
FMR2
ARHGEF6
AGTR2
RPS6KA3
OPHN1
GDI1
PAK3
PQBP1
PAK3
OPHN1
PAK3
IL1RAPL1
OPHN1
ARHGEF6
RPS6KA3
SLC6A8
OPHN1
PAK3

HEIGHT
1.27
0.98
0.94
1.15
1.07
1.15
1.13
1.05
1.00
1.05
1.06
1.06
0.00
1.04
0.84
1.04
1.05
0.91
1.04
1.03
1.24
0.96
1.02
0.98
1.16
0.96
0.88
0.93
0.96
1.04
0.92
0.86
0.89
0.99
0.96
1.00
0.90
0.89
1.00
1.04
1.12
0.62
0.97
0.96
1.00
0.83
0.88

AREA
1.19
0.91
1.10
1.02
0.94
1.06
0.99
0.92
0.85
0.94
0.95
0.96
0.00
0.94
0.77
0.96
1.01
0.89
1.01
1.00
1.22
0.94
1.03
1.00
1.18
1.01
0.95
1.01
1.01
1.13
1.01
0.96
0.99
1.13
1.11
1.16
1.06
1.05
1.18
1.27
1.35
0.75
1.20
1.18
1.27
1.05
1.09

CMS-11775
HEIGHT
1.22
1.24
1.24
0.71
0.91
0.92
1.02
1.12
1.00
0.90
0.92
0.96
0.00
1.09
0.82
0.98
1.03
1.08
0.98
0.72
0.96
1.02
0.91
0.86
1.32
1.01
1.06
1.09
0.92
1.05
0.92
1.18
1.06
0.83
1.00
1.00
1.24
1.21
0.95
1.05
1.37
2.11
0.85
0.81
1.39
1.35
1.20

AREA
1.12
1.16
1.35
0.72
0.84
0.86
0.95
1.04
0.92
0.84
0.87
0.86
0.00
0.98
0.78
0.90
0.91
0.97
0.91
0.69
0.92
0.98
0.90
0.84
1.31
1.03
1.08
1.13
0.95
1.12
0.99
1.27
1.15
0.92
1.08
1.12
1.39
1.37
1.09
1.20
1.54
2.33
1.00
0.95
1.65
1.62
1.42
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FACL4 exon 10

FACL4 exon 15

FACL4 promoter region

Table 3. Red arrow depicts
MRX MLPA detects exon
15 FACL4 deletion in two
brothers. The FACL4
deletion was known in this
kindred but one breakpoint
was unknown. The MLPA
narrowed the breakpoint
region to be between exons 10
and 15.

Case #11774 is a four-year-old male with significant speech delay and no definitive
etiology. He was born at 36 weeks weighing 5 pounds 13 ounces. He had a short
umbilical cord wrapped around his neck. He spoke three words at age 1, then, lost those
words a few months later. He has had normal FRAXA and routine chromosomes were
normal, MRI, MRS acylcarnitine profile, lactate, pyruvate and serum amino acids.
Case 11775 (brother of 11774) is 2 years of age and has seizures, a worse temper than
his older brother, is often uncooperative and weighs 40 pounds and has always been
big. He is mildly dysmorphic and has a wide nasal bridge, deep set eyes, well defined
eyebrows and widely spaced teeth. He is on carnitor and coenzyme Q for his suspected
metabolic disorder.
The FACL4 gene encodes fatty acid CoA ligase 4 and is known to be associated
with non-specific X linked intellectual disability. COL4A5 is located at Xq22.3 and
alterations in this collagen gene causes Alport syndrome (Longo, I. 2003). Another
investigator at Greenwood Genetic Center was studying the same COL4A5/FACL4
deletion and knew one breakpoint of the deletion to be in exon 1 of COL4A5 gene but
the other breakpoint was not yet known. The MRX MLPA with data points at exon 10
and exon 15 facilitated in finding the breakpoint in exon 12 of the FACL4 gene. The
mother was later screened on the MRX MLPA and found to be a carrier of the deletion
as expected (Figure 7).
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Figure 7.
FACL4 DELETION
2.00

Patient Sample 1_DNA-20000
1.50

Patient Sample 2_cms11773
1.00

`

Patient Sample 3_cms11774
Patient Sample 4_cms11775

0.50

0.00

PEAK #
MRX chart 1

Figure 7. The FACL4 deletion as seen on MRX MLPA. At the MLPA FACL4
exon 15 probe (number 13), CMS11773 (orange) is the mother showing half the
gene dosage of normal. The male children CMS11774 (pink) and CMS11775
(yellow) at probe number 13 show a complete loss of dosage.
Again OPHN1 gave odd results and they were discarded. DNA-20000 (dark
blue) is a normal male control.
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FMR2 Point Mutation
The MRX MLPA for patient # 11701 had a peak with a low signal of 0.37 at
exon 4 of FMR2 (Table 4). The other data points for the FMR2 gene were shown to be
near 1.0, and were considered within the normal range of 0.65. to 1.35. This low value
was reproduced numerous times which warranted further study. Primers were designed
to flank the MRX probe of interest. A FMR2 c.474 C>T (p.P158S) alteration was
found by sequencing the region where the FMR2 MLPA exon 4 probe hybridized.
Sequence data found the mother also to be a carrier of this change (Figure 7). This is an
unreported change in the literature and SNP databases. Thus, polymorphism studies
were undertaken to determine the likely clinical relevance of this finding. A primer set
was designed to modify the sequence to produce an XbaI restriction site if the
individual was positive for the c.474 C>T change. A group of 658 normal controls, 295
college students plus 363 newborn screening samples of unknown sex were amplified
and digested with XbaI. The PCR product only digested if there was the same base
change as in the patient. In males one band would be found at 138 bases if normal, and
if abnormal a band of 114 bases would appear due to a base change and digestion. The
small decrease in size between bands made analysis subjective. To have greater
confidence in interpreting the data, a female control (mother) was used, having one
normal allele and one affected allele gave a double band. In females a double band
would signify the change while a single larger band was normal. In males it was easier
to differentiate the small difference when compared to a reference of a normal and an
abnormal allele. There were twelve positives in the restriction controls. However, when
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they were sequenced none of the individuals in the normal cohort was found to have the
c.474C>T alteration (Figure 8).
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GENE

Table 4. MLPA data showing low FMR2 signal in exon 4.

synthetic
UTY
DBY
CNTRL
GDI1
FMR1
FACL4
FMR2
TM4SF2
FMR1
ARHGEF6
RPS6KA3
FACL4
ARX
ARHGEF6
DCX
ARX
IL1RAPL1
FMR2
FACL4
FMR2
TM4SF2
DCX
FMR2
IL1RAPL1
SLC6A8
PQBP1
DCX
IL1RAPL1
FMR2
ARHGEF6
AGTR2
RPS6KA3
OPHN1
GDI1
PAK3
PQBP1
PAK3
OPHN1
PAK3
IL1RAPL1
OPHN1
ARHGEF6
RPS6KA3
SLC6A8
OPHN1
PAK3

CHROM
OR
EXON
2q14
Y-.014.5
Y.014.0
Xq11.2
Xq28
Xq27.3
Xq22.3
Xq28
Xp11.4
Xq27.3
Xq26
Xp22.2
Xq22.3
Xp22.1
Xq26
Xq23
Xp22.1
Xp22.1
Xq28
Xq22.3
Xq28
Xp11.4
Xq23
Xq28
Xp22.1
Xq28.1
Xp11.23
Xq23
Xp22.1
Xq28
Xq26
Xq24
Xp22.2
Xq12
Xq28
Xq23
Xp11.23
Xq23
Xq12
Xq23
Xp22.1
Xq12
Xq26
Xp22.2
Xq28.1
Xq12
Xq23

CONTROL AVE
HEIGHT
0.03
0.01
0.02
0.02
0.04
0.03
0.03
0.03
0.03
0.04
0.05
0.05
0.02
0.03
0.03
0.04
0.03
0.02
0.02
0.01
0.02
0.03
0.03
0.01
0.02
0.02
0.01
0.02
0.02
0.02
0.03
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.02
0.01
0.01
0.00
0.02
0.01
0.01
0.01
0.01

AREA
0.03
0.01
0.02
0.02
0.04
0.03
0.03
0.02
0.03
0.04
0.05
0.04
0.02
0.03
0.03
0.04
0.03
0.02
0.02
0.01
0.02
0.03
0.03
0.01
0.02
0.02
0.01
0.02
0.02
0.02
0.03
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.02
0.01
0.01
0.00
0.02
0.01
0.02
0.01
0.01

11701
HEIGHT

AREA

1.08
1.10
1.00
1.23
1.06
1.18
1.14
1.15
1.00
1.08
1.01
1.04
1.13
1.05
0.98
0.98
0.99
0.97
1.09
1.00
1.10
0.93
1.03
0.36
1.06
0.99
0.90
0.99
0.98
0.95
0.81
0.90
0.89
0.98
0.94
0.93
0.87
0.91
0.96
0.92
1.04
0.84
0.93
0.79
0.89
0.74
1.06

1.01
1.03
1.13
1.07
0.93
1.05
1.01
1.01
0.88
0.97
0.91
0.93
1.05
0.96
0.90
0.93
0.94
0.93
1.05
0.98
1.09
0.92
1.05
0.37
1.10
1.05
0.97
1.07
1.07
1.06
0.92
1.02
1.01
1.13
1.08
1.08
1.04
1.08
1.15
1.14
1.26
1.06
1.15
0.98
1.08
0.95
1.36
0.99

Figure 8. FMR2 Sequencing and restriction data.
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Table 4. FMR2 exon 4
(red text and arrow)
shows a low value of 0.37.
Other data points for FMR2
(blue text and blue arrows)
appear to be in the
normalized range near 1.0,
depicting a normal value.

PROBAND

B

MOTHER

Figure 8A. Point
mutation found in
FMR2.
Proband is
hemizygous for the c.
474 C> T change and
the mother is
heterozygous.

NORMAL CONTROLS

Figure 8B. Xba1
restriction of 658
normal controls.
Normal controls are
single banded while
the restriction site of
XbaI in the Mother
with FMR2 change is
double banded.

The proband when restricted had a 17 base difference than the full length PCR
product of 138 bases. It was extremely difficult to see the small drop in size on an
agarose gel. This necessitated using the mother as a control made two bands, making it
easier to see the restriction result.
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Figure 9A. Patient
with FMR2 mutation
at age three.

Case #11701. (Figure 9A) The patient with
the FMR2 point mutation has developmental delay, delayed speech, motor skills,
and learning problems. He is tall, macrocephalic, with a broad forehead referred by
(Dr. Leah Burke, Burlington, Vermont). The mother’s X inactivation study shows
that she has random activation (52:48). Recent data shows the mother and the
maternal grandmother both have the c.474 C>T change (Figure 9B).
Kindred 9225
Figure 9B Pedigree of cases
11701. The mother is a carrier of
the change. The maternal
grandmother has been found to
carry the change as well.

●

11701

11702
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FMR2 Background
CGG triplet repeats that cause fragile X syndrome, are well known in the FMR1
gene, which is closely related to FMR2. FMR2 is distal to FMR1 and is separated only
by LOC100128690, LOC100132556 and MIRN514-2 at Xq27.3. Expansion repeats are
considered to be relatively rare in FMR2. However, It has been deemed noteworthy to
screen for FMR2 in patients that are negative for FMR1 expansions (Knight, S. J.
1996). The prevalence of FMR2 to that of FMR1 triplet repeat expansions is small and
for every FRAXE (FMR2) expansion detected there will be at least 25 fragile X cases
(FMR1) found (Brown, W.T. 1996). Point mutations in the FMR2 gene have not been
reported. The intellectual disability of the FMR2 patient is generally milder than that of
FMR1, and accumulated data suggest no consistent dysmorphology. It appears that the
main clinical features are speech delay, reading and writing problems, learning
difficulties and behavior concerns (Knight, S. J. 1996). It appears that this change is
consistent with the loss of function FMR2 phenotype and is suspected to be the cause of
disease.

51

CHAPTER SIX
RESULTS
XNP Duplication Causes ATRX syndrome
After designing the synthetic MLPA probes, working conditions were refined to
validate the new Synthetic MLPA test. As a part of the validation process 55 normal
males and 51 normal females were screened. All the samples gave a normal result with
each probe value to be within the range expected with the data normalized to1.0.
During the initial screening of the hypotonia cohort, using the synthetic MLPA,
a duplication in XNP was identified (Figures 11A & B). . After confirming the result in
the affected proband, the need to test other family members (K8922) was apparent in
order to determine if the duplication segregated with the phenotype. The family
members chosen for screening were six obligate carrier females with 100% skewed X
inactivation, one normal father and two additionally intellectually disabled males
(Figure 10). Each of the affected males exhibited developmental delay, alpha
thalassemia, and dysmorphic facies consistent with the clinical diagnosis of ATRX
Figure 10.
syndrome.
.
Heart Defect
Affected Male
Carrier Female

2

B C
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A. Pedigree of K8922 with
XNP duplication. The carrier
female (2) and A, plus B of the
two affected brothers (B and C)
were used in duplication size
and expression status studies.

A

B.
B

A

C

B. Three affected males with ATRX A,B,C from
the XNP duplication family K8922.
Case report:
The family pedigree (K8922) studied (Figure 10) consists of three males in two
generations having severe mental retardation. Obligate carriers appear normal due to
highly skewed X-inactivation patterns.
A, was born to healthy parents: father age 29 years and the mother age 33
years. An older half-sister was healthy. Delivery was by Cesarean delivery, birth weight
was 5.9 lbs and length 21 inches. Hemoglobin inclusions were noted during infancy
screening and throughout childhood he had chronic microcytosis and hypochromia.
Low motor tone was present from birth and all developmental milestones were delayed.
He walked at 30 months and said his first words at two years. He had repeated
respiratory infections including pertussis and respiratory syncytial virus.
At age 3.5 years, his head circumference was 47 cm (3rd centile), height of 99
cm (50th centile) and weight of 14.8 kg (50th centile). His nasal root was broad and
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epicathal folds were present. The lips were full and mouth open. Musculoskeletal and
genital examinations were normal.
At age 6 years, his height was 109 cm (60th centile), head circumference was 49
cm ( 3rd centile) and weight was 21.6 kg ( 70th centile). The nasal root was full and
inner canthal measurement was 3.1 cm (85th centile). Facial findings were as before
with small nose, open mouth, full lips and tented upper lip. The alveolar ridge was
broad and teeth widely spaced. He drooled but peripheral muscle tone appeared normal.
Neuromuscular and skeletal examinations were normal. Digital fingerprint pattern
included two tall arches and eight ulnar loops. MRI showed bifrontal atrophy. He
scored 27 on the Vineland adaptive behavior scale.
B, was delivered from breech presentation at 34-35 weeks, weighing 2.16 kg .
He walked at age five years and never developed significant speech. He had chronic
constipation. At age 35 years, he had a height of 155 cm (<3rd centile). The eyes were
recessed, the midface hypoplastic, and the philtrum short, but he did not have hypotonic
facial characteristics. He had blunting of fingers 2-5 and the palms were excessively
wrinked. The left elbow had limited extension and toe 2 overlapped toe 3. The testes
were small (1.5X2.5 cm). There was no spasticity. Testing with the Vineland scale gave
a score of less than 20. Blood smear was positive for HgbH inclusion with brilliant
cresyl blue staining.
C, weighed 2.95 kg at term delivery. He walked at age 19 months, developed a
few words at an unknown age and used up to 10 words appropriately as an adult. His
height was 170 cm (20th centile), weight was 60.9 kg (<3rd centile) and head
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circumference 56.7 cm (50th centile). Ears and were posteriorly angulated with deficient
lower helix formation. The right hand was held deviated to the ulnar side. The palms
were excessively wrinkled and fingertip dermal partterns were five arches, one low
ulnar loop, and four ulnar loops. Deep tendon relexes were normal. Genetalia was
normal adult. IQ was <20. (Attending clinician of the K8922 is Dr. Roberta Pagan,
Walla Walla, WA).
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XNP Test Results
The XNP duplication was found in all three affected males and six obligate
carrier females, demonstrating, it segregates with the phenotype of the family members.
The fact that the affected males and carrier females are concordant for the XNP
duplication adds to the strength of this finding as the likely cause for the features of
ATRX in this family (Figures 11A & B).
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A. Synthetic MLPA normalized data depicts the XNP duplication. XNP exons 9
and 17, shown by peaks 1 and 15 respectively, demonstrate the XNP duplication by
giving normalized values of 1.5 and above. The normal male (CMS-2570) in this
family, has values that do not approach 1.5 or greater, demonstrating the lack of
duplication in this person.
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Figure 11B
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11B XNP duplication MLPA data is depicted on a graph.
For visualization of the duplicated exons in the males with ATRX syndrome
the MLPA was graphed, showing the duplication in XNP exons 9 and 17,
(peaks 1 and 15) but not in exons 2 and 36 (peaks 4 and 6).

Figure 12.

Figure 12. Determining the duplication breakpoints. The blue region shows the
XNP duplication spans from exon 2 through exon 31 (exons noted in red squares).
The white areas depict where there is only one copy of XNP. The numbering above
the dark blue line indicates the base in the gene where primers started. The primer
names are below the dark blue line.
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Real time PCR was performed to narrow the duplication breakpoints. FGF16
(proximal), PGK1 and ATP7 (distal) genes flank either side of the XNP gene and were
determined to have normal dosage. Real time primer sequences may be found in
Appendix C.
Testing across intron 2 produced duplicated results through to exon 3. The
MLPA XNP exon 2 probe shows that exon 2 was not duplicated. In contrast, the real
time results showed numerous times and with different primer sets, that exon two, is in
fact duplicated. Later, the MLPA XNP exon 2 probe became problematic and was taken
out of calculations. The qPCR method appeared more reliable for walking across intron
1 and using this technique allowed for the determination of the 5’ endpoint of the
duplication. As the breakpoint region was narrowed, repetitive Alu sequences became
prevalent, making it very difficult to design reliable primers for real time. Primers then
became unacceptable as the region became so repetitive that 2-3 peaks would appear on
the disassociation curve.

With the hope of sequencing across the breakpoint

boundaries, taking the real time primers and pairing them so they would PCR into
amplicons of 1-2.5KB, then sequencing this PCR product proved to be fruitless due to
the repetitive nature of the area, and the exact breakpoint was never found. Relying on
the qPCR data, it was determined that we were within 2,699 bases, placing it between
XNP exons1 and 2. The 3’ breakpoint was located between XNP exons 31 and 32.
Again the sequence in the intron became riddled with Alu repeats making it impossible
to continue qPCR. We came within 7,480 bases of the breakpoint (Figure 12).
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The XNP gene was sequenced in this family providing normal results. Once the
duplication was found on MLPA the XNP transcript was sequenced looking for
differences in splicing or breakpoints and it was found to be normal. A Northern blot
was done to determine the relative amount of XNP expression. Although amplification
was possible from the XNP transcript, the Northern blot shows that the amount of XNP
transcript was minimal and not enough to be visually seen using the exon 9 XNP probe
(Figure 13). This gives a good indication that the partial duplication disrupts the gene
and a viable full-length transcript is not made.
Figure 13. XNP Northern blot shows no transcript for the affected
males 1 and 2. The obligate carrier 3 has transcript to the degree of the
normal females 4, 5 and normal males 6, 7.
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5

6

7

A Western blot was attempted eight times with no success of protein transfer.
The antibody was tested and found to be in working order. Due to the protein being
very large it is felt that it may not be released from the nucleus or is not transferring out
of the gel. The sample of the proband was also sent to Nimblegen technologies to have
an X chromosome array confirm the duplication. Due to the XNP region being
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repetitive there were a limited number of probes in the area and confirmation was
unclear due to the limits of the array. The Nimblegen array detected a 244kb
duplication centromeric of XNP. This duplication was in the BRACE gene region and to
confirm this duplication two sets of qPCR primers were designed. The qPCR data did
not confirm the BRACE duplication. Further, it was not confirmed on an OGT X array
platform.
Problems with the Western blot and the Nimblegen array led to testing with the
Oxford Gene Technologies (OGT) X chromosome array CGH that had good coverage
in the XNP region. This platform was run to confirm the XNP duplication data derived
from MLPA and qPCR (Morey, J. S. 2006) and to narrow and/or confirm the
duplication breakpoints (Figure 14). The OGT X chromosome array clearly
demonstrates the duplication and confirms the breakpoint on the 3’ end, but does not
have enough data points on the 5’ end to determine a more precise region for the
breakpoint.
Figure 14A.
A.

Figure 14A. The OGT Array clearly shows the XNP duplication.
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14B. OGT Array shows the XNP duplication breakpoints. Blue
and Red arrows indicate OGT array probes. The (blue arrow left)
ACGH_69901c probe and (blue arrow right) ACGH_69936c probe
indicate there are 33,525 bases between the probes on the 5’ end.
The (red arrow left) ACGH_70104c probe and (red arrow right)
ACGH_7016c probe indicates there are 68,978 bases between the
probes on the 3’ end. The large distances between these probes are
possible due to the repetitive nature of these regions.

ATRX Background
ATRX syndrome is a rare X-linked syndrome characterized by severe to
profound mental retardation, characteristic facial dysmorphism, genital anomalies and
other somatic findings. Affected patients are expected to have -thalassaemia, severe
developmental delay with little or no language and seizures, which are present in
approximately 30% of affected individuals (Gibbons, R. 2006). The presence of thalassaemia is not required in order to confirm a suspected clinical diagnosis of ATRX
syndrome. This syndrome results from mutations in the XNP gene and carrier females
nearly always have highly skewed X-inactivation patterns favoring their normal X
chromosome (Muers, M. R. 2007). ATRX protein with 2492 amino acids is widely
expressed and demonstrates alternative splicing events that generate three isoforms that
convey tissue specificity (Villard, L. 1997). The protein contains a zinc finger motif
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and is related to the SNF2/SWI family of transcription regulators and has been
demonstrated to have a role as a regulator of chromatin remodeling which dictates
DNA accessibility at numerous loci including the alpha-globin cluster and other
unknown target genes that are critical for development (Villard, L. 1997), (Argentaro,
A. 2007). In the mouse model, known chromatin remodeling proteins, Daxx and
MeCP2, are that are found to interact with ATRX. (Xue,Y. 2003). Human homologs of
these genes are known to be associated with mental retardation. ATRX and Daxx in
mice make an ATP-dependent chromatin remodeling complex while MeCP2 mutations
appear to disrupt ATRX localization (Nan, X. 2007). In humans, the large majority of
all pathogenic XNP mutations (greater than 90%) can be detected in either the zinc
finger or helicase functional domains (Villard, L. 1997), (Xue, Y. 2003).
A report published during the course of this study of an intragenic duplication of
XNP was shown to cause ATRX syndrome by disrupting synthesis of XNP transcript
(Thienpont, B. 2007). In this report, we identify a new X-linked family with an XNP
duplication that results in loss of full-length messenger RNA that leads to a classical
clinical presentation of ATRX syndrome. In cases such as these with normal XNP
sequencing results, other diagnostic methodologies such as MLPA and CGH may be
helpful in identifying the underlying etiology.
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CHAPTER SEVEN
RESULTS
L1CAM and SKI Duplications
The L1CAM/NEMO duplication (Figure 15A) was found on the synthetic
MLPA probe kit. Confirming the duplication using the MECP2 MLPA kit from MRC
Holland found that the MECP2 gene was also duplicated and spanned from SLC6A8 to
NEMO. This sample was transferred to a project being conducted at the Greenwood
Genetic Center as an additional patient exhibiting a MECP2 duplication (Friez, M. J.
2006).
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Figure 15A The synthetic probes find duplications in L1CAM and
1p36. The L1CAM duplication is depicted by the red arrows. The
SKI (1p36) duplication is shown by the white arrows.
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Table 5.

Table 5. MLPA summary sheet depicting the L1CAM and SKI
duplications. Patient data is compared to the average of normalized
controls, making a deletion to be near .5 with autosomal and 0 with Xlinked and a duplication to be near 1.5 with autosomal and above 1.5
with X-linked.

1p36 Background
1p36 deletions account for .15-1.2% of idiopathic developmental delay and
intellectual disability. It is a newly recognized segmental aneusomy condition with an
estimated incidence of 1/5000 newborns. Routine cytogenetic karyotyping and FISH
find most 1p36 deletions. Phenotypic features appear to correlate with the size of the
deletion. The distal genes contribute to the general phenotypic features of the
syndrome, while the deletions in the more proximal regions correlate with specific
features. There are significantly more maternally derived deletions than paternally
derived deletions with most being de novo events. There are multiple breakpoints with
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unclear mechanisms. (Wu, Y.Q. 1999). Patients exhibit a distinct craniofacial
appearance, with a tower skull, prominent forehead, microcephaly, deep set eyes,
straight eyebrows, epicanthus, midface, hyoplasia, broad nasal root/bridge, long
philtrum, pointed chin; associated with brachy/camptodactyly and short feet. 100% had
mild to profound developmental delay and intellectual disability and 95% had
hypotonia. 75% had eye/vision problems, 70% of the patients had central nervous
system anomalies and heart defects and 40% had hearing impairment and skeletal
anomalies (Battaglia, A. 2008), (D'Angelo, C. S. 2006), (Shapira, S. K. 1997).
In the hypotonia cohort and the group of cohorts of patients with clinical
diagnosis and normal sequencing results, duplications and deletions of SKI (1p36) were
found. The SKI probes on the synthetic kit were the autosomal controls. These four
1p36 deletions and one patient with two duplications and one deletion were tested on
the MRC Holland 1p36 MLPA kit (Figure 15B) for further evaluation. Two of the four
patients confirmed the synthetic MLPA finding. There were problems with the other
two non-confirming samples, one had little DNA available and the other had DNA of
questionable quality. To determine if the DNA was of good quality in the confirming
and non-confirming samples, they were tested on the MECP2 MLPA kit. If the sample
looked normal with clean data and little background noise on this kit, the data was
considered reliable.

Patients, 56560 and 60175 confirmed with the specific 1p36

MLPA kit from MRC Holland and two platforms of Array CGH as well as by FISH.
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Figure 16. Case 56560 . Patient with the common dysmorphic features of 1p36
deletion syndrome.

Case 56560.

This male patient has multiple

dysmorphic features, recurrent respiratory infections and
developmental delays (Figure 16). Medical history reveals
that he was born at 36 weeks to a 20-year-old mother who
was previously a drug user. Birth weight was 7 pounds 7
ounces and a length of 21 ½ inches. His head circumference is 46.5 cm, which is the
50th percentile. The head is tilted to the left with the ear meeting the shoulder. There is
a broad nasal bridge and the pupils are equal, round and reactive to light. There is mild
to moderate hypotonia. He has a very similar face to those with ATRX with an open
inverted V-shaped mouth, short neck and developmental delays. He has cupped fleshy
ears lobules, short nose and repetitive behaviors. The hemoglobin and karyotype tests
were normal. From a respiratory standpoint when the patient gets the least little cold it
turns into pneumonia. Gastrointestinal standpoint is that he stays constipated. He has a
normal karyotype.
The family history indicates that the mother has frequent bronchial episodes.
The mother’s half brother that is 19 years old is slow and lives with her. Her other half
brother is an average learner. The maternal grandmother is 37 years old and has a
history of psychiatric illness. The father also has bronchial episodes but is generally
healthy. The father has a brother who is slow and another brother that is normal. There
is a first cousin on the mother’s side that has spina bifida and another cousin with
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congenital heart disease (The attending physician for this family is Michael Borja, M.D.
Statesville, NC).
1p36 Results
This patient was first found in the hypotonia cohort in one of the initial runs
with the synthetic MLPA. Later, under another number it appeared again in the L1CAM
cohort. The 1p36 kit gave atypical results and further confirmation was done to resolve
the data. The patient appeared to have two deletions and one duplication in a very short
span on the p arm of chromosome 1. The genes shown to be duplicated are TNFRS18,
TNFRS4, SCNN1D, DVL1, GABRD, SKI, PEX10, TNFRS14 and ARMD2. The larger
deletion includes, DFFB, NPHP5, ICMT, CAMT1, TNSFS9 and PARK7 genes. The
smaller deletion included genes, RIZ1, PRMD2 and CASP9.
The Spectral Genomics Array CGH was an “in house” method used to
determine if the duplications and deletions confirmed in this patient. The Spectral Array
CGH not only confirmed the duplication and deletions, it also found another deletion
on the q arm of chromosome 1 that the 1p36 MLPA was incapable of discovering
(Figure 17.). Another array CGH platform, Agilent 4X44 array was also used to test
this patient. This array system found the two deletions and one duplication on the p arm
and the deletion on the q arm of chromosome 1. Fluorescent In Situ Hybridization
(FISH) studies revealed one of the duplications (Figure 17C) and the deletion (Figure
17B) in patient 56560. The other duplication was too small to be detected by the probes
used.
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Figure 17A 1p36 MLPA normalized
results for 56560 shows the
duplication in blue and the deletion in
red.
17B. Spectral Genomics Array CGH
ideogram of the 1p36 region,
confirming the MLPA data. The blue
marker signifies the duplication and the
red markers signify a deletions.
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Figure 17C.

Figure 17C. The 1p36
36 duplication in patient 56560 is confirmed by
FISH studies. The red signal signifies the centromeric region while the
green signal marks the 1p36 region at the end of chromosome. The
white arrow shows there is a more intense green signal than at the red
arrow, suggesting duplication.
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Figure 17D.

Figure 17D. The 1p36 deletion found in 56560 is
confirmed by FISH studies. The red signal signifies the
centromeric region while the green signal marks the 1p36
region at the end of chromosome. The red arrow marks the
green signal at the end of the normal chromosome 1. The
white arrows show there is no green signal at the end of
chromosome 1, suggesting a deletion.
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Case 60175: Male born in 1993 with a birth weight of 5.6 pounds, a head
circumference of 30cm, and a body length of 44cm. This patient has severe intellectual
disability and the sample was submitted for L1CAM testing due to hydrocephalus.
Delayed motor skills and speech with intellectual disabilities accompanied by seizures
were also noted in the clinical report. The patient, showing a 1p36 deletion on the
synthetic probe set and the 1p36 MRC Holland MLPA (Figure 18.A) was tested on the
Spectral Array CGH (Figure 18.B) This CGH reported a deletion of at least 3Mb in the
1p36 region, validating the MLPA result. This patient was also run on the Agilent
Array to confirm the previous findings by the Cytogenetics Department at the
Greenwood Genetic Center. This array platform found the 1p36 deletion, but also found
1 Mb duplication at 2p25. The Agilent platform reported the 1p36 deletion spans
almost 4Mb between 1p36.32 and p36.33 (Figure 18.C). The two array platforms, due
to probe location and coverage, reported slightly different sizes when calculating the
deletion.

FISH analysis also confirmed the 1p36 deletion (Figure 18.D). Clinical

significance is clear even with the number of CNVs located within this deletion. The
genes encompassed by the deletion, that are known protein coding genes, included on
the MLPA kit are; HES4, GIP2, AGRN, TNFRSF4, TNFRSF18, CAB45, SCNN1D,
DVL1, GNB1, GABRD, SKI, PEX10, FLJ10782, RNFRSF14, ARPM2, PRDM16, TP73
and DFFP.
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1p36 Patient 60175 Results
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Figure 18A 1p36 MLPA indicates a deletion in 1p36 region in sample 4,
60175 (yellow line). Each peak around the .5 value of the normalized data
signifies an autosomal deletion. Samples 1-3 that are running along the 1.0
value are normal.
18B
Chromosome 1

Figure 18B Spectral Genomics Array
CGH ideogram shows at least a 3 MB
deletion at 1p36. The CGH was performed
to confirm the 1p36 deletion. Indicating it
was not terminal, but was contiguous.

72

C

.

Figure 18C Agilent 4X44K Oligo Array CGH identified a
deletion in patient 60175 that is approximately 4Mb in
size. This array has better coverage, giving a tighter estimate
on the size of the deletion.

D

18D. 60175 1p36 deletion confirmed by FISH studies. The green
signal indicates the 1p36 region while the red signal indicates the
centromeric region. The arrow shows there is a missing green signal on
the end of chromosome 1, indictating a deletion.
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CHAPTER EIGHT
RESULTS
Xq25 Duplication
A duplication of Xq25 spanning 4 known genes (Figure 20) was found on
routine MECP2 MLPA testing (Figure 19) in a patient with a clinical presentation
resembling Rett syndrome. The Xq25 duplication encompasses the BORCL1, ELF4,
PDCD8/AIF and RAB33A genes.

qPCR was used to measure if there is a

corresponding increase in expression relative to the duplication. The size of the
duplication and approximate breakpoints will be demonstrated on an X chromosome
array CGH (Figure 21). Determining the parental origins of this duplication was also
addressed.
Of the four known duplicated genes only two appear to be over-expressed, AIF
(apoptosis inducing factor) and RAB33A (Figure 25.B). Our patient with an abnormal
clinical presentation resembling Rett syndrome is normal for both MECP2 and CDKL5.
Parents were tested on the MECP2 MLPA and were found to be normal, making the
duplication a de novo event. Array CGH confirmed the duplication in the Xq25 region.
It is a speculated that two over-expressed genes, AIF and RAB33A, play a significant
role in the phenotype of this patient.
To determine the change in expression of these two genes and how it affects
other pathways and expression profiles, a broad literature search was done to find
candidate genes that might be affected. qPCR was used to find which of the candidate
genes had their expression levels deviate from the norm. The first set, targeting the
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RAB33A pathway, consisted of qPCR on a group of candidate genes, primarily Rab
genes and their associates.
Secondly, for the AIF gene, a commercial qPCR array system (SuperArray Profiler)
targets different genes that are associated in the apoptosis pathway.
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Figure 19.

Figure 19. The Xq25 duplication was found on routine MECP2 MLPA
testing. The red arrow marks the increase that approaching 1.5 at number
16. This is the Xq25 control peak in the MECP2 MLPA, depicted in the
patient. The yellow, green and blue lines are normal samples while the
purple line with decreases at numbers 8 and 10 with a value of 0.5 is a
female with a deletion in exons 3 and 4 of MECP2.

Figure 20.

Figure 20. Genes
affected by Xq25
duplication. The
255kb duplication
encompasses four
known genes
BCORL1, ELF4,
PDCD8 and
RAB33 and three
unknown genes
LOC729571,
LOC728584 and
LOC643986.
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Case 1 Background.
This family is from Ecuador and was referred to the Kennedy Krieger Institute for
neurologic and genetic evaluation for microcephaly in their second child. The patient
was a 5.5-pound female baby born to a 30-year-old woman following an uncomplicated
pregnancy. The mother was known to have uterine myoma, but there was no bleeding
or cramping during pregnancy. It was noted that the proband did not move much in
utero but no other difficulties were noted. She was smaller than her sibling at birth. She
required oxygen for the first three months of life and this appears secondary to reflux.
At 1 month of age, there were concerns about hemoglobin, however this was
subsequently determined to be unremarkable. At 4 months of age, the parents became
concerned with her development presuming it was no longer reflux associated. She has
mainly motor delays, but now manifests language delays as well. At 14 months old she
can stay seated, however, she cannot get seated on her own. She is not yet cruising. She
has been getting physical therapy since 4 months of age. There are also concerns about
her fine motor use of her hands. She has some oral motor difficulties. She does choke
quite a bit, but does not appear to be in respiratory distress when this occurs. There
have been no seizures. They feel her vision and hearing are normal. There appears to
have been EMG nerve conduction, which was unremarkable.
Xq25 Proband Physical Examination and Report.
Gerald Raymond M.D. reports from the Kennedy Krieger Institute Neurology
Clinic in July 2005 that the proband is now 14 months and has had two MRI’s which
are unremarkable. Her weight is less than 5 percentile at 8.1 kilograms, her height at 76
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cm is less than 50 percentile, and her head circumference is at the 50 percentile at 43.5
cm. She is a pretty girl with no acute distress sitting in the office. She is visually
attentive and smiling. Head shape is normal; sclerae is clear, conjunctiva pink, pupils
equal, round and reactive to light. Extraocular movements are intact, ears are orally
formed, and tympanic membranes were normal. Nose and mouth are unremarkable.
Neck was supple with no masses. Abdomen was soft, non-tender without mass or
organomegaly. Genitalia were unremarkable, back was straight and the extremities
reveal a normal pattern. Neurologically, she is awake and alert. There was a lot of
babbling but no words. Cranial nerves II-XII were intact. Motor exam showed her
generally to be hypotonic with good strength and normal muscle mass. She was noted
to have some hand wringing as well as flex her hands open and closed several times
during the visit. At one point while she was becoming upset, she appeared to be
breathing rapidly, almost bordered on a persistent hyperventilation.
Xq25 Data Results
The MECP2 MLPA indicated a duplication in the Xq25 region. To further
investigate this finding, a DNA sample was submitted for testing on the NimbleGen X
chromosome array system. Meanwhile, parental DNA was obtained and tested on the
MECP2 MLPA; both parents appear normal for the duplication indicating the
duplication was a de novo event.
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On the NimbleGen array system the duplication was found to span from
bases 128,889,500 to 129,165,000 on the X chromosome (Figure 21).
Figure 21.

Figure 21. The 275 kb Xq25 Duplication on the NimbleGen X
chromosome array is depicted by the raised line with the endpoints
indicated by the arrows.

Figure 22. Determining which
X is inactivated. The X 296.60 is
from mother and with a very high
peak height indicates the mother’s
X is methylated and inactive.
The 275.85 X is from the father
with a low peak height indicating
this paternal X in the proband is
the active one.

Proband and parents were tested for X inactivation (XI). The proband has 92:8
ratio consistent with highly skewed XI chromosome (Figure 22). XI testing uses a
methylation sensitive enzyme, targeting the androgen receptor (AR) gene, on the X
chromosome. This test uses the different number of triplet repeats in each allele to
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distinguish the two X chromosomes in the female. The loss of restriction on the inactive
X is due to methylation interfering with the enzyme. If there is no methylation present,
the restriction enzyme cuts the DNA therefore, making PCR impossible. This unique
length of sequence is labeled and separated using capillary electrophoresis, giving a
value to each X chromosome corresponding to the number of AR repeats. It is possible
to determine which X chromosome came from which parent by their unique sizes. The
degree of methylation signifies the activation status of the X chromosome.

If

methylation is high, the peak is low, and the gene is inactivated. If methylation is low
the peak is high and the gene is active. The maternal peak 296.60 is nearly completely
inactivated while the father’s peak is active (Figure 22), depicting the active ratio of 8%
maternal to 92 % paternal. Because two genes on the X chromosome in the Xq25
region being over-expressed, led to the interpretation that the duplication is on the
paternally inherited X chromosome (275.85).
In order to further confirm which parental X chromosome is preferentially
expressed, each family member had various X-linked genes sequenced in an attempt to
find coding region SNPs that would be informative at the RNA level. These genes were
L1CAM, STK9, MECP2 and MED12. Sequencing of MED12 identified a SNP that
shows quite clearly which X chromosome is expressed in the daughter when the DNA
to the RNA transcript is analyzed (Figure 23). Many genes on the inactive X
chromosome escape inactivation in at least a fraction of the cells. RAB33A and AIF do
not appear to escape inactivation indicating they are likely to be dosage sensitive
(Brown, C. J. 1197).
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DNA
RNA
Mother

Proband

Father
Normal
Ctrl
Female
Figure 23. The MED12 gene SNP reveals which X is preferentially active.
The mother has a “C” and the father has an “A” at this nucleotide in MED12.
The daughter and a normal control are heterozygous for the “A” and “C” in the
DNA. In the RNA, the affected daughter has the “A” expressed at a higher
level (92%), (red arrow), than the “C” (8%). Therefore, the preferentially
expressed X chromosome was inherited from the father. Notice the normal
female having a 60/40 X inactivation pattern shows almost equal expression
for both X chromosomes (bottom right red arrow).
qPCR expression studies were performed for and four known genes
(ELF4, BCORL1, AIF and RAB33A) were encompassed by the duplication. Of these
genes, only RAB33A and AIF exhibit over-expression. To confirm the qPCR findings,
Northern blots were performed (Figures 24 A & B). The Northern blot probed with AIF
did not separate the 18S (1861 bases) and AIF (1836 bases) band due to a 25 base
difference in length between these transcripts. Due to the inability to separate the bands
of interest, no additional AIF Northerns were attempted (Figure 24.A). The RAB33A
blot appeared to transfer well, but low hybridization and wash temperatures (42°C &
55°) were necessary making the results for the blot dark and messy. The 5S rRNA runs
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around 1020bp and these bands look equal in intensity. The RAB33A mRNA is 711bp,
just under the 1000 base and above the 500 bp ladder band. The patient band is slightly
more intense than the control, confirming the qPCR data of higher expression (Figure
24.B) than normal controls. The ladder bands are on the right ranging from 5002000bp.
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Figure 24A
A

B

Figure 24B
A

B

C

C

Figure 24A Northern
Gel equal amounts of
RNA loaded. In the AIF
Northern (left) and the
RAB33A Northern (right),
using the rRNA bands to
monitor the calculated
10ug of RNA loaded,
shows the RNA samples
are equal A. female
control, B & E are the
Xq25 duplication patient.
C, D and F are male
controls and L is the RNA
ladder.

D

D

E
28S
18S
1861bp
AIF
1836bp

F

E

F L

L
2000bp
5S
1000bp
RAB33A
711bp
500bp

Figure 24B Northern blots. AIF probe. A. is a female control, B &
E are the Xq25 duplication patient. C, D and F are male controls and
L is the RNA ladder. The blot on the left did not separate the bands
of the 18S at 1861bp from the AIF band of 1836bp. The RAB33A blot
on the right shows this gene at 711bp is expressed at a slightly higher
level than the control, while the 5S band is equal in intensity.
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Many qPCR expression experiments took place before the criteria for reliable
data was obtained. Finding RNA from cell lines will have different expression values,
although not necessarily contradictory to the final conclusion, but expression is altered
by the age of the cell line. If the cells are newly grown, RNA expression appears to be
more robust than cells that have been growing for a longer period of time. If the cells
are not started in unison unreliable data will be produced. To avoid this phenomenon
RNA was taken directly from blood via PAX tubes. These samples had to be DNased
before reverse transcription to eliminate any DNA contamination. cDNA was made,
diluted to 30ng/ul and qPCR’d giving reproducible data that proved to be reliable.
The Xq25 proband expression was compared to expression in normal
controls.

Each gene encompassed by the Xq25 duplication was qPCR’d to look for

any change in expression compared to normal controls. Two of the genes, ELF4 and
BCORL1 appear to be having normal gene expression (Figures 25A&B).
25A

Figure 25A Two genes ELF4 and BCORL1, have normal expression. NL,
MC1, FC1, FC2, and MC2 are all normal controls. Patient is the Xq25
proband.
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Two of the genes, AIF and RAB33A appear to have higher expression
than the normal controls. RAB33A expression is over two fold higher whereas AIF is
slightly over expressed (Figure 25B).
25B

Figure 25B Two of the genes AIF and RAB33A in the proband (53271A)
had over expression compared to normal controls D (or DMC), 20000, CS,
KF, and FC30. The RAB33A gene was expressed over two fold that of normal
Global Expression
Changes
controls while the AIFRAB33A
gene expression
was elevated
by 0.45 above normal.

A small cohort of ID patients was compared to normal controls to examine
expression changes in a group of Rab genes and/or genes affiliated with the Rab
pathways. Due to the Rab genes working in concert to perform their normal
function, these genes may have a dysregulated pattern of expression in individuals
with ID. This cohort analyzed consisted of:
•

A female with a MECP2 mutation

•

A male FMR1 patient with 300 repeats

•

A female Xq25 duplication patient

•

A female suspected of having ATRX syndrome but with negative XNP
testing
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•

A male patient with an unknown diagnosis

•

A normal female control

•

A normal male control

All were tested for expression level of 26 genes, primarily Rab, Ras and Rho
genes that are known to be associated with RAB33A or its co-regulator genes. RAB33A
is a member of the small GTPase super family, and is expressed in the brain,
lymphocytes and normal melanocytes. In the brain, it is present throughout the cortex
as well as the hippocampus. RAB33A is regulated by DNA methylation of a specific
promoter region proximal to the transcription initiation site (Sexton, T. 2007). The
MECP2 gene, (methyl CpG binding protein 2), may have influence on the RAB33A
promoter region and therefore, inadvertently control expression for not only RAB33A,
but its co-regulators and associates.
The following genes are associated with RAB33A, its co-regulator RAB3A and
genes associated with Rab hubs and pathways. The first gene, CABC1, was tested to see
if the apoptosis pathway was altered due to a slight increase in AIF gene expression. A
different platform was used to continue expression studies on the AIF gene. Each of the
following Rab genes has been cited in the literature to play a part in the concerted Rab
cycles found in brain cells:
CABC1 is a chaperone-encoding gene located at 1q42.1 that has 14 exons
producing a protein of 368 amino acids. It is expressed in the brain, digestive, cardio
vascular and nervous systems. It mediates P53 inducible apoptosis through the
mitochondrial pathway (Gene Atlas, Baylor College).

86

FXR2 is a FXA-related protein and is located at 17p13.1, has seventeen exons
that produce a protein of 673 amino acids. It is involved with nuclear localization
signaling, nuclear export signaling and RNA export. This protein is known to interact
with at least 66 other proteins (BIOGRID, (Ay, N. 2007). This gene is up-regulated
when MeCP2 is over expressed in the hypothalamus in mice (Chahrour, M. 2008).
GDI1 is a GDP dissociation Inhibitor 1 and is located at Xq28. It has 11 exons
and produces a protein of 447 amino acids. It is found in the CNS and brain where it
plays a role regulating neuronal differentiation and brain development (Pylypenko, O.
2006). A GDI1 duplication of 250 KB has been reported in a female with mild ID with
an IQ of 58. This patient had neonatal seizures and cyanotic crisis, walked at 14
months, and had no speech until 15 months. She shows psychomotor delay and learning
disabilities, microcephaly, hyperkinesias and other mild dysmorphic features such as a
medial eyebrow flare and deep palate. Significant GDI1 overexpression of 2.8-5 fold
was found compared to controls. Mother demonstrated 100% skewed XI (Madrigal, I.
2007). Prenylated Rab GTPases occur in the cytosol in their GDP-bound configurations
bound to a cytosolic protein termed GDP-disassociation inhibitor (GDI). Rab GDI
complexes represent a pool of active; recycling Rab proteins that can deliver Rabs to
specific and distinct membrane bound compartments.

Rab delivery to cellular

membranes involves the release of GDI; the membrane associated Rab protein then
exchanges GDP for GTP. GDI displacement factor (GDF) caused the release of each of
these endosomal Rabs from GDI. GDF displayed a great enhancement rate on RABS 5,
7, 9 but cannot react with RAB1. Rab-GDI complexes localize Rabs to the correct
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intracellular compartments (Dirac-Svejstrup, A. B. 1997). MeCP2 activates Rab7 in
mice (Chahrour, M. 2008). Prenylation is an important modification for Rab
interactions. RAB7 interacts with REP and GDI, only if prenylated. The non-prenylated
to prenylated RAB7 / REP interactions increase 4 fold, while the GDI dependence on
prenylation is more dramatic, non-prenylated to prenylated RAB7 interactions increased
1000 fold. GDI has minimal interaction with un-prenylated RAB7 protein.
MYO5A is located at 15q21.1 and has 40 exons and is an actin binding
organelle motor protein myosin 5A. It is expressed primarily in the CNS, brain and
blood. It is found in the intracellular cytoplasm and is associated with microtubules,
nucleus and the centrosome. The protein is 1855 amino acids long. Mutations cause
severe developmental delay. Although the presence of all three RAB27A, MYO5A and
Melanophilin

proteins

is

crucial

for

the

trafficking

of

melanosomes,

neurodevelopmental abnormalities are specific for MYO5A deficiency (Gissen, P.
2007).
NIF3L1 is part of the NIF3 family and is located at 2q33-q34. It has seven
exons producing a 351 amino acid protein. It is expressed in the CNS and lymphoid
system. Its function is in neuronal differentiation and cell life (Gene Atlas, Baylor
College). NIF3L1 interacts with at least 38 other proteins including Rab proteins
(BIOGRID, (Ay, N. 2007). MeCP2 activates this gene in the hypothalamus in mice
(Chahrour, M. 2008).
PAK1 is a part of the Rho small GTPase family, which is critically involved
in the regulation of spine and synaptic properties. Protein kinase PAK1 is directly
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associated with and activated by the Rho GTPases.

PAK1 knockout mice show

changes in the actin cytoskeleton and the actin binding protein cofilin. These results
indicate that PAK1 is critical in hippocampal synaptic plasticity via regulating cofilin
activity and the actin cytoskeleton (Asrar, S. 2008). It is becoming apparent that the
Rho families of small GTPases and their downstream targets have a major function in
regulating CNS development. This emphasizes the importance of PAK1 in regulating
neuronal polarity, morphology, migration and synaptic function (Nikitina, T. 2007).
RABAC1 is a RAB acceptor and is located at 19q13.13. It has five exons that
produce a 185 amino acid protein. It is expressed in the endocrine, digestive systems,
the pituitary and brain. It is a GDI displacement factor. This protein interacts with 57
other proteins, most of them being Rab proteins as it serves as a Rab trafficking hub.
RAB11B: Is a RAS oncogene located at 19q12 and has five exons that produce
a protein made of 218 amino acids. Its primary expression is unknown, but it is found
as a GTP binding protein, one that is involved with regulating the transcription protein
transport (Gene Atlas, Baylor College).
RAB17 is a part of the RAS family and is located at 2q37.3. It has six exons that
produce a 212 amino acid protein. It is expressed in the lymphoid and digestive
systems, blood and pancreas. It is involved with protein transport (Gene Atlas, Baylor
College).
RAB22A is in the RAB family and is located at 20q13 and has seven exons
producing a protein of 194 amino acids. Its primary expression is unknown but it is

89

known to play a part in cellular trafficking and transport and interacts with RABAC1
(BIOGRID, (Ay, N. 2007), (Gene Atlas, Baylor College).
RAB23A is a Ras oncogene located at 6p11.2-12.3 and has seven exons
producing a protein of 237 amino acids. It is a negative regulator of hedgehog and in
mice it has been shown to cause NTD abnormal somites, polydactyly and poorly
developed eyes. (Gunther, T. 1994). Nonsense mutations of Rab23A in 'open brain'
mice were found to cause recessive embryonic lethality with neural tube defects,
suggesting a species difference in the requirement for RAB23 during early
development. The discovery of RAB23 mutations in patients with Carpenter syndrome
implicated hedgehog signaling in cranial suture biogenesis; this was an unexpected
finding given that craniosynostosis is not usually associated with mutations of other HH
pathway components. The finding also provides a new molecular target for studies of
obesity, which is a consistent feature of Carpenter syndrome (Jenkins, D. 2007).
RAB27A is a RAS oncogene located at 15q15-q21.1 and has six exons
producing a protein 221 amino acids long. It is expressed in the digestive system,
lymphoid system, reproductive system, skin and blood. It is found in immune defense,
regulatory signaling and transport, fusion of vesicles with their appropriate membrane
receptors. Mutations cause type II Griscilli syndrome (OMIM 607624) an autosomal
recessive disorder characterized by hypo-pigmentation of the skin, silvery gray hair and
large clumps of hair pigment in the hair shaft. RAB27A is high in melanocytes and cells
of the haematopoietic system and other secretory cells (Gissen, P. 2007). Mutations in

90

RAB5A and RAB27A cause these proteins to be retained on the ER membrane and are
not delivered to their native locations (Wu, Y.W. 2007).
RAB33A: Located at Xq25, has two exons that produce a protein with 237
amino acids and is expressed in the lymphoid immune system, CNS, brain and visual
eye. It is a transport/carrier protein and is associated with membrane fusion. It is a
chaperone for nucleotide free Rabs, based on the interaction between Rab8 and MSS4
(Itzen, A. 2006). It has a putative GDI interaction site based on the interaction between
S. cerevisiae Ypt1 and its guanine nucleotide dissociation inhibitor (GDI) (Rak, A.
2003). It also has an effecter interaction site based on interactions between Rab3A and
the effector domain of Rabphilin-3A (PubMed 10025402). RAB33A is also involved
with development and is found to play a role in the differentiation of embryonic stem
cells to neurons. Gene expression profiles looking to determine genes involved with
guided differentiation found up-regulated (two fold) expression from Serpini1 and
RAB33A at E15 which decreased with embryonic age, but maintained steady expression
throughout adulthood (Lee, M. S. 2006). In mice, changes in MeCP2 expression upregulate RAB3A (Chahrour, M. 2008) a co-regulator of RAB33A.
RAB33A is localized to the medial Golgi cisternae. Together with other cisternal Rabs,
RAB6 and RAB6A, it is believed to regulate the Golgi response to stress and is likely a
molecular target in stress activated signaling pathways. GTPase activating proteins
(GAPS) interact with GTP-bound Rab and regulate hydrolysis of GTP to GDP. GAPs,
which can accelerate hydrolysis of bound GTP over 2000-fold, can accelerate both
activation and deactivation in cells with variable inhibitory effect. The GTP bound state
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of the Gά subunit is active and deactivation is caused by hydrolysis of bound GTP to
GDP (Turcotte, M. 2008). Guanine nucleotide dissociation inhibitors or GDI further
regulate Rabs, which facilitate Rab recycling by masking C-terminal lipid binding and
promoting cytosolic localization. Most Rab GTPases contain a lipid modification site at
the C-terminus (Dumas, J. J. 1999), (Itzen, A. 2006), (Rak, A. 2003), (Ostermeier, C.
1999).
RAB3A is a Ras Oncogene located at 19p13.1. It has five exons that produce a
protein of 220 amino acids. It is located in the CNS and is most abundantly expressed
in the brain. It is present in all synapses and it is involved in calcium dependent
neurotransmitter release. Mutations in two genes implicated in RAB3A regulation are
associated with neurodevelopment defects (Gissen, P. 2007). Recessively inherited
changes lead to defects in catalytic and non-catalytic subunits of RAB3GAP cause
Warburg Micro syndrome (OMIM 600118) and Martsolf syndrome (OMIM 212720)
respectively. RAB3GAP specifically converts RAB3A GTP to GDP and thus may
determine the timing of dissociation of RAB3A from synaptic vesicles. The neuronal
migration defects and microgenitalia may be secondary to abnormal vesicular secretion
of neurotransmitters and of hormones produced by the hypothalamic/pituitary axis. In
concordance with this hypothesis, rab3gap gene knockout mice accumulate the GTPbound form of Rab3a in the brain, which leads to the inhibition of calcium dependent
glutamate release from cerebrocortical synaptosomes. It is suggested that the
abnormality in exocytosis is due to suppressed dissociation of the Rab3a from synaptic
vesicles resulting from abnormal conversion of GTP-Rab3a to GDP-Rab3a
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(Ostermeier, C. 1999), (Johannes, L. 1994). RAB3A is activated by MeCP2 in the
hypothalamus in mice and is up-regulated in mice with an increase in expression of
MeCP2 (Chahrour, M. 2008). Rab proteins are involved with tethering and are thought
to function upstream of the soluble N-ethylmalemide-sensitive factor attachment
receptor proteins (SNARE). RAB3A is implicated in the fine tune control of synaptic
vesicle release. In Rab3a deficient mice, pre-synaptic activities were quickly attenuated
following a series of repetitive stimuli (Yamaguchi, K. 2002). It is also implicated in
synaptic plasticity since Mossy fiber long term potential was reduced in Rab3a
deficient mice. Rab GTPases are necessary for docking and fusion in membrane
trafficking pathways in conjunction with the SNARE components. The GTP bound
forms of Rab proteins recruit their effecter proteins and this exchange process is
regulated by guanine nucleotide exchange factors (GEF). The GEFs identified thus far
are personalized to their specific Rab and have no similar amino acid sequence between
them. The RAB3A GEF is a regulator of multiple pathways. This finding demonstrates
Rab GEF is clearly a regulator of RAB3A. There is also high expression in pancreatic
islet cells where it plays a negative role in insulin secretion. RAB3A interacts with
RAB27A and is a co regulator of RAB7 and RAB40B. Rab3a in mice shows, behavioral
abnormalities, including disturbance of the circadian rhythm and sleep homeostasis
(Handley, M.T. 2007), (Dumas, J. J. 1999).
RAB40B: Is a RAS oncogene located at 17q25.3 and has eight exons that
produce a protein made of 278 amino acids. It is found primarily in the brain, breast
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and lung. RAB40B is found in a vesicular trafficking pathway of secretory vesicles
(Gene Atlas, Baylor College).
RAB4B: Is a RAS oncogene located at 19q13.2 and has seven exons that
produce a protein of 213 amino acids. It is found in the lymph system, pancreas,
exocrine, female breast and bone. It is a lipid anchor of the cytoplasmic side of the cell
membrane. (Gene Atlas, Baylor College) This gene is activated by MeCp2 in the
hypothalamus in mice (Chahrour, M. 2008).
RAB5C is in the RAS oncogene family. It is located at 17q21 and has six exons
that produce a protein of 216 amino acids. It is expressed in the lymph, immune and
reproductive systems, lung and skin (Gene Atlas, Baylor College. It is involved in
endocytosis and protein transport. It regulates membrane traffic into and between early
endosomes as well as vesicle transport along microtubules. RAB5C is an integrinassociated protein and positive regulator of integrin traffic. RAB5C and its effector
EEA1 mediate docking/fusion of early endosomes by interacting with syntaxin 13 and
NSF (N-ethylmaleimide sensitive factor (NSF) (Pellinen, T. 2006).
RAB6A is in the RAS oncogene family. It is located at 2q14-q21 and has eight
exons producing a 208 amino acid protein. It is expressed in the CNS, lymphoid system
and respiratory system. It regulates membrane trafficking from the Golgi to the
Endoplasmic Reticulum (ER).
RAB8A is of the RAS oncogene family and is located at 19p13.1 and has eight
exons that produce a 207 amino acid protein. It is expressed in the CNS, lymphoid and
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digestive systems. It is involved with neurotransmitter release (Gene Atlas, Baylor
College).
RAC1 is a RHO-RAS like gene located at 7p22 and has 8 exons producing a
protein of 192 amino acids. It is found in the lymph system, brain, pancreas and
secretory pathways. It is a GTP binding protein and is associated in the cell cycle,
signaling, and regulation of actin cytoskeleton. It is involved with RHO A, L1CAM,
CDC42, and PAK in axon repulsion (Gene Atlas, Baylor College).
RAC2 is a RHO-RAS related gene located at 22q13.1. It has seven exons to
produce a protein of 192 amino acids. It is expressed in the lymph system, blood and
connective tissue (Gene Atlas, Baylor College).
RHO A is part of the RAS family and is located at 3p21.2. It has five exons that
produce a 193 amino acid protein. It is expressed in the CNS, lymphoid system and
blood. It is found to mediate distinct actin cytoskeleton changes, cell-to-cell adhesion
and motility (Gene Atlas, Baylor College).
RHOU is a RHO GTPase located at 1q42.11 and has three exons that produce a
protein of 270 amino acids. It is a CDC42 homolog and activates PAK1. RhoGDI has
multiple functions in regulation of Rho family GTPase activities (Gene Atlas, Baylor
College). Rho GTPases are molecular switches cycling between active GTP-bound and
inactive GDP-bound forms. C-terminal prenylation allows them to associate with
membranes where they can interact with, and activate their effectors. Several levels
tightly control their activation state and accessibility. Activation through GDP_GTP is
catalyzed by GEF Guanine exchange Factors and promotes downstream signaling. GAP
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GTPase activating proteins accelerate the intrinsic GTPase activity to inactivate the
protein and terminate the signal. Rho-GTPase dissociation inhibitors (Rho-GDIs),
Extract Rho family GTPases from membranes and solubilize them in cytosol (Dovas,
A. 2005).
SNAP29 is a synaptosomal associated protein located at 22q11.21 and has five
exons producing a protein consisting of 258 amino acids. It is expressed in the brain,
lymphoid, immune and reproductive systems. In the brain it is a neurotransmitter of
modular synaptic transmission. Mutations cause cerebral dysgenesis, neuropathy,
ichthyosis, keratoderma, microcephaly, sensorineural deafness, optic disc hypoplasia,
facial dysmorphism, intracranial abnormalities and death. SNARE proteins are “soluble
N ethylmalemide-sensitive fusion attachment protein receptor protein” SNARE
proteins become active acquiring GTP with the aid of the Rab activator molecule.
SNAP29 is homologous to SNAP25 in that is contains two predicted coiled-coil regions
that can participate in the formation of the core complex; however it lacks the
palmitoylated membrane attachment domain found in SNAP25. It was known that
SNAP29 can associate with syntaxin 6 and may have a role in the intracellular
trafficking of the IGF1 receptors and other proteins in neuroectodermal tissues
(Sprecher, E. 2005).
WASF1 is part of the WAS Protein family and is located at 6q21-q22. It has 10
exons that produce a protein of 559 amino acids. It is expressed in the blood, neurons,
lymphoid system and pancreas. It is a regulator of actin organization and is downstream
of the RAC pathway (Gene Atlas, Baylor College).
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The following chart is the schematics of the pathways involving the genes
studied in the Xq25 project. Red and blue arrows note the MECP2 and RAB33A gene
interactions, while black arrows indicate trafficking control, with secondary protein
interactions depicted as yellow ovals. RABAC1 is a central hub sorting and sending
different proteins to their correct destination in the cell. Many times localization
proteins, motor proteins, effectors or modifiers are added before the proteins are sent to
their final destination. RAB33A and RAB3A are positive co-regulators of each other.
MECP2 is regulated by CREB1 through a negative feedback loop. RAB1A regulates
CREB1, and with CREB1 activation, comes the release of CREB repressor protein.
Patients with mutations or dosage aberrations in these core genes are found to have
global dys-regulation (Figure 26).
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MECP2 and RAB33A Interactions
Figure 28.
UPREGULATES

DOWNREGULATES

TRAFFICK
REGULATION

PROTEIN
INTERACTIONS

PRIMARY
INTERACTION

OTHER
PROTEIN

GENE

PAK1

RAC1

WASF1

RAC2
FXR2
RAB4B
RAB22A

SNAP29

RAB27A

RAB11B
MECP2
RAB1A
RAB40B

RAB33A

NIF3L1

CREB1

RAB6A

HRAS
RAB3A

RAB17
RAB7

RHOA
RAB8A
RABAC1
CABC1

RAB5C

RAB4A

GDI1

98

MY05A

RESULTS
Expression Screening
qPCR was performed on each of these genes on the small cohort mentioned
previously. The results show that there are patterns of expression in each gene among
differently affected patients. Below is the summary of the qPCR findings showing
under and over expression (Table 6).
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GENE

Xq25 ATRX

FMR1 UNKN

MECP2

CABC1

1.45
1.73
1.09
0.70
2.67
0.55
1.40
1.80
1.87
1.60
1.40
0.70
2.75
2.11
2.73
1.00
0.78
0.84
1.14
1.13
0.84
0.93
0.90
0.97
1.03
1.40

1.30
1.06
0.96
0.91
1.34
0.72
0.92
1.17
1.68
1.05
0.42
0.64
0.70
1.38
1.52
1.13
0.77
0.69
1.05
0.90
0.68
0.88
0.84
0.71
0.88
4.50

1.85
1.57

FXR2
GDI1
MYO5A
NIF3L1
PAK1
RAB 1A
RAB 11B
RAB 17
RAB 22A
RAB 23A
RAB 27A
RAB 33A
RAB 3A
RAB 40B
RAB 4B
RAB 5C
RAB 6A
RAB 8A
RAB AC 1
RAC 1
RAC 2
RHO A
RHOU
SNAP 29
WASF1

0.84
0.85
1.30
0.97
2.22
0.80
0.63
1.63
1.65
1.72
1.05
1.37
2.75
1.00
2.13
1.20
1.02
1.35
1.15
1.51
0.91
0.96
0.88
1.17
1.44
0.82

1.09
0.90
1.01
0.76
1.17
0.82
0.90
1.01
0.95
1.04
1.12
0.82
0.41
1.83
1.50
0.60
1.14
0.83
0.96
0.81
0.71
0.86
1.00
1.88
0.79
0.83

1.80
1.50
1.40
0.94
1.30
0.66
0.67
1.40
1.97
1.30
1.50
2.09
1.14
0.46
0.93
0.84
0.73
0.79
0.86
0.92
0.73
0.71
0.81
1.67
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EXPRESSION
OVER (above 1.30)
UNDER (under 0.70)
NORMAL (0.71-1.29)
Table 6.
qPCR Expression values for a
small cohort of ID individuals.
The samples were all derived
from blood via a PAX tube and
RNA isolated, DNAsed and
reverse transcribed. The cDNA
was diluted to 30ng/ul +/1ng/ul. In each run all samples
were compared to the same
normal control male.

There were some genes that would not qPCR to an acceptable degree of quality
satisfaction and were removed from the results. These genes are RAB26, CDC42,
ILRAPL1, REP, H-RAS, and RAB7. A set of normal controls was first run to test the
primers for reliable results. Differences in RNA expression between samples coming
from cell lines and blood gave the same overall result, but with different magnitudes.
To remove the different source variable, blood samples were used for all subsequent
testing. Expression of each gene was run for each sample in triplicate with the
housekeeping gene run in duplicate. The critical threshold (CT) average of the samples
was subtracted from the CT average of the housekeeping gene. This value was
subtracted from the normal male control CT value and multiplied by 2, commonly
known as the delta, delta CT method. Each gene was qPCR tested twice for validation
of the original results.
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Figure 27. Similar patterns of expression among ID patients.
27A The FMR1 positive patient is compared to the Xq25 duplication patient.
27B The ATRX, XNP normal patient is compared to Xq25 duplication patient.
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Figure 28. Similar patterns of expression.
28A The ID patient with no known etiology is compared to the Xq25
duplication patient.
28B The MECP2 deletion is compared to the patient to the Xq25
duplication patient.
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CHAPTER NINE
RESULTS
RT2 Profiler Super Array
Determining what role the over-expression of AIF may play in the Xq25
patient’s disorder is undetermined. AIF is an apoptosis-initiating factor, but it has two
other roles it performs in the cell, a role in the respiratory chain complex I and a potent
redox function. The harlequin mouse mutation is a proviral insertion into the AIF gene.
This mutation displays 80% loss of gene expression and it is mentioned that these
mutant mice have progressive degeneration of terminally differentiated cerebellar and
retinal neurons. (Klein, J. A. 2002). AIF is also found in the multiprotein signaling
complexes in the postsynaptic terminal of central nervous system synapses. These
multiprotein signaling complexes are essential for the induction of neuronal plasticity
and cognitive processes in animals. This find makes AIF a potential target for future
testing and resequencing of X-linked cognitive disorders (Laumonnier, F. 2007). Loss
of AIF causes disturbances in cell cycle regulation and this dys-regulation has been
implicated in neurodegenerative disorders. Animals in which have AIF is down
regulated undergo unscheduled cell cycle re-entry, a molecular mechanism by which
free radical damage can lead to neuronal death (Klein, J.A. 2002). There appears to be
information about down-regulated AIF expression, but little information concerning upregulation of the gene. Can up-regulation cause an increase of redox activity? Is the
optimal mitochondrial respiratory function disturbed by up regulation of AIF
(Stambolsky, P. 2006)? These are questions that need to be answered but not in this
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project. The question asked in this project is, what does AIF over-expression in our
Xq25 patient do to the expression of other genes in its own and other apoptosis
pathways? To look at the expression levels of genes in a patient that may have pathway
changes, a small array system that targets only genes known to be involved in the
pathway of interest is commercially available. The SuperArray by Bioscience
Corporation called the RT2 Profiler PCR Array is not as global as the array CGH or a
large-scale expression array system. Instead these arrays are pathway focused gene
expression of a precise and specific known pathway. RT2 Profiler PCR Array combines
the quantitative performance of the SYBR® Green-based real time PCR with multiple
gene profiling capabilities of a microarray (Arikawa, E. 2008). The PCR array is a 96
well format containing 84 related genes, 5 housekeeping genes and three controls
(Figure 29).

Figure 29.
The RT2
Profiler TM
PCR Array
layout.
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The genes of the apoptosis pathway were explored using RT profiler by
comparing two normal controls to the Xq25 duplication patient with increased
expression of AIF. 84 genes were screened, but 12 were removed due to conflicting or
unreliable results from the analysis data. In the Xq25 duplication patient the following
genes were found over expressed in the apoptosis pathway, BCL2, BIRC3, BNIP3,
TNFRSF10B, TRAF3, and GAPDH. The under expressed genes in the patient are,
BAG1, BCL2L11, BID, NAIP, BNIP3L, CARD6, CARD8, CASP1, CASP10, CASP4,
CASP5, CASP8, CASP28, CD40LG, DAPK1, FASLG, IGF1R, LTBR, MCL1, PYCARD,
CD27, TNFSF10, TNFSF8 and TP53BP2 (Table 7).
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Figure 30

Figure 30. RT2 profiler indicates numerous changes in the apoptosis
pathways in the Xq25 patient. The overall gene expression for the
SuperArray is automatically plotted on a dot plot graph by the software. The
patient has 5 genes over-expressed and 24 genes under-expressed showing
they are outside the normal range. The few genes that appear to be outside
the range in the normal controls were also out of range to a greater degree in
the patient. These genes were marked as unreliable results and were removed
from the analysis.
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Figure 31A

Figure 31B

Figure 30.B & C. RT2 Profiler normal controls scatter plot. This indicates
both normal controls have the majority of the data points well within the
normal expression range in the apoptotic pathway.

Figures 31. A&B. The scatter plot shows that the controls have the
majority of their genes within the normal range.
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Table 7.
Gene

Gene extended name

RED = OVER EXPRESSION

Gene Information
BLUE = UNDER EXPRESSION

BCL2

Antagonist of cell death located in
B-CELL CLL/Lymphoma 2 Mitochondria

BIRC3

Baculoviral IAP repeatcontaining 2

BNIP3

BCL2/adenovirus E1B
Intracellular, cytoplasm, organelle,
19kDA interacting protein 3 mitochondria, inner

Tumor necrosis factor
TNFRSF10B receptor superfamily

Unknown

Apoptosis inducing receptor TRAIL-R2

TRAF3

TNF receptor-associated
protein

Tumor necrosis factor (TNF)-receptor
associated factor 3

GAPDH

Glyceraldehyde-3phosphate dehydrogenase

Triggering apoptosis when Tran located
to the nucleus

BAG1

BCL2 associated
athanogene

Intracellular, cytoplasm, organelle,
mitochondria, inner

BCL2L11

BCL2 -like 11 apoptosis
facilitator

Intracellular, cytoplasm, organelle,
mitochondria, inner

BID

BH3 interacting domain
death agonist

Inhibits FAS mediated apoptosis

NAIP

NLR family, apoptosis
inhibitory protein

Neuronal apoptosis inhibitory protein,
telomeric copy

BNIP3L

Bcl2/adenovirus e18 19kDa Intracellular, cytoplasm, organelle,
interacting protein3
mitochondria, inner

CARD6

Caspase recruitment domain A bundle of six antiparallel alpha helices
family member 6
consisting the caspase recruitment domain

CARD8
CASP1
CASP10
CASP4
CASP5

Caspase recruitment domain CARD inhibitor of NF-Kappa Bfamily member 8
activating ligands
Stored in the mitochondrial
Caspase 1, apoptosis-related intermembrane space and released into
cysteine peptidase
cytosol after appropriate apoptotic stimuli
Stored in the mitochondrial
Caspase 10, apoptosisintermembrane space and released into
related cysteine peptidase cytosol after appropriate apoptotic stimuli
Stored in the mitochondrial
Caspase 4, apoptosis-related intermembrane space and released into
cysteine peptidase
cytosol after appropriate apoptotic stimuli
Stored in the mitochondrial
Caspase 5, apoptosis-related intermembrane space and released into
cysteine peptidase
cytosol after appropriate apoptotic stimuli

108

DAPK1

Stored in the mitochondrial
Caspase 8, apoptosis-related intermembrane space and released into
cysteine peptidase
cytosol after appropriate apoptotic stimuli
Role of sCD40L in numerous disease
CD40 ligand TNF
pathologies and having ability to activate
superfamily
proximal and distal immune responses
Calcium/calmodulin-dependent
Death associated protein
serine/threonine kinase which acts as a
kinase
positive regulator of apoptosis

FASLG

FAS ligand, a pro-apoptotic protein
Fas ligand TNF superfamily induced by DNA damage

CASP8
CD40LG

CD27

Insulin-like growth factor 1
Unknown
receptor
Involved in lymphoid organ development
and apoptosis through interaction with
Lymphotoxin beta receptor TRAF3
Involved in programming of
differentiation and concomitant
maintenance of viability but not of
Myeloid cell leukemia
proliferation: isoforms 1 inhibits
sequence 1
apoptosis while isoforms 2 promotes it
Moving in cells undergoing apoptosis
PYD and CARD domain
from the cytoplasm to the perinuclear
containing
periphery
Preligand assembly domain (PLAD) in
CRD1 mediating ligand-independent
CD27 molecule
receptor assembly and signaling

TNFSF10

Tumor necrosis factor
ligand superfamily

TNFSF8

Tumor necrosis factor
ligand superfamily

IGFIR
LTBR

MCL1
PYCARD

TP53BP2

Inducing apoptosis in the brain

Inducing cell death and reducing cell
proliferation of other lymphoma cell lines
Enhancing p53-induced apoptosis, the
Tumor protein p53 binding DNA binding and transactivation function
protein 2
of TP53

Table 7. Genes found misregulated on the RT2 profiler.
Expression changes, red over expressed, blue under expressed, in
the Xq25 patient when compared to normal controls in the
apoptotic pathway.
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This method allows for the visualization of the global changes affecting other
apoptotic pathways due to over-expression on the AIF genes. An alternative
explanation is that some of these genes are misregulated due to over-expression of
RAB33A.
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CHAPTER TEN
DISCUSSION

This study consists of a screening of Ras, Rho and Rab genes with MLPA. Of
the 1152 patients screened from various ID cohorts, duplications as a cause of disease
were established to be rare. In this large group only two patients with duplications were
found, the XNP duplication in one individual and the patient having both GDI1 and
PQBP1 duplicated. The XNP gene sequencing results were initially reported as normal
due to some XNP transcript being present, although further study eventually
demonstrated that full-length XNP mRNA did not exist or was present in a very low
concentration. cDNA sequencing of the transcript was possible most likely due to very
low copy number or large fragments of the transcript being available for amplification.
This suggested there was at least some amount of mRNA transcribed in this patient.
Not until the Northern blot was it shown that the mRNA transcript was at a small
fraction of the normal concentration. Using qPCR to plot the end points of the
duplication, it was determined to be a partial duplication spanning from exon 2 through
31. This partial duplication disrupted the gene and prevented normal synthesis of fulllength mRNA transcript. The PQBP1 duplication portion of the GDI1 and PQBP1 did
not confirm with qPCR, but the GDI1 duplication did. These genes are on different
regions on the X chromosome, and are not in the same vicinity. A pseudogene or copy
number variant (CNV) may be giving the effect of duplication in the PQBP1 gene.
Having a smaller footprint, qPCR hybridization may possibly be more specific. MRC
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Holland has had probes in the past that produced unusual results, removed them from
the kits and replaced them with a potentially better performing probe. A new MLPA
test may clarify this contradiction.
Later, a serendipitous find during MECP2 MLPA diagnostic testing was added
to this project due to the interest in duplications. This duplication is in the Xq25 region
and spans the genes BCORL1, ELF4, AIF and RAB33A. The affected female has a
phenotype resembling Rett syndrome, but with no mutation in either MECP2 or
CDKL5. How one or more of the duplicated genes causes a similar phenotype to Rett
syndrome was addressed by qPCR and RT SuperArray. Looking for interactions among
genes, dosage changes on a broader scale were explored to determine if there might be
a pattern to the genes misregulated that cause intellectual disability. There may be
concerted expression directed by one or more genes in the pathway. When two genes
control the expression of the same group of genes in the same pathway by some linking
factor, they may give similar results in clinical findings.
There were other X-linked duplications and deletions discovered during the
course of this study that appear to be clinically significant. The screening of 300
patients from two cohorts, males with ID and hypotonia and male probands with a
suspected X-linked etiology, with the MRX MLPA kit by MRC Holland and the
synthetic probe set discovered a FACL4 deletion and a patient with an FMR2 point
mutation. There were also autosomal dosage aberrations detected at 1p36 in two
patients with phenotypes similar to known X-linked conditions.
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FACL4 Deletion
The FACL4 deletion was found on the MRX MLPA. At the time it was
unknown that other work at Greenwood was being performed to determine the
breakpoints of this previously detected deletion. The FACL4 deletion was an alteration
that had been identified in a kindred with two affected males. The males were already
being treated for Alport syndrome. In the literature, a patient with a deletion in three
genes located at Xq22.3, COL4A5, FACL4 and AMMECR1, produced an Alport
syndrome phenotype. FACL4 deletion alone is known to be associated with nonspecific X linked intellectual disability and alterations in the protein disrupt the
pathway of lipid metabolism (Longo , I. 2003). The affected males were found to have
a deletion from exon 1 of COL4A5 through exon 12 of FACL4. The MLPA data
narrowed the breakpoint range to be between exon 10 and exon 15 of the FACL4 gene.
Later, with sequencing the breakpoint was found to be in exon 12 of the FACL4 gene.
FMR2 Missense Mutation
The FMR2 point mutation was found while screening the cohort of males with
apparent X-linked intellectual disability with the MRC Holland MRX MLPA kit. The
probe for exon 4 in the FMR2 gene had very low with a value of 0.07. Upon further
investigation, sequencing identified an FMR2 c.474C>T (p.P158S) alteration within
the probe ligation site. The subsequent change was analyzed on the “Sorting Intolerant
From Tolerant” (SIFT) (Ng, P. C. 2001) and Polyphen (prediction of functional effect
of human nsSNPs) programs and the change was predicted to be tolerated due to
changes in this amino acid across non-mammalian species. To pursue the finding
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further, a primer set was designed to modify the sequence to produce an XbaI
restriction site if the individual was positive for the c.474 C>T change. 658 normal
controls were restricted and there were 12 positives found, but upon sequencing all
were found to be normal. This result assists in making a better case that this change
may, in fact, be the cause of the features in the patient. Expansions in the triplet repeat
associated with methylation of FMR2 are quite rare, and are reported 25 fold less
common than FMR1 triplet repeat expansions associated with Fragile X syndrome
(Brown, W. T. 1996), (166 Knight, S. J. 1996). The phenotype of this patient is
compatible with an FMR2 related diagnosis, with the main clinical features being lack
of dysmorphic features, speech delay, reading and writing problems, learning
difficulties and behavior concerns (Knight, S. J. 1996). Most IQ tests identify them to
be low normal or mildly retarded, with an average of 70, but the range is broad and
some are apparently normal suggesting tissue mosaicism (Brown, W. T. 1996). FMR2
missense mutations have not been reported in the literature, likely due to the rarity of
trinucleotide expansions and subsequent lack of interest from a sequencing standpoint
in this gene. An increased number of normal controls are necessary to be more
confident about the potential pathogenicity of the point mutation detected in this case.
The patient with the FMR2 point mutation has developmental delay, delayed speech,
delayed motor skills, and learning problems. The unaffected mother of the child was
sequenced and found to be a carrier. Later, the maternal grandparents were sequenced
and the grandmother was found to have the change but is also unaffected. In the clinical
records it was found that the X inactivation of the mother was normal. There are no
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other family members on the maternal side exhibiting learning and developmental
disabilities making it difficult to establish segregation of the alteration with disease. In
the future, we hope to identify additional maternally related males that may be useful in
determining with greater certainty, the clinical significance of this alteration.
GDI1 and PQBP1 Duplication
Both GDI1 and PQBP1 appeared to be duplicated by MLPA in one affected
patient. However, qPCR was only able to confirm duplication in the GDI1 gene, but not
in PQBP1. Alterations in these genes are known to cause intellectual disability
(Madrigal, I. 2007). It is unclear if this finding is the cause of disease. Expression of
the two genes needs to be explored to verify they are in agreement with the qPCR data.
MRC Holland now has kits that screen other regions of both genes that may help to
clarify the initial findings.
Synthetic MLPA Probe Set
The design and development of the synthetic MLPA probe set afforded the
ability to find dosage aberrations in X-linked genes that are usually only sequenced
during the course of diagnostic testing. The most significant finding with the synthetic
probe set was a partial duplication in a patient from the ID with hypotonia cohort. In
this kindred, there are three affected males in two generations that exhibit features of
ATRX syndrome. ATRX syndrome is caused by loss of proper XNP protein function
(Villard, L. 1997). Initial sequence-based XNP diagnostic testing was unable to confirm
the clinical diagnosis in this family. The obligate female carriers were tested for Xinactivation status and were highly skewed, which is consistent with the clinical
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diagnosis in the males. Only after designing a synthetic MLPA kit that included several
probes for the XNP gene was the partial duplication discovered. The proband in this
family had intellectual disability, hypotonia and suspected X-linked etiology. Other
family members were tested by MLPA with affected males and obligate carrier females
being concordant for the XNP duplication. The breakpoints of the duplication were
refined using qPCR, with results indicating that the duplication only affects the XNP
gene. The flanking genes FGF16, ATP7 and PGK1 were all found to have normal
dosage. Using qPCR and working inward from the ends, moving across the XNP gene,
the duplication was found to span from exon 2 through 31. Due to the highly repetitive
nature of the introns the breakpoints were found to lie intronic between exon 1 and 2
within a 2,699 base span and between exons 31 and 32 within a 7,480 base region. Alu
repeats were prevalent in the breakpoint areas and this repetitive region, which made
developing further qPCR primers to define the breakpoints at the nucleotide level
impossible. These Alu repeats are the probable cause of the duplication. On further
review, the MLPA probe for XNP exon 2 appeared unreliable due to giving false
positives on large number of samples and the initial results for this single exon were
discounted. Each XNP exon 2 positive was further studied by qPCR and determined to
be false, giving confidence that there were no other XNP duplications overlooked by
this study.
Duplications have been found in other X-linked genes causing mental
retardation (Bauters, M. 2008), (Wang, N. J. 2008), (Ahn, J. W. 2007), (Depienne, C.
2007), (Kirchhoff, M. 2007), (Madrigal, I. 2007), (Thienpont, B. 2007), (Torres-Juan,
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L. 2007), (Sharp, A. J. 2005), (Woodward, K. J. 2005). The MECP2 gene located at
Xq28 is associated with Rett syndrome in females. Mutations and loss of function of
the gene is characterized in females by a period of normal development for the first 6 to
18 months followed by progressive deterioration and degenerative mental retardation
(Chahrour, M. 2007), (Villard, L. 2007), (Moretti, P. 2006). A loss of MECP2 causing
Rett syndrome in males is typically thought to be an X-dominant condition that is
expected to be lethal in hemizygous males (Van Esch, H. 2005) (Moog, U. 2005).
Duplications of MECP2 causing overexpression of the gene are found in males with
syndromic mental retardation. Males with MECP2 duplications are quite different than
their female Rett counterparts. They clinically exhibit hypotonia at birth and develop
symptoms with psychomotor developmental delay occurring very early in life. Later in
life other common symptoms include hypotonia that gives way to spasticity,
predominantly of the lower limbs seizures and recurrent infections. MECP2 profiles an
example of the difference in the phenotype that may be derived from over-expression
versus loss of function in genes (Bauters, M. 2008), (Van Esch, H. 2005). The XNP
gene expression status of the K8922 family with the XNP duplication is one that is the
same as the phenotype caused by mutations that delete, truncate or inactivate ATRX
protein (Gibbons, R. 2006), (Villard, L. 1997). The Northern blot revealed the cause of
disease was not due to two-fold expression of the XNP gene, but rather a nearly
complete loss of XNP expression. Our observations are consistent with the loss of
normal XNP transcript due to a position effect of the duplication. At this time,
delineation of the location and orientation of the duplication is not complete. What is
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clear is that loss of ATRX protein causes the clinical presentation in the affected males
of this family. The Nimblegen X-Array had limited coverage in the XNP region and
was deemed supportive but not conclusive evidence for the duplication. This array
system also noted a 244kb duplication centromeric to the XNP gene. CGH using the
OGT X-Array clearly confirmed the MLPA and qPCR duplication findings. This
platform failed to confirm the other centromeric duplication found by the Nimblegen
array. High-resolution mapping of the XNP duplication breakpoints has proven to be
difficult due to highly repetitive sequence found in this region, particularly in the
intronic regions containing the suspected endpoints. It is the repetitive nature of these
areas that may have lead to this intragenic duplication. In highly homologous segmental
duplications, an enrichment of Alu sequences has been found in the vicinity of the end
points and in 27% of these duplications, they terminate within an Alu repeat
(Woodward, K. J. 2005). While designing qPCR primers for intronic XNP sequences,
BLASTS (NCBI) many times brought up Alu sequence. DNA repair mechanisms of
double stranded breaks (DSBs) repaired by homologous recombination and nonhomologous end joining can cause deletions and duplications. During crossing over
mispairing between homologous segments, strand slippage and unequal sister
chromatid exchange can also generate deletions and duplications.
High resolution of the duplication end points cannot be resolved due to the
repetitive nature of this area and the OGT array does not have representative data points
in the 5’ area between exons 1 and 3, but does confirm that exon 31 is the last exon of
the duplication. Duplications play an important role in mental retardation and under
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expression of the XNP protein appears to be the causative agent of ATRX syndrome in
this family (Thienpont, B. 2007). Other similar cases of novel duplications interfering
with synthesis of normal transcript from X-linked genes will likely become apparent
with the implementation of high-resolution dosage based methodologies. These
duplications will likely produce a similar phenotype to nonsense mutations and
deletions. Duplications that are responsible for a two-fold increase in expression in this
gene may very well lead to a clinically distinct phenotype. We conclude that much is
yet to be learned about gene duplications and their mechanisms that cause disease.
L1CAM/NEMO Duplication
An L1CAM/NEMO duplication was found using the synthetic MLPA kit in the
hypotonia cohort and was subsequently tested on the MRC Holland MECP2 MLPA kit
for confirmation. Instead of independently doing follow up with this find, it was turned
over to a project being conducted at the Greenwood Genetic Center on MECP2
duplications in males. This work which resulted in two papers: Recurrent infections,
hypotonia and mental retardation caused by duplication of MECP2 and adjacent region
in Xq28 (Friez, M. J. 2006) and Nonrecurrent MECP2 duplications mediated by
genomic architecture-driven DNA breaks and break induced replication repair (Bauters,
M. 2008). Xq28 duplications that include MECP2 appear to be variable in length and
involve different flanking genes from patient to patient. The clinical findings are all
very similar in males with these duplications and these features are due to the MECP2
gene being involved in each case. Therefore, it appears that MECP2 plays the largest
role in most of the features of this syndrome. The MECP2 duplications and the XNP
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duplication have many features in common. Included in these features are the degree of
Alu interspersed repeats that appear to be high at each breakpoint in the XNP
duplication. Contrary to the MECP2 GC rich region interspersed with Alu, the introns
of XNP have long runs of As and Ts with Alu repeats interspersed. The size of the XNP
duplication (244 kb) is slightly larger than the MECP2 duplications that range from 0.3
to 2.3 Mb. This may be an artifact of the large size of the XNP gene. The XNP
duplication is contiguous and does not appear to be a part of a larger complex
rearrangement (Bauters, M. 2008).
1p36 Duplications and Deletions
1p36 deletions are known to cause developmental delay and intellectual
disability (Battaglia, A. 2008), (D'Angelo, C. S. 2006), (Yu, W. 2003), (Shapira, S. K.
1997). We considered the SKI gene a candidate gene for a Rett-like phenotype and
using this gene located at 1p36 as an autosomal control on the synthetic MLPA kit
allowed simultaneous dosage determination in this region. Of the accumulative results
from all the cohorts screened, five patients were found to have a 1p36 deletion or
duplication. Two of the five patients confirmed by array CGH and/or FISH. Of the
three remaining, one patient had a limited amount of DNA available and the family was
out of contact for a blood redraw and two samples were deemed to have degraded
DNA. These samples were run on the MRC Holland MLPA MECP2 kit to address the
DNA data integrity concerns and failed. Degraded DNA is known to give false readings
with MLPA and these findings are now considered false positives.
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The two male patients, #60175 (from the L1CAM sequencing negative cohort)
and #56560 (from the ATRX sequencing negative cohort) confirmed on the MRC
Holland 1p36 MLPA kit, which became available approximately a year after than these
initial findings. Although his routine karyotype was normal, the #56560 patient data on
the 1p36 kit was interpreted as a complex rearrangement with one duplication and two
deletions. His phenotype included developmental delay along with severe intellectual
disability and respiratory infections. His physical features of clinical interest were a
broad nasal bridge, mild to moderate hypotonia, V-shaped mouth and a short neck. This
phenotype is very reminiscent of ATRX syndrome except for the respiratory problems
that appear to be similar to these seen with MECP2 duplications. With good reason,
most of his testing to date had focused on genes on the X chromosome. This patient
also had the Spectral Genomics Array CGH test to sort out what appeared to be noisy
MLPA data. MLPA is normalized data and when duplications are detected other data
points not involved drop below the normal range of 1.0. With deletions, normalized
MLPA data points not involved in the deletion rise above the normalized value of 1.0.
This patient having one duplication and two deletions made it very difficult to sort the
artifacts of normalization from the real duplication and deletions. The array CGH
confirmed the MLPA findings plus added another deletion on the q arm of chromosome
1. The significance of this deletion is unknown. The GGC Cytogenetic Laboratory ran
FISH only on the p arm of chromosome 1. This confirmed the larger duplication and
deletion, but did not find the smaller deletion due to technical limitations. The parents
of # 56560 were found to be normal on the MRC Holland 1p36 MLPA. It would be
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very difficult to single out one of these deletions or duplications as the cause of the
disease, and one must assume that the gains and losses found in these genes all
contribute in some way to the phenotype.
The second patient (#60175) has severe intellectual disability, hydrocephalus,
delayed speech, delayed motor abilities and seizures. He originally came in for L1CAM
testing. He was found positive for a 1p36 deletion with both the synthetic and the MRC
Holland 1p36 MLPA. Unlike the former patient this deletion was singular, large and
covered approximately 3-4 MB. The Spectral Genomics Array CGH was performed
and confirmed the deletion found by MLPA. This patient also had a second array run,
the Agilent 4X44K Oligo Array, to confirm the previous findings. Clinical significance
is clear in this region because the deletion is quite large and appears to be contiguous,
even though there are many known smaller CNVs located within the deletion. The
FISH data confirmed the array data and a report sent to the attending physician stating
this deletion was likely the disease-causing agent in this patient.
The two very different presentations of disease caused by duplications and
deletions in the 1p36 region of these two patients demonstrate how dosage aberrations
can produce very diverse clinical conditions. Both patients were found using the
synthetic probe set, one with duplication, and the other with a deletion of the SKI gene.
Although each patient has a deletion(s), these deletions were in slightly different
regions on chromosome 1 and did not include many of the same genes. The #56560
patient’s MLPA data found the duplication included TNFRS4, TNFRS18, CAB45,
SCNN1D, DVL1, GNB1, GABRD, SKI, PEX10, FLJ10782, and ARMD2 genes and the
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two deletions included DFFB, NPHP5, ICMT, CAMT1, TNSFS, PARK7, and then
RIZ1, PRMD2 and CASP9. The #60175 patient’s MLPA data shows a contiguous
deletion with the loss of HES4, GIP2, AGRN, TNFRSF4, TNFRSF18, CAB45,
SCNN1D, DVL1, GNB1, GABRD, SKI, PEX10, FLJ10782, ARMD2, PRDM16, TP73
and DFFP. One patient (#56560) had SCNN1D, DVL1, GNB1, GABRD, SKI, PEX10
duplicated while the other (#60175) had these genes deleted. The changes in the #
56560 patient again adds differences in gene dosage, both up and down in a small
region. The clinical differences among these patients (#56560 and #60175) are caused
by multiple variables. #60175 has a 1p36 deletion and which is characterized by severe
intellectual disability, delayed growth, seizures, malformations, hearing and vision loss,
distinct facial features, congenital heart defects and nervous system anomalies. These
features may or may not be present, depending on the size of the deletion. Intellectual
disability varying from mild to severe is one such feature that is dependent on the size
of the deletion. #56560 having one duplication and two deletions has features that are
due to the different components of a complex rearrangement.
Xq25 Discussion
During routine diagnostic MECP2 MLPA testing, a female was discovered to
have an Xq25 duplication based on an abnormal ratio of a control probe. Born to
normal parents, the proband has developmental delay, hypotonia, displays hand
wringing and when upset breathing becomes unusually rapid. She has a normal MRI.
Her phenotype is similar to that routinely seen in females with a loss of MECP2 protein
function (Jordan, C. 2007), (LaSalle, J. M. 2007), (Nikitina, T. 2007). By array, the
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duplication was found to start at base 128,889,500 to 129,165,000 on the X
chromosome, making a 275.5Kb duplication. After analysis of the breakpoints on the
Nimblegen array, the duplication was found to encompass four known genes and three
unknown genes. This study focused on the four known genes, BCORL1, ELF4, AIF,
and RAB33A. Breakpoint analysis from the array data appear to be in regions that are
void of genes, therefore gene disruption, protein truncation or a loss is less likely to
contribute to the phenotype. Using qPCR it was found that two of the four known
genes were over- expressed due to the duplication. This is interpreted to mean that
over-expression of either and one or both may be the cause of the disease. Duplications
in the X chromosome have been shown to cause disease in females when the affected
chromosome is not preferentially inactivated (Muers, M. R. 2007), (Tachdjian, G.
2004), (Armstrong, L. 2003), (Portnoi, M. F. 2000), (Monaghan, K. G. 1998), (GarciaHeras, J. 1997). Initial qPCR findings show normal expression in BCORL1 and ELF4
and over-expression in AIF and RAB33A. To determine which X the proband inherited
from each parent, the father was tested to use his androgen receptor repeat length from
the XI assay as a marker to discriminate between the maternal vs. paternal X
chromosome (Allen, R. C. 1992). The mother had normal X inactivation and both
parents were normal on the MRC Holland MECP2 MLPA, which initially identified the
duplication. This makes the Xq25 duplication appear to be a de novo rearrangement.
The X inactivation of the proband was found to have a 92:8 ratio. The X inactivation
studies implied that the paternal X was the one being preferentially expressed in the
daughter. It is known that females with a duplication on one X chromosome often have
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preferential inactivation of that chromosome and appear normal, but these findings
more typically occur when the duplication is familial. This implies that some X
chromosome duplications do not cause abnormal phenotypes in females and are passed
through generations where others cause abnormalities and are more likely de novo
events (Garcia-Heras, J. 1997), (Portnoi, M. F. 2000), (Tachdjian, G. 2004). To further
confirm which X, (maternal vs. paternal) was being preferentially expressed,
sequencing was performed on numerous X-linked genes looking for a heterozygous
coding SNP that would show skewed expression in an RNA sample. A MED12 SNP
was identified which allowed characterization of the parents and the daughter’s
genotype. The mother’s DNA had a C nucleotide and the father’s DNA had an A
nucleotide and the daughter was heterozygous having both the A and the C. The normal
control was also heterozygous having both the A and the C. The RNA was then reverse
transcribed and sequenced using cDNA as a template. This result clarified which X is
expressed and it appears to be in agreement with the known X-Inactivation ratio
previously discussed. The RNA sequence showed clearly that the daughter was
expressing the father’s X at 92% and the mother’s at 8%. This leads to the belief that
the father’s X-chromosome is the one that is preferentially active and harbors the
duplication that has already been implicated by demonstrated over-expression of
RAB33A and AIF. This also suggests that the over-expression of the AIF gene does not
cause rampant premature death in the cells. Excessive apoptotic events are predicted to
not be compatible with life because AIF is also known to play roles in the synaptal
complex and during early development (Laumonnier, F. 2007). Both genes, RAB33A
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and AIF are normally inactivated on the inactive X chromosome, indicating these genes
may be dosage sensitive and cause for disease when misregulated (Brown, C. J. 1997).
Given the expression of RAB33A and AIF two additional studies were pursued.
One study focused on Rab and Ras gene changes in expression while the other study
focused on AIF and explored expression in other apoptotic pathway genes. Both
studies used qPCR on different platforms. The RAB33A study focused on Rab, Ras and
Rho genes that had the potential to be associated with the MECP2 phenotype, while the
AIF study recognized and noted the changes caused by over-expression of AIF relative
to other factors involved in apoptosis.
The Rab gene family is very closely linked and many of these members interact
and have expression levels that are interdependent upon each other (Gurkan, C. 2005).
The Rab gene family performs essential cell duties involving trafficking, recruitment
and endo/exocytosis of proteins. They also play a part in scaffolding, membrane
budding, vesicle release and many more cellular functions. When these genes are
compromised in some way, causing defects in the vesicle trafficking machinery, the list
of associated human disorders is substantial. The Rab cycle consisting of (REP) Rab
escort protein, (RabGGT) Rab geranylgeranyl transferase, (GDI) RabGDP dissociation
inhibitor, (RabGEF) Rab guanine nucleotide exchange factor, and (RabGAP)
RabGTPase activating protein must all work in concert. A deviation in one of these
genes that is a part of a specific Rab cycle will bring about changes in other parts of the
system. Multifactoral conditions have already been linked to abnormalities in vesicle
trafficking, contributing to diseases such as type 2 diabetes and Alzheimer disease,
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while Tau, a microtubule-associated protein has been found in dementia, and
neurodegenerative disorders (Gissen, P. 2007). The effect of multiple genes being
misregulated in the Rab family is predicted to cause some form of phenotypic
expression with clinically significant relevance.
In the proband, expression studies of twenty six genes (Figure 26) thought to be
involved with RAB33A found that twelve of these genes were over-expressed and three
under-expressed. In comparison, a MECP2 female patient had twelve genes overexpressed and three under-expressed. Nine of the over-expressed genes in the MECP2
patient were also over-expressed in the Xq25 patient. There were no under-expressed
genes that coincided. Another patient referred for ATRX testing and was found to have
normal XNP sequencing result, displayed similar results in expression changes when
compared to the Xq25 proband. This patient had eleven genes over-expressed and one
gene under-expressed. Six of the eleven genes that were over-expressed coincided with
the Xq25 patient and five matched the MECP2 proband in over-expression. ATRX is
known to interact with MECP2 (Nan, X. 2007) and this patient may have another
mechanism impeding that interaction causing the profile seen on qPCR. The underexpressed gene in the pseudo-ATRX did not match the Xq25 or the MECP2 probands.
This data is supportive that there may be a reproducible profile of certain genes that are
affected in some intellectually disabled populations. Review: Figures 27.A&B and
28.A&B.
MECP2 gene mutations with loss of protein function cause Rett syndrome a
neurodegenerative developmental disorder in females. In males, MECP2 over-
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expression due to gene duplication causes a different developmental disorder.
Therefore, it appears MECP2 is extremely sensitive to dosage differences with loss of
function mutations and whole gene duplications manifesting different phenotypes.
MECP2 has been found to be primarily an activator of over 2500 genes and secondarily
a repressor of over 400 in the hypothalamus in mice (Chahrour, M. 2008). MECP2
binds to the promoters of genes with CREB1. CREB1 a transcriptional activator is
found at the promoter of genes MECP2 appears to activate. MECP2 also activates
CREB1 by binding its promoter. This also produces a CREB1 induced microRNA
(miR132) that represses MECP2 translation, thereby, making a negative regulatory
loop. MECP2 repression does not involve CREB1. It is not surprising to find that
mutations in the genes regulated by MECP2 or CREB1 produce a Rett-like phenotype
when disrupted. An example in mice is the ataxin 2 binding protein 1(A2bp1), a gene
that regulates splicing of neuronal genes, is a repression target of MeCP2. Disruption
of A2BP1 has been identified in patients with ID and epilepsy and autism susceptibility.
Another gene, GAMT is a target of MECP2 activation. Patients with GAMT deficiency
suffer severe ID, absent or limited speech development, seizures and hypotonia
(Chahrour, M. 2008).
By searching literature and following pathways of genes that influence one
another led to the following logic. There will be genes in common that demonstrate
abnormal expression levels that are due to either loss of MECP2 function or RAB33A
over-expression. RAB33A is a co-regulator of RAB3A, which in turn is a welldocumented hub. RAB1A, which is over-expressed in the Xq25 proband, interacts with
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CREB1 the co-activator of MECP2. MECP2 is shown to up regulate RAB3A. MECP2
interacts with CREB1 as a co-activator but not as a repressor. Loss of MECP2 would
lead to the loss of protein of the genes activated by both MECP2 and CREB1. Genes
that MECP2 represses on its own would be up-regulated, while genes regulated by
CREB1 alone may be up-regulated due to more CREB1 available due to the loss of
MECP2 interactions.

Searching the database BIOGRID, a database that has pulled

data of gene interactions together from major publications, making available protein
interactions via a search is a quick and powerful tool to use for gene interactions (Ay,
N. 2007). BIOGRID has found that CREB1 interacts with RAB1A and the Chahrour et
al. paper has determined and validated the CREB/MECP2 relationship as well as a
MECP2/RAB1A relationship. Another gene over-expressed in the Xq25 proband is
RABAC1. Many genes interact with RABAC1, these are GDI1, RHOA, RAB5C, RAB7,
RAB22A, RAB4A, RAB6A, HRAS, NIF3L1, RAB17, RAB33A, CABC1 and FRX2.
RABAC1 does not control expression levels directly, but plays a large role in the
synchrony of the cell trafficking of proteins. RABAC1 is a Rab acceptor hub that directs
protein trafficking in the cell, making it a good candidate for causing disease. All of
these genes mentioned were chosen first from literature searches and deemed good
candidates for abnormal expression in the Xq25 patient due to RAB33A overexpression. Later, BIOGRID (Ay, N. 2007) confirmed the linked interactions of these
proteins, plus added to the number of genes that may be affected due to an increase or
decrease of interactions that may affect many other proteins downstream. The
downstream cascade grows as a consequence of over expression in these twelve genes
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in the Xq25 proband and the effect is magnified when looking at other genes that may
also interact.
The following interactions are taken directly from the BIOGRID database. In
the results, the CABC1 gene was over expressed in the MECP2 patient and the Xq25
patient and this gene is known to associate only with RABAC1. FXR2 is also overexpressed in the MECP2 and Xq25 patients and interacts with 66 other known genes,
thereby causing a potential cascade of dysregulated pathways. The MECP2 patient is
shown to have up-regulation of the GDI1 and MYO5A genes where the Xq25 patient
does not, but both are up regulated for NIF3L1. NIF3L1 interacts with 38 other genes
including an apoptosis repressor gene NOL3. PAK1 is under-expressed and RAB27A is
low in the Xq25 patient. RAB27A interacts with 42 other proteins, some of which are
expressed only in the brain. Genes over-expressed in the Xq25 patient are RAB1A,
RAB11B, RAB17, RAB22A, RAB23A, RAB33A, RAB3A WASF1 and RAB40B; whereas,
the corresponding genes over-expressed in the MECP2 patient are RAB33A, RAB1A,
RAB22A, RAB23A WASF1 and RAB3A. The most important gene is likely RAB3A as it
interacts with 35 other genes and is co-regulated with RAB33A and up regulated by
MECP2.
It should be noted that the expression of the NIG3L1, RAB11B, RAB17,
RAB22A, RAB33A, RAB40B, SNP29, and RABAC1 is over-expressed in the patient that
came in for ATRX testing and found to have normal sequencing. In this patient, the
only other gene over-expressed that is different from those found in the Xq25 patient is
the SNAP29 gene. This gene interacts with 15 other proteins including some found in
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brain, but mostly those that have vesicle-membrane-fusion properties. These aid the
vesicle to fuse with the membrane, become one, and with this secrete the cargo of the
vesicle to the outside of the cell. In the synaptal complex this is a crucial function for
normal brain functioning.
The FMR1 patient has a high level of RAB17, RAB40B, WASF1 and low levels
of RAB23A. RAB17 interacts with chromatin remodeling protein CHMP6 and WASF1
interacts with 11 other proteins. Little is known about RAB23A as there is no data for
known protein interactions. The unknown patient had a very different profile than the
others studied. The only genes over-expressed were RAB3A and RAB40B while
RAB33A and RAB4B were under-expressed. The MECP2 patient also had RAB4B
under-expressed.
The RAB genes in this study and those in the Chahraur et al. paper (167
Chahrour, M. 2008) provide more insight into genes regulated by MECP2 and how a
similar phenotype might be generated (Table 8).
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Table 8.

SUMMARY OF GENES FOUND REGULATED BY MECP2
THAT INTERACT WITH RAB FAMILY GENES
1

2

3

4

UP
DOWN
#
GENE ACTIVATED REGULATED REGULATED
INTERACTIONS BY MECP2 BY MECP2 BY MECP2
FXR2 53
8
4
1
NIF3L1 34
3
2
0
PAK1 27
2
1
1
WASF1 6
1
0
0
RAB3A 17
1
2
0
RAB1A 16
4
0
1
RAB27A 20
3
0
2
RAB11B 1
0
0
0
RAB17 3
1
0
0
RAB22A 1
0
0
0
RAB33A 4
0
1
0

5
PERCENT
GENE
INTERACTIONS
WITH MECP2
25%
15%
15%
17%
18%
31%
25%
0%
33%
0%
25%

Table 8. Summary of genes regulated by MECP2 that interact with
Rab family genes. These genes were under or over-expressed in this study
in the Xq25 patient and have interactions with other genes. Of these genes
in column 1, some are regulated by MECP2, columns 2, 3, and 4
(Chahrour, M. 2008). Column 5 is the percent of the total number of gene
interactions regulated by MECP2 that also interact with the specific Rab.

There are eight of the genes in this Rab study that are listed in the Chahrour et
al. paper. These regulated genes are RAB1A, FXR2, NIF3L1, SNAP29, RAB27A,
RAB3A, PAK1 interacting protein and WASF1. The cascade continues as these genes
have interactions with numerous other genes that are also regulated by MECP2. Each of
the genes in this study interacts with a secondary level of genes. The number of
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secondary interaction genes is listed in Table 4. and a percentage of these are activated,
up-regulated or down-regulated by MECP2. The percentage is the number of genes
regulated by MECP2 over the total number of known gene interactions for that specific
gene. Specific genes may be seen in Appendix F. Some of these genes are recognized to
be associated with intellectual disability diseases whereas the unknown genes may be
good candidates for further study. The patterns of expression with the qPCR of the
clinically different patients in their Rab and Ras genes remind us that dysregulation of
one gene is not likely alone in causing disease. It is appreciated that many genes, acting
in concert with the interactive pathways cause disease. This phenomenon is again seen
in a very different gene, AIF. This gene is known to play a role in synaptic protein
complexes and is crucial for proper development (Delettre, C. 2006), (Modjtahedi, N.
2006), (Vahsen, N. 2006), (Ishihara, N. 2005), (Vahsen, N. 2004), (Klein, J. A. 2002).
There is up and down regulation occurring from the over-expression of AIF in the Xq25
patient. The RT2 Profiler

TM

PCR SuperArray clearly shows there are genes over and

under-expressed in other apoptotic pathways in this patient that are not in the normal
controls. There were a small number of genes that were over-expressed to questionable
degrees in one or the other control and these genes were removed from analysis as
being false positives. Many runs would have to be done for significant statistical
analysis, but exploring a new methodology while visualizing the expression status of
the apoptosis pathway in the Xq25 patient was accomplished. The list from the RT
Profiler Super array of genes found in apoptosis pathways that appear to be upregulated compared to two normal controls are BCL2, BIRC3, BNIP3, TNSFRSF10B,

133

TRAF3 and GAPDH. Surprisingly there were more genes down-regulated with AIF
over expression. These down regulated genes are; BAG1, BCL2L11, BID, NAIP,
BNIP3L, CARD6, CARD8, CASP1, CASP10, CASP4, CASP5, CASP8, CASP28,
CD40LG, DAPK1, FASLG, IGF1R, LTBR, MCL1, PYCARD, CD27, TNFSF10,
TNFSF8 and TP53BP2. It appears there are mechanisms that are in place to keep
apoptosis pathways in check, suggesting AIF is a repression regulator of other apoptotic
pathways. It is known that when a cell signals damage, an apoptotic cascade is set in
motion. If one apoptosis mechanism falls short then another will initiate. Once cellular
pathways commit to one mechanism or pathway, it will accomplish the process
(Munoz-Pinedo, C. 2006), (Chu, C. T. 2005), (Ishihara, N. 2005), (Joza, N. 2001). It is
speculated that with a large number of Caspase genes down regulated, that AIF has
some repressor activity that prevents the Caspase apoptotic pathway from initiating.
These apoptosis genes are not Rab, Ras or MAPK like those seen throughout this
project, but it is interesting to note that there are also global changes initiated by one
gene being misregulated. The idea of one-gene one- disease may be replaced by a
specific set of gene expression changes that lead to one disease. As qPCR and
expression arrays become more commonplace, the mechanisms and interactions of
genes among and between each other will be better understood.
Discussion of Methods Used
Both the commercial MRX and the synthetic MLPA kits were cost effective means
to screen the genes of interest. The total number of patients screened was 1152 with a
cost in materials of approximately $10/ patient. However, this type of screening has its

134

limitations due to the relatively small number of loci actually being targeted. MLPA
probes are designed to reveal changes in copy number in specific genes or regions and
if changes are present, give high confidence that this is a disease causing change.
Whereas, Array CGH has much more potential to screen a larger number of genes,
although, copy number variations often make determining the significance of novel
findings more difficult. At the time of this study the cost of Array CGH would have
been 30-50 fold higher compared to MLPA. Although Array CGH pricing has
decreased in the last year it would have been still more costly and cumbersome than the
MLPA. The decision on choice between these methods for dosage differences should
be carefully determined by the size of the group to be screened, if the genes to target
are specific or unknown and how much money is available to do the screening.
Specialized equipment is also needed for Array CGH, an ozone scrubber, and a chip
reader with software and lab-ware for the processing of slides. MLPA on the other hand
uses a PCR machine and a sequencer, which is common equipment in most molecular
labs. The positive side of Array CGH is that it covers the whole genome not just
specific areas and breakpoints can be narrowed down faster by careful inspection of the
data point changes if the coverage is good. Dosage differences are compared to copy
number variants to determine if the change is possibly disease causing. Many times
both MLPA and Array CGH need to have follow-up testing such as FISH or qPCR to
confirm the findings. FISH may provide answers to the location and orientation of the
copy number change and may help define breakpoints and the genes involved.
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Whereas, qPCR can narrow the breakpoint region and can perform expression analysis
for each gene involved and can determine which genes are probable cause of disease.
OGT X chromosome array is a specific array for genes on the X chromosome. This
type of array gives much more specificity and has better coverage than the whole
genome arrays if one is looking for X-linked dosage differences. The ability to
determine breakpoints with this array system is done more easily due to increased
coverage. The cost is reasonable, but the array equipment is still needed. This system
may have been the best choice if it had been available and cost was not a factor for this
initial study.
qPCR appears to be very reliable. It is fairly fast and effective in screening large
numbers of samples or genes. Using this method to confirm MLPA data led us to find
that many of the positive MLPA’s were false positives. Most were exon 2 deletions and
duplications of XNP due to the MLPA probe not quantifying correctly. To close in on
the breakpoints of the XNP gene, qPCR was a good method of choice. When the
sequence became too repetitive it was easy to determine if the data was reliable or not.
This was apparent when normal controls had odd values and differed insignificantly
from one run to the next.
qPCR for expression studies is reliable if certain measures are taken to limit as
many variables as possible. Primers must have an efficiency 90% or above. All samples
are made into cDNA, quantified and then diluted to 30ng/ul +/- 1 ng/ul. These samples
were from the same source, meaning that RNA’s from cell lines and blood cannot be
compared on the same run. Cells appear to have different expression levels of mRNA
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than blood and the two should not be compared to one another in the same experiment.
All experiments except Northern Blots where larger quantities of mRNA were needed
used blood as the RNA source. The RNA was DNased due to having large differences
(6 fold or more) in expression among controls. Once DNased, values were more
uniform across controls and the sample were used with confidence of having no DNA
contamination. qPCR is so sensitive it is obvious when something is not right with the
experiment. qPCR should be expanded to screen moderate sized cohorts for dosage and
expression levels. A qPCR machine is needed as extra equipment, but once this is
acquired it is reasonable in cost to perform.
The qPCR array system which is used to target specific areas or pathways, have
more data points than the MLPA, but less than the Array CGH. This method may be
more effective in increasing the gene coverage in large cohorts at a reasonable price.
Expression studies done one gene at a time are done with a comfortable degree of
confidence if as many variables are taken out of the experiment as possible, as
mentioned above. Many genes may be screened at one time and by repetition statistical
significance may be achieved. Setting up a 96-well template with primers dried in the
wells and then stored allows for the reduction of set up time. Reproducibility should
increase and finer mapping should be achieved by choosing specific areas of interest.
Once a set of primers is validated and primer efficiency known, it can easily be placed
in a group of gene primers to do a mass screening or in a group for targeted screening.
Standard deviation differences would be eliminated as the reaction master-mix of sybr
green, that is multi-channel pipetted into the plate at equal volumes, has the cDNA
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already added. This accomplishes the same amount of template being put into all the
wells and therefore takes away another experimental variable. This can be used not
only for expression studies, but also for gene dosage in specific regions. This array
system can be used for diagnostic purposes or general research. More work is needed to
develop and expand this method for later screenings.
Discussion of Future Experimentation
The diverse projects that came out of the initial research have opened up new
questions and ideas. Some of the strengths and weaknesses will be discussed and what
further experimentation might be done to answer some new questions that have been
developed during the course of this study.
The beginning of this study starting with MLPA screening, with the first screening
of two cohorts consisting of 95 males exhibiting hypotonia and varying degrees of
intellectual disability (ID) and another of 205 (194 males and 11 females) individuals
with nonsyndromic ID and suspected X-linked etiology were screened by the MRX and
synthetic MLPA.

Another five cohorts totaling 552 patients with normal sequencing

results for one of the X-linked genes (XNP, L1CAM, UBE3A, FGD1 and STK9) were
only screened by the synthetic MLPA. MRX MLPA was not used to test this normal
sequencing results cohort. In the future these five cohorts should be screened by the
MRX MLPA to be more confident that there are no dosage aberrations in the genes
covered by this kit.
The findings of the initial screening, the GDI1 and PQBP1 duplications, the FACL4
deletion, and the FMR2 missense mutation were all found on the MRX MLPA,
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whereas, the XNP duplication and the 1p36 duplications and deletions were found using
the synthetic kit. The GDI1 and PQBP1 duplications had significantly high values on
the MLPA. The PQBP1 duplication would not confirm on the qPCR, whereas the GDI1
duplication did. With no further use of this MRX MLPA kit until recently, screening of
another cohort found that the PQBP1 duplications and now deletions appear in 20% of
the samples. These PQBP1 probes will be taken from further consideration. If a PAX
tube for RNA can be acquired, expression studies will be performed to determine if the
GDI1 duplication alters transcript dosage and may be the cause of disease. The XNP
duplication was explored to a great extent. A Western blot would have confirmed
further the loss of transcript but the mechanism and cause of disease was quite clear
with the Northern blot. Due to the high degree of Alu sequences in the introns of the
XNP gene where the duplication endpoints appear to be, this intragenic duplication
mechanism may be of unequal crossing over or strand slippage. FISH data, which is
forth coming will give more insight on the mechanism of this duplication event.
The COL4A5-FACL4 deletion was the known cause of disease in the two brothers
and no further investigation is needed.
The FMR2 missense mutation was found to segregate in the maternal females,
giving them carrier status, but there were no other family members screened to see if
the mutation was in the normal males. There were circumstances that did not allow for
additional family members to be screened at the time. Possibly in the future, and no
other family members have the mutation, more normal controls should be screened due
to the rarity of changes in the FMR2 gene.
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The 1p36 duplications and deletions presented themselves like known X-linked
diseases and this led to the testing of genes only on the X chromosome. For diagnostic
consideration, patients with ATRX phenotype and found to have normal sequencing
results should have X inactivation studies done on the mother. This may give insight to
further testing on the X chromosome such as duplication testing or if the mother is not
skewed, referred to 1p36 testing or Array CGH. Patients with a MECP2 duplication
phenotype and found normal should be screened by the MRC Holland 1p36 MLPA kit
or Array CGH. 1p36 deletions are one of the more common aberrations in the ID
population, occurring in 1-5/10,000 births. The following are the many features these
three diseases have in common (Table 9). The MECP2 males may be singled more
easily by recurrent infections and ATRX by alpha-thalassemia, but not all patients
present these manifestations.
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Table 9. 1p36, ATRX and MECP2 duplications in males have features in common.
1p36 Deletion OMIM

ATRX (Orphanet Jnl of Rare Disease) MECP2 Duplications (Pediatrics)

Many have no Alpha Thalassaemia
Mild to severe-related to deletion size Severe

Severe developmental delay and
ID

Delayed growth

Growth retardation

Hypotonia

Hypotonia

Hypotonia

Difficulties in sucking and feeding

Severe feeding problems

NL at birth head size fails to increase NL at birth head size fails to increase

Microcephaly

Boys have underdeveloped genitals Genital abnormalities

Hypoplastic genetalia

Seizures 70%

Seizures 30%

Seizures

Cleft lip jaw or palate

Narrow Palate

Hearing and vision impairment

Sensorineal deafness/optic atrphy

Short, broad head (microcephaly)

Hypotonic face, short nose

Large fontanel

Large fontanel

Mild facial dysmorphism

Prominent forehead
Straight eyebrows and deepset eyes
Flat nose and nasal bridge

Flat face

Flat midface

Short midface and low set ears
Midface hypoplasia
Ears had upturned lobes
Small mouth with down turned
corners
Large mouth, open and tented upper lip Small mouth, open and drooling
Pointed chin and asymmetry
Congenital Heart defects 40%
Hydrocephalus or cerebral atrophy

Neurological deterioration
Recurrent respiratory infections
Spasticity

The Xq25 duplication study has found patterns to the gene expression in the Ras
and Rab families. In this patient, the over expression in RAB33A located in the Xq25
duplication causes a similar pattern of expression that is found in a patient with a
MECP2 deletion. The Xq25 patient has a Rett like phenotype and was sent in for Rett
diagnostic testing.

The over expression of one Rab gene may cause similar up

regulation in other Rab genes due to co-regulation effects among this gene family. The
disease NF1 has up-regulated Ras activity. How a MECP2 deletion causes a similar
pattern is linked to the interactions with CREB the cAMP response element binding
protein transcription factor. Downstream activation of the MAKP (mitogen activated

141

kinase protein) cascade stimulates phosphorylation of the transcription factor CREB
and may also enhance gene transcription by phosphorylating a transcription factor
called CBP, which has histone acetyltransferase activity. Acetylation of histones
weakens their interactions with DNA resulting in an open configuration that promotes
transcription. CREB1 binds directly to the DNA but has been associated with coactivators such as CBP and MECP2 (Johnston, M. V. 2003), (Chahrour, M. 2008).
CREB1 is a stimulus-induced transcription factor activated by a diverse array of
extracellular signals. CREB1 activation is enhanced by MECP2, but it is not solely
dependent on MECP2 for its expression. Once CREB1 is activated it binds to specific
DNA sequences CRE (TGACGTCA) in their transcriptional regulatory region and their
expression is induced by increase in the intracellular cAMP levels. This activation also
removes the repressive action of CREB2 (Johnston, M. V. 2003). MECP2 then joins
CREB1 to co-activate a large number of genes (Chahrour, M. 2007).

Loss of the

CREB1 (ATF2) protein is lethal early in life in animal models (Chen, X. 2008). It is
well known the roles the Ras and Rab gene family plays in exocytosis and neuronal
plasticity via dendrite formation (Flint, J. 1999). One known link of the Ras and CREB1
is RSK2 mediated CREB phosphorylation stimulated by Ras-MAPK cascade and is
involved with cognitive development. RAB3A and CREB were both found to be
regulated by MECP2 (Chahrour, M. 2008). RAB3A is a small GTPase protein that
plays a role in the recruitment of synaptic vesicle exocytosis. It is the most abundant
Rab protein in the brain (Flint, J. 1999).
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CREB1 expression increased as MECP2 expression increased. CREB2 inhibits
many genes at the CRE site, with increase in CREB1 expression the repressive
regulation of these genes would be decreased. In mice Creb1 has functionally related
mediators of camp signaling in the nucleus, Creb1, Crem and Atf1. In Creb1 deficient
mice, Crem is up-regulated and Atf1 partial substitutes for Creb1. In humans there
appears too many “CREB-like genes available as well and looking for mutations
diagnostically in these genes may prove fruitless.

Looking at the genes that are

regulated by CRE in their promoter regions or in clusters as enhancers may give a more
specific search. Using the CREB Target Database (Salk Institute) and sorting through
the 20,000 plus genes screened, taking only the Rab genes found the following. This
suggests a closer look at many of the Rab genes expressed in the brain for mutations,
transcript expression and the pathways the play a role in.
There is little information on which transcription factors activate MECP2 except
that MECP2 has a CRE half site and is negatively regulated by CREB1. Further
investigation need to be done to identify the transcript regulation of MECP2. The Rab,
Ras and Rho genes are known to play a major role in ID. The up and down-regulation
is controlled by mechanisms and related pathways amongst themselves and those
associated with CREB1 and MECP2. Interestingly of the genes screened in the Xq25
study 21 out of 26 have some degree transcriptional control from CREB1. Of those
RAB3A, RAB4B, RAB5C, RAB6A and PAK1 all have a full CRE site in their promoter
region. Of these five genes RAB3A was up-regulated and PAK1 was down-regulated,
the others were normal. This strongly indicates repression and expression control by
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these factors. MECP2 is a know repressor, but is not associated when co-activating with
CREB1. More work is needed on CREB1 and its abilities to repress transcription and to
understand the mechanisms and pathways. Other Rab genes with full sites may be
candidates for ID causing genes.

Table 10. CRE site = Full Site/Half Site: All occurrences of full site “H”
(TGACGTCA) or half site “h”(TGACG/CGTCA) CREs in -5Kb-1Kb region of the
transcription start site. “F” is a full CRE site within the promoter. t= tata box present,
T= tata box present in this species only.
RAB10

RAB10, member RAS oncogene family ht
RAB11A, member RAS oncogene
RAB11A
ht
family
RAB11B, member RAS oncogene
RAB11B
family
ft ht
Rab11-FIP2 KIAA0941 protein
h
Rab11-FIP3 eferin
Fh
RAB11-FIP4 rab11-family interacting protein 4
h
RAB13
RAB13, member RAS oncogene family ht
RAB14
RAB14, member RAS oncogene family H ht h
RAB15
RAB15, member RAS onocogene familyh
RAB17
RAB17, member RAS oncogene family ht h
RAB18
RAB18, member RAS oncogene family ht h
RAB1A
RAB1A, member RAS oncogene family h
RAB1B
RAB1B, member RAS oncogene family h
RAB2
RAB2, member RAS oncogene family ht
RAB20
RAB20, member RAS oncogene family none
RAB21
RAB21, member RAS oncogene family H ht
RAB22A, member RAS oncogene
RAB22A
h
family
RAB23
RAB23, member RAS oncogene family h
RAB23A
RAB23, member RAS oncogene family h
RAB24
RAB24, member RAS oncogene family h
RAB25
RAB25, member RAS oncogene family F
RAB27A, member RAS oncogene
RAB27A
h
family
RAB27A
RAB27A, member RAS oncogeneh
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NM_016131
NM_004663
NM_004218
NM_014904
NM_014700
NM_032932
NM_002870
NM_016322
NM_198686
NM_022449
NM_021252
NM_004161
NM_030981
NM_002865
NM_017817
NM_014999
NM_020673
NM_016277
NM_183227
NM_130781
NM_020387
NM_004580
NM_183234

RAB27A
RAB27A
RAB27B
RAB28
RAB2B
RAB2L
RAB30
RAB31
RAB32
RAB33A
RAB33B
RAB34
RAB35
RAB36
RAB37
RAB38
RAB39B
RAB3A
RAB3B
RAB3C
RAB3D
RAB3GAP150
RAB3IL1
RAB3IP
RAB40A
RAB40B
RAB40C
RAB4A
RAB4B
RAB5A
RAB5B
RAB5C
RAB6A
RAB6B

family
RAB27A, member RAS oncogene
f
NM_183235
family
RAB27A, member RAS oncogene
h
NM_183236
family
RAB27B, member RAS oncogene
h
NM_004163
family
RAB28, member RAS oncogene family h
NM_004249
RAB2B, member RAS oncogene family HT H h NM_032846
RAB2, member RAS oncogene familyht h
NM_004761
like
RAB30, member RAS oncogene family h
NM_014488
RAB31, member RAS oncogene family ht
NM_006868
RAB32, member RAS oncogene family h
NM_006834
RAB33A, member RAS oncogene
none NM_004794
family
RAB33B, member RAS oncogene
h
NM_031296
family
RAB34, member RAS oncogene family HT h NM_031934
RAB35, member RAS oncogene family h
NM_006861
RAB36, member RAS oncogene family ht
NM_004914
RAB37, member of RAS oncogene
family
h
NM_175738
RAB38, member RAS oncogene family none NM_022337
RAB39B, member RAS oncogene
ht
NM_171998
family
RAB3A, member RAS oncogene family H ht h NM_002866
RAB3B, member RAS oncogene family ht
NM_002867
RAB3C, member RAS oncogene family h
NM_138453
RAB3D, member RAS oncogene family h
NM_004283
rab3 GTPase-activating protein, nonht h
NM_012414
catalytic subunit (150kD)
RAB3A interacting protein (rabin3)-like 1h
NM_013401
RAB3A interacting protein (rabin3)
none NM_022456
RAB40A, member RAS oncogene
family
ht
NM_080879
RAB40B, member RAS oncogene
h
NM_006822
family
RAB40C, member RAS oncogene
h
NM_021168
family
RAB4A, member RAS oncogene family ht h
NM_004578
RAB4B, member RAS oncogene family HT
NM_016154
RAB5A, member RAS oncogene family h
NM_004162
RAB5B, member RAS oncogene family ht
NM_002868
RAB5C, member RAS oncogene family HT h NM_004583
RAB6A, member RAS oncogene family H f h NM_002869
RAB6B, member RAS oncogene family ht
NM_016577
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RAB6C
RAB7
RAB7L1
RAB9A
RAB9B
RAB9P40
RABAC1
RABEP1
WASF1
SNAP29

RAC1

RAC2
WASF1
SNAP29
NIF3L1
MYO5C
GDI1
CABC1
PAK1
MECP2

RAB6C, member RAS oncogene family none NM_032144
RAB7, member RAS oncogene family HT h NM_004637
RAB7, member RAS oncogene familylike 1
ht h
NM_003929
RAB9A, member RAS oncogene family ht
NM_004251
RAB9B, member RAS oncogene family h
NM_016370
Rab9 effector p40
none NM_005833
Rab acceptor 1 (prenylated)
h
NM_006423
rabaptin, RAB GTPase binding effector
protein 1
Hh
NM_004703
WAS protein family, member 1
ht h
NM_003931
synaptosomal-associated
protein,
h
NM_004782
29kDa
ras-related C3 botulinum toxin substrate
1 (rho family, small GTP binding protein
Rac1)
none NM_198829
ras-related C3 botulinum toxin substrate
2 (rho family, small GTP binding protein
Rac2)
ht h
NM_002872
WAS protein family, member 1
ht h
NM_003931
synaptosomal-associated
protein,
h
NM_004782
29kDa
NIF3 NGG1 interacting factor 3-like 1
(S. pombe)
ht h
NM_021824
myosin VC
ht
NM_018728
GDP dissociation inhibitor 1
h
NM_001493
chaperone, ABC1 activity of bc1
h
NM_020247
complex like (S. pombe)
p21/Cdc42/Rac1-activated kinase 1
HT F h NM_002576
(STE20 homolog, yeast)
methyl CpG binding protein 2 (Rett
syndrome)
h
NM_004992

Table 10. Rab genes with CRE binding sites in their promoter or promoter
region. The highlighted in red genes are the genes from the Xq25 study. The CRE
binding is signified by an “H” for a full CRE and a “h” for half a CRE binding site
within the promoter region. The “T” is for this species only having a TATA box
and the “t” is for TATA box found across species. The “F” is a full CRE binding
site in the promoter.
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The Xq25 study approached only a small portion of gene regulation amongst
and between ID causing genes. The Rab, Ras and Rho gene families are known to play
a major role in ID. Patterns of expression within these families may give a greater
insight to the pathways associated ID. Continued work on Rab expression is shown by
the gaining interest in the literature. Development of qPCR arrays will help in
identifying these changes in expression in these genes by a fast, reliable and efficient
method. Gene expression has proven to be complex and there is much more work to be
done.
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APPENDIX A
Probes for Synthetic MLPA
FAM** GGGTTCCCTAAGGGTTGGA... M13 PRIMER LEFT
5’
GTGCCAGCAAGATCCAATCTAGA. M13 PRIMER RIGHT
Probe = 121 nt’s without primers with 59% G-C
Overall length is 163 nt’s TM= 83 0C
FGD1 exon 2 left
5' GGGTTCCCTAAGGGTTGGA.....CCCTTCCTGCAGGGCTGCACCAGGG
AAACCGGATCCTGGTTAAAAGTTTGTCCCTTGACC 3’
FGD1 exon 2 right
5’ P- CTGGCCAAAGCCTAGAGCCTCATCCAGAAGGTCCCCAG
CGGCTTCGCTCAGACCCAGGTCC TCTAGATTG GATCTTGCTGGCAC 3’
Probe = 99 nt’s without primers with 55.6 % G-C
Overall length is 141 nt’s TM= 81.6 0C
FGD1 exon 18 left
5' GGGTTCCCTAAGGGTTGGA CTGACAGAAGGCATGTCTTCAAGATCA
CCCAGAGCCACCTCAGCTGGTACTT … - 3’
FGD1 exon 18 right
5’ P-CAGCCCTGAGACAGAGGAACTACAGCGACGCTGGATGGCTGTG
CTTG. .TCTAGATTGGATCTTGCTGGCAC 3’
Probe = 90 nt’s without primers with 54.3% G-C
Overall length 132 nt’s TM= 80.1 0C
Nemo exon 2 left
5' GGGTTCCCTAAGGGTTGGA... CCTGTGACTCCCCTGCTGCCTTTCTCTT
TCAGCCCTTGCCCTGTTGGATG
Nemo exon 2 right
5’ P-AATAGGCACCTCTGGAAGAGCCAACTGTGTGAGATGGTGC. TCTA
GATTGGATCTTGCTGGCAC 3’
Probe = 63 nt’s without primers with 50% G-C
Overall length 105 nt’s TM= 80.50C
L1CAM exon 16 left
5' GGGTTCCCTAAGGGTTGGA... GAATTTGAGGACAAGGAAATGGCGCCT
GAAAAA
L1CAM exon 16 right
P-TGGTACAGTCTGGGCAAGGTTCCAGGGATCTAGATTGGATCTTGCTG
GAC 3’
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Probe = 96 nt’s without primers with 52% G-C
Overall length 138 nt’s TM= 800C
L1CAM exon 24 left
5' GGGTTCCCTAAGGGTTGGA..CTTCCCTTTCGCCACAGTATGTCAGCTA
CAACCAGAGCTCCTACACG
L1CAM exon 24 right
5’ P-CAGTGGGACCTGCAGCCTGACACTGACTACGAGATCCACTTGTTTA
AGTCTAGATTGGATCTTGCTGGCAC 3’
Probe = 106 nt’s without primers with 39 % G-C
Overall length is 148 nt’s. TM= 74 0C
STK9 exon 1 left
5' GGGTTCCCTAAGGGTTGGAGCCATGTTTTGTGGCTTGCATCAAAAGA
GGAGTTTGTCTTCATGAAGATTC 3’
STK9 exon 1 right
5’ P-CTAACATTGGTAATGTGATGAATAAATTTGAGATCCTTGGGGTT
GTAGGTGAAGGTCTAGATTG GATCTTGCTGGCAC 3’
Probe = 76nt’s without primers with 45% G-C
Overall length = 115nt’s TM= 87.6 0C
UBE3A exon 4 left
5' GGGTTCCCTAAGGGTTGGAGAAGACTCAG AAGCATCTTC CTCAAGGATA
GGTGATAGCT CA
UBE3A exon 4 right
5’ P-CAGGGAGACA ACAATTTGCAAAAATTAGGCCCTG ….
TCTAGATTGGATCTTGCTGGCAC 3’
Probe = 58 nt’s without primers with 43% G-C
Overall length is 98 nt’s. TM= 81.79 0C
UBE3A exon 6 left
5' GGGTTCCCTAAGGGTTGGACTGAGGGTCAGTTTACTCTGATTGG 3’
UBE3A exon 6 left
5’ P-CATAGTACTGGGTCTGGCTATTTACAATAACTGTCTAGATTG
GATCTTGCTGGCAC 3’
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Probe = 110 nt’s without primers with 63% G-C
Overall length 152 nt’s TM=85.9
SKI exon 4 left
5' GGGTTCCCTAAGGGTTGGAGAAGCTGACTGTGGACACCCCAGGAGCCC
CAGAGACGCTGGCGCCCGTGGCTGCCCCAGAG
SKI exon 4 right
5’ P-GAGGACAAGGACTCGGAGGCGGAGGTGGAAGTTGAAAGCAGGGA
GGAAT. TCTAGATTGGATCTTGCTGGCAC 3’

Probe = 121 nt’s without primers with 61% G-C
Overall length 163 nt’s TM=84.1
SKI exon 6 left
5' GGGTTCCCTAAGGGTTGGAGAAGGAGAAGCTGCGGGAGGCCACGGA
GGCCAAGCGTAACCTGCGGAAGGA
SKI exon 6 left
5’ P- GATCGAGCGTCTCCGCGCCGAGAACGAGAAGAAGATGAAA
GAGGCCAACGAGTCACGGCTGCGCCTG TCTAGATTGGATCTTGCT
GGCAC 3’
Probe = 80 nt’s without primers with 44.3% G-C
Overall length is 122 nt’s. TM= 74.90C
ATRX exon 2 left
5' GGGTTCCCTAAGGGTTGGACATTGCAAGTCGTGGAGGAGAACTTGTTT
CTTCAGATTC 3’
ATRX exon 2 right
5’ P-TGATGAGTGTGCAAGGAAGTCATGAAGCTTCTGCACCAATGTCTAG
ATTGGATCTTGCTGGCAC 3’
Probe = 126nt’s without primers with 36.7% G-C
Overall length is 168 nt’s. TM= 74.70C
ATRX exon 17 left
5' GGGTTCCCTAAGGGTTGGAGATAGAAATTGAAGATGCTTCACCCACC
AAGTGTCCAATAAC
ATRX exon 17 middle
5’ P- AACCAAGTTGGTTTTAGATGAAGATGAAGAAACCAAAGAACCTATRX exon 17 right
5’ P- TTAGTGCAGGTTCATAGAAATATGGTTATCAAATTGAAACCTCTA
GATTGGATCTTGCTGGCAC 3’
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Probe = 54 nt’s without primers with 46 % G-C
Overall length is 96 nt’s. TM= 73.2 0C
ATRX exon 9 left
5' GGGTTCCCTAAGGGTTGGAGAAAATGATTGACCTGTTGTCCACAAGCA-3’
ATRX exon 9 right
5’ P-GTGCAGCTCACAATCCCATGAAGCCTCTAGATTGGATCTTGCTGG
CAC 3’
Probe = 66 nt’s without primers with 50% G-C
Overall length is 108 nt’s. TM= 75.2 0C
ATRX exon 36 left
5' GGGTTCCCTAAGGGTTGGACTCCTGGCTGGCTTGTCTACTTAATGCTA
ACGC -3’
5’ P-CTGTACTTAGCATTAAGTAGACAAGCCAGCCAGG ..TCTAGATTG
GATCTTGCTGGCAC 3’
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APPENDIX B
XNP Study Real Time Primers
GENE

ORIENTATION

NAM

SEQUENCE 5' > 3'

XNP RT

FORWARD

9060

TTC ATT TTG CTC ATT TGA AGT CAG

XNP RT

REVERSE

9060

TCT ATA AGT CAA ATG TTA CCC ACC CA

XNP RT

FORWARD

13080

AGA GTC TTG CTC TGT CGC CC

XNP RT

REVERSE

13080

GAT CGC SCG TCT GCA CAC C

XNP RT

FORWARD

3000

AAT GGC CAG AAG ACA AGA GGA AG

XNP RT

REVERSE

3000

GCC AGG TCA TCG GTT TAT TTT CCT

XNP RT

FORWARD

257280

TTC TCC TTT GCT TAT GAA GCT TGG TTT G

XNP RT

REVERSE

257280

CCC ATC AGA CTA ACA GCG ACC T

XNP RT

FORWARD

254440

GTT CTT TTT GCT TAG GAT TCA TTG GCT A

XNP RT

REVERSE

254440

TGC TCA GGG AAA TCA GAG AGG A

XNP RT

FORWARD

10000

TTT CAG ATA ACC TTC CTT CTA CCA CTT

XNP RT

REVERSE

10000

AGG AAA AAT GAG GTT AGA AGC ACA AC

XNP RT

FORWARD

1-2E

CTC ATT GGG ACT GGT TAG GCA

XNP RT

REVERSE

1-2E

CTT CTG TCA CCC TCC ATG GG

XNP RT

FORWARD

1-2D

GAG AGA ATA TGG GAG GTA GAA T

XNP RT

REVERSE

1-2D

CCT GAC CCC AAC TAG CAT CCT

XNP RT

FORWARD

31-32B

GGG ATT GCT GGG TCA AAT GT

XNP RT

REVERSE

31-32B

GCG ATT CCT CAA AGA CCT AGA GG

XNP RT

FORWARD

1-2B

GGA CTG TAC TGC TGC CAT CTC

XNP RT

REVERSE

1-2B

CCA TCT CCA CCA AAA AAA TAC GAA AAC CA

XNP RT

FORWARD

1-2C

GTT CAA GCG ATT CTC CTG CCT CA

XNP RT

REVERSE

1-2C

GAC CAG ATC ACA AGG TCA GGA G
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XNP RT

FORWARD

1-2A

CAA AAA GTG GGT AAA GGA TAT GAA CAG
ACA

XNP RT

REVERSE

1-2A

CCA AAA GTG TAA AAG TGT TCC TAT TTC TCC

XNP RT

FORWARD

31-32A

GGT TTG GTT TTC TGT TCC TTC ATT AGT TTG

XNP RT

REVERSE

31-32A

ACA AAA GCA AAG TCA TGG AAT CAA CCT AC

XNP RT

FORWARD

31-33B

CCC AGT AGT TTT CTT TCT CTC TTC TCC

XNP RT

REVERSE

31-33B

CAA AAA GAG GTA GAA GGA GAG GGA G

XNP RT

FORWARD

31-33A

XNP RT

REVERSE

31-33A

TTT GTT TGA TTA TTT CCT GGC GGT GTT TG
GAG GTA GAA CAT ATA AGA GGT AGA ATA
AGT TC

XNP RT

FORWARD

31-33C

XNP RT

REVERSE

31-33C

GGT TTT CCA TGT CTC TGT TTG CTT CAG
TAA AAG AAC TAG AGA ACC AAG AGC AAT
CAA ACC

XNP RT

FORWARD

254800

ATC CTT TCC CCA TTG CTC GTT

XNP RT

REVERSE

254800

ACA GCC ATC TGT TCT TTG ACA A

XNP RT

FORWARD

12721

AAG TGA TGT TTT GTC CTT CAC AGC

XNP RT

REVERSE

12721

GCA AAG GCA TTA TAC ACC TCC TG

XNP RT

FORWARD

11500

AGG AGG CTG AGG CAA AAT TG

XNP RT

REVERSE

11500

CGG AAT CTC ATT CTG TCG CC

PMM2 RT

FORWARD

CDG1A

GGG TCA CAT CAG CAA TGG C

PMM2 RT

REVERSE

CDG1A

GTA CAG ATG AAG GCT CCC CCT

XNP RT

FORWARD

EXON 1

GAA AAC AGT ACC GCT GAG CCC AT

XNP RT

REVERSE

EXON 1

TCT TTC GGC TAA GCA ACA CAC AGG

XNP RT

FORWARD

31-33D

XNP RT

REVERSE

31-33D

CCT TGG TCT CTT CTG CTA TTG ATA GTT TG
AGC TAA GAA TCA CGA TAA AAC AAT ACA
GGA GC

XNP RT

FORWARD

EXON 34

CTT ATT TCT TGC ATT CTT CTA GGA CCT CAT T

XNP RT

REVERSE

EXON 34

TTG CTG GGT TAC GGT TTG GCA TTA TC

XNP RT

FORWARD

EXON 36

AGT TCT GTA TTG AGT ATC TTA AGT A

XNP RT

REVERSE

EXON 36

GAA AAT ACA ATA AAG AGC ACA ACA CA
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XNP RT

FORWARD

EXON 10

ATT GGC ACA TTT ATT TCT ATT TTG ATT C

XNP RT

REVERSE

EXON 10

GCT CAC CCT CAT CTC CTG

XNP RT

FORWARD

EXON 35

ACA GTA ATA AGG AGT AAA TAG AAA AT

XNP RT

REVERSE

EXON 35

TTC TTA CCA TCT GTT GTT TTG TC

XNP RT

FORWARD

EXON 1 B

TAA GAC TCC AGT GCA TTT CTA TCG TAA CC

XNP RT

REVERSE

EXON 1 B

CAA GCG AAC GCC TTC CCA AAC AC

XNP RT

FORWARD

EXON 31

GGG AAC CAT GGA AGA TAA GAT TTA TGA TC

XNP RT

REVERSE

EXON 31

AGTATCCCTCTTCTTCTTCTTTTCTGAATTAG

XNP RT

FORWARD

EXON 29

CAG CAG CAG GTG GAG CGT CAT TTT

XNP RT

REVERSE

EXON 29

AGG GTC ATC TAA TAA GTC TGG CTC AAA AG

XNP RT

FORWARD

EXON 9

XNP RT

REVERSE

EXON 9

GAACAATGTAGGTAGGTAATA AGATGAGCTAA
AAGACATCA
ATGACGATACTATGAAAGACAAAC

XNP RT

FORWARD

EXON 17

GAC CAT TGC TTG AAT GAT TTC TTT GAG CTT

XNP RT

REVERSE

EXON 17

TTG TTA TTG GAC ACT TGG TGG GTG AA

XNP RT

FORWARD

INTRON 2-3D

CTT TAT GGA GCA GGC TGG AGT C

XNP RT

REVERSE

INTRON 2-3D

TGC CTC AGC TTC CCT ATG TTT GTC

XNP RT

FORWARD

EXON 3

GGA AAA CAG CAA GGA AGA GGT AAG

XNP RT

REVERSE

EXON 3

CAC AAC AAT AAC AGA AAC AAT GAA CAC C

XNP RT

FORWARD

2-3 E

TCA CAG CAA CTT CCA CCT CC

XNP RT

REVERSE

2-3 E

CGC CTG TAA TCC CAG CAC TT

XNP RT

FORWARD

EXON 14

AAG AGG AGG AGG AAG ATG AAA ATG ATG AT

XNP RT

REVERSE

EXON 14

TCG CTC ACG CTC CCT CTC AG

XNP RT

FORWARD

EXON 2

GCA ATG AAT CAA AAC ACA GGT AAA T

XNP RT

REVERSE

EXON 2

CTG CTC TCT GAA TAA AAT AAA TGG

XNP RT

FORWARD

INTRON 2

ACC GTG CCC AGC CCC TTT G

XNP RT

REVERSE

INTRON 2

CTA GAC ATG GAT GGT GGT GGT GAA
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XNP RT

FORWARD

255000

CTT CCA GCT TTT GCC CAT TC

XNP RT

REVERSE

255000

TAT ACG ACA AAC CCA TGG CCA

XNP RT

FORWARD

254220

CCT TTC CCC ATT GCT CGT TT

XNP RT

REVERSE

254220

ACA GCC ATC TGC TCT TTG ACA A

XNP RT

FORWARD

256500

GGG ATT GCT GGG TCA AAT GTT

XNP RT

REVERSE

256500

TGG CGA TTC CTC AAA GAC CTA

XNP RT

FORWARD

10500

AAT TGC TTG AAG CCG GGA G

XNP RT

REVERSE

10500

GGT GGT GAT ATC TCG GCT C

XNP RT

FORWARD

14400

GAC GGA TTC TTG CTG TGT TGC

XNP RT

REVERSE

14400

CCA AGA TCA TGC CAC TGC ACT

BRACE RT

FORWARD

A

CCA TCC TCT CAC CTT ATA CCC AGC

BRACE RT

REVERSE

A

CCT TGC TGG TGA CTG ATG ATT GGG

BRACE RT

FORWARD

B

GCT CAT TCT ATC TTA TCA TCC TTT CAG AAC C

BRACE RT

REVERSE

B

ATC CCT GAG TGG TGG TAG AGT AGC

FGF-16 RT

FORWARD

FGF-16

CAC CCT CAC AGA AGA AAC TCA CAC

FGF-16 RT

REVERSE

FGF-16

CGT TTA GTC CTG TAT CCC TCC C

ATPA7 RT

FORWARD

ATPA7

ATT TCT GTT CAG GGT ATG ACT TGC

ATPA7 RT

REVERSE

ATPA7

GAG AGG AAT TAA TGG GTC AAA GAA AA

ARX RT

FORWARD

EXON 1

AAT CAG TAC CAG GAG GAG GG

ARX RT

REVERSE

EXON 1

GGT CAG CGG AGC AGG CA

ARX RT

FORWARD

EXON 4

GCC TTC CCG AGC CTA CC

ARX RT

REVERSE

EXON 4

CTG ATG AAA GCT GGG TGT CG

FACL4 RT

FORWARD

EXON 10

ATG ATG CTG TCT GGA GGG G

FACL4 RT

REVERSE

EXON 10

GTC CCA GCA CCA CAT GAT TC

FGD1 RT

FORWARD

EXON 2B

GAT CCT GGT TAA AAG TTT GTC CCT TGA C

FGD1 RT

REVERSE

EXON 2B

CCA CTT CTC TGC TCT TTT CCA GGA C
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FGD1 RT

FORWARD

EXON 18B

GAC AGA GCA TAT GCA AAA CCA GTT AGA AG

FGD1 RT

REVERSE

EXON 18B

GTG ATC TTG AAG ACA TGC CTT CTG TCA

FGD1 RT

FORWARD

EXON 18

CGC CAG GAT GTG AAA GCC CA

FGD1 RT

REVERSE

EXON 18

TCC TCC ATC TCC CTG TCC T

FGD1 RT

FORWARD

EXON 2

CTC AGA GAA ACC CAA TAC CCC A

FGD1 RT

REVERSE

EXON 2

GTG CCC GCT TCA GTG GTG

FGD1 RT

FORWARD

EXON 3

TTC ACC ATG TTA GCC AGG CTC

FGD1 RT

REVERSE

EXON 3

GGC CTC TCC TGA CTA TCC CTT CCT

FMR2 RT

FORWARD

EXON 4

CTA ATA CAC AGC AAC AGA AAA TCA AAA
CCT

FMR2 RT

REVERSE

EXON 4

GGC TTG AGA CTG GTC CTG TG

FMR2 RT

FORWARD

EXON 1

CCT GGC CGC TAT GGA TCT ATT CG

FMR2 RT

REVERSE

EXON 1

CAA CAC CTA CCA CTG CTG CTC CAA

PQBP1 RT

FORWARD

EXON 1

CCC TCT GCT CCC CCA TCC C

PQBP1 RT

REVERSE

EXON 1

CGG TAG GGA TGG ATG TCA GG

PQBP1 RT

FORWARD

EXON 4

CAA GTA GAA TGA TAG TGG AT

PQBP1 RT

REVERSE

EXON 4

CCC ACA AGA AGA AAT GAA G

PGK1 RT

FORWARD

PGK1

GTC TTC ATC TCT TCC TCT TCT C

PGK1 RT

REVERSE

PGK1

CCC TTC CCT TCT TCC TCC

STK9 RT

FORWARD

EXON 11

GGA AAG CAG CAC ATT GTC TAA TAG G

STK9 RT

REVERSE

EXON 11

CCA CAC AAC TCC TTA ATT GTG GTT C

STK9 RT

FORWARD

EXON 16

STK9 RT

REVERSE

EXON 16

AAC TCA AGG AAA AAG AGA AGC AAG G
TCA GAA AGA GAC ATA ATA CAG TGC AAA
AAT

UBE3A RT

FORWARD

EXON 5

TGA GAT AAA AAT GAA CAA GAA AGG CGC
TAG AA

UBE3A RT

REVERSE

EXON 5

ATG TAG TTA TTA TTC CTG TCC GTT ACC AC

UBE3A RT

FORWARD

EXON 6

GGA GAA GAA AGA AGA AAC AAG AAA GGT C
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UBE3A RT

REVERSE

EXON 6

CTA GCA GCC CAA CTT ACC CG

UBE3A RT

FORWARD

EXON 4

ATT GCA TTT TAC AGA TCA GGA GAA CC

UBE3A RT

REVERSE

EXON 4

TGT TCC TAT CTC CCA TTT ACT GCT A

GDI1

FORWARD

EXON 5

CGATGAGAATGACCCCAAGACC

GDI1

REVERSE

EXON 5

CCACCCAGCTTCCCCTCAC

SLC6A8

FORWARD

EXON 8

CGAGGCAGGCGTGGGCAT

SLC6A8

REVERSE

EXON 8

TTGGAAACGGAAGTAGTAGGAGGC

SLC6A9

FORWARD

EXON 12

CCTTCGCCCTGTCCTCCATGCT

SLC6A8

REVERSE

EXON 12

GCCCAGGAGGTGCAGCGG

ATRX

FORWARD

EXON 14

AAGAGGAGGAGGAAGATGAAAATGATGAT

ATRX

REVERSE

EXON 14

TCGCTCACGCTCCCTCTCAG

ATRX

FORWARD

EXON 29

CAGCAGCAGGTGGAGCGTCATTTT

ATRX

REVERSE

EXON 29

AGGGTCATCTAATAAGTCTGGCTCAAAAG

FACL4

FORWARD

EXON 10

ATGATGCTGTCTGGAGGGG

FACL4

REVERSE

EXON 10

GTCCCAGCACCACATGATTC

ARX

FORWARD

EXON 1

AATCAGTACCAGGAGGAGGG

ARX

REVERSE

EXON 1

GGTCAGCGGAGCAGGCA

ARX

FORWARD

EXON 4

GCCTTCCCGAGCCTACC

ARX

REVERSE

EXON 4

CTGATGAAAGCTGGGTGTCG
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APPENDIX C
RAB Associated Gene Real Time Primers
GENE

ORIENTATION

NAME

SEQUENCE 5' > 3'

BCORL1-B

FORWARD

BCORL1-B-EFF

GTGACCTCCTACATAATCCTCCTG

BCORL1-B

REVERSE

BCORL1-B-EFF

CCTTGGGCATGGTGGTGATTTC

CABC1

FORWARD

CABC1 RT-EXP

CAGATGCTGAGCATCCAGGAT

CABC1

REVERSE

CABC1 RT-EXP

TCATCTGCTTCAGTGGCATGA

CDC42

FORWARD

CDC42 RT-EXP

CCCAAGACCACAGTGACTACAG

CDC42

REVERSE

CDC42 RT-EXP

GATGTCCTCGCCCTCCCA

FXR2

FORWARD

FXR2 RT EXP

TGGAGGTTTATTCTCGAGCCA

FXR2

REVERSE

FXR2 RT EXP

GGCATCACAGGCAGCATATTC

GDI1-RT

FORWARD

GDI1-RT-EXP

GAGACCACGGACCCTGAAAAG

GDI1-RT

REVERSE

GDI1-RT-EXP

CAAAGTGTGTGGTGGCATCGTAG

MYO5A

FORWARD

MYO5A RT EXP

CGAGGAAGGAAAGGATTTGGA

MYO5A

REVERSE

MYO5A RT EXP

AGCACAGCAGGCTCATGAAGA

NIF3L1

FORWARD

NIF3L1 RT EXP

CATCCTTCCAAAFCTCCCAAC

NIF3L1

REVERSE

NIF3L1 RT EXP

CCGTCAATTCCTTTCACTGCA

RAB 26

FORWARD

RAB 26 RT-EXP

TGTGGTGAAGAGGGAGGACG

RAB 26

REVERSE

RAB 26 RT-EXP

CAAGGGCGGCAGCAGGA

RAB 27A

FORWARD

RAB 27A RT-EXP

GTTATGGGACACAGCAGGGCAG

RAB 27A

REVERSE

RAB 27A RT-EXP

CCCATAGCATCTCTGAAGAACGC

RAB 7

FORWARD

RAB 7 RT-EXP

CCTTCTCGCTTCTGTCCTCCG

RAB 7

REVERSE

RAB 7 RT-EXP

CCTGTCATCCACCATCACCTCC

RAB11B

FORWARD

RAB11B EXP-RT

CAAAGTGGTGCTCATCGGGGAC

RAB11B

REVERSE

RAB11B EXP-RT

GATGCTGCGGGTGGCGAAC
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RAB17

FORWARD

RAB17 RT EXP

TGCGCTTCTGGTGTACGACAT

RAB17

REVERSE

RAB17 RT EXP

TTGTTGCCCACCAGCATCA

RAB1A

FORWARD

RAB1A RT EXP

CAGCAGGCCAGGAAAGATTT

RAB1A

REVERSE

RAB1A RT EXP

TCCTGCAGCCACTGTTTAACA

RAB22A

FORWARD

RAB22A RT EXP

GGTGAAAGAGCTTCGACAGCA

RAB22A

REVERSE

RAB22A RT EXP

TCGGCGTAGTCCTTTGCATCT

RAB23

FORWARD

RAB23 RT-EXP

CAGGCTTGTGTGCTCGTGTTCT

RAB23

REVERSE

RAB23 RT-EXP

CAGTGCCTCAGCTTCCTCATTC

RAB3A

FORWARD

RAB3A EXP-RT

CTTGGGTTCGAGTTCTTTGAGGC

RAB3A

REVERSE

RAB3A EXP-RT

CGCCGTGTCCAACGACTCG

RAB33A

FORWARD

RAB33A EXP-RT

CCTGCCTGACCTTCCGCTTC

RAB33A

REVERSE

RAB33A EXP-RT

CCTGACCTGCTGTGTCCCAC

RAB40B

FORWARD

RAB40B EXP-RT

GACTACAAGACGACCACCATCCT

RAB40B

REVERSE

RAB40B EXP-RT

GGGAGTAGGAGCGGAATATGGTA

RAB4B

FORWARD

RAB4B EXP-RT

GTGGGTGGGAAGACTGTGAAG

RAB4B

REVERSE

RAB4B EXP-RT

CAGGTCCTTCTTGTTGCCACAG

RAB5C

FORWARD

RAB5C RT EXP

AACATCGTCATTGCACTCGC

RAB5C

REVERSE

RAB5C RT EXP

CAGCAAACTGTTGTCGTCTGC

RAB6A

FORWARD

RAB6A RT EXP

CCTATCAGGCAACAATTGGCA

RAB6A

REVERSE

RAB6A RT EXP

AAACGTTCCTGACCCGCAGTA

RAB8A

FORWARD

RAB8A RT EXP

GGACGCCTTCAACTCCACTTT

RAB8A

REVERSE

RAB8A RT EXP

TTGTGATCGTCCGAAACCG

RABAC1

FORWARD

RAB AC1 RT EXP

TGTGGTGACGTCCCCTATGTT

RABAC1

REVERSE

RAB AC1 RT EXP

TCTCGGCCAAAGAGCACAA

RHOA

FORWARD

RHOA RT EXP

CCTGTGGAAAGACATGCTTGC

RHOA

REVERSE

RHOA RT EXP

CATCCACCTCGATATCTGCCA
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ROU

FORWARD

ROU RT EXP

CATCCCTACTGCCTTCGACAA

ROU

REVERSE

ROU RT EXP

TGTCAAATTCATCCTGTCCGG

SNAP29

FORWARD

SNAP29 RT EXP

TCCAAACCAGTAGAGACCCCA

SNAP29

REVERSE

SNAP29 RT EXP

TGGCCTGGTACTTTGCTTCCT

WASF1

FORWARD

WASF1 RT EXP

ATTTCACGCATGCCCCCTA

WASF1

REVERSE

WASF1 RT EXP

GGCAGGACGTGAATGTTGAGA

RAB1A

FORWARD

RAB1A RT EXP

CAGCAGGCCAGGAAAGATTT

RAB1A

REVERSE

RAB1A RT EXP

TCCTGCAGCCACTGTTTAACA

RAC1

FORWARD

RAC1 RT EXP

CCGTGCAAAGTGGTATCCTGA

RAC1

REVERSE

RAC1 RT EXP

GGATCGCTTCGTCAAACACTG

RAC2

FORWARD

RAC2 RT EXP

GATGCAGGCCATCAAGTGTGT

RAC2

REVERSE

RAC2 RT EXP

GCTTGCTGTCCACCATCACAT

ELF4

FORWARD

ELF4 RT EXP

GGCAACCGAAGTACCTCACCTG

ELF4

REVERSE

ELF4 RT EXP

CTTAGTGCCCGCCCCATTGTC

PDCD8/AIF

FORWARD

AIF RT EXP

TTCTGTGTTAGTCCTTATTGTGGGCTTAT

PDCD8/AIF

REVERSE

AIF RT EXP

CCTTTTTCTGTTTCTGTTCTGGTGTCAG
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APPENDIX D
SEQUENCING PRIMERS

GENE

ORIENTATION

NAME

SEQUENCE 5' > 3'

CDKL5

FORWARD

CDKL5 EXON 2

TAAGATTGGTTACTAGAGTACTGC

CDKL5

REVERSE

CDKL5 EXON 2

GACACACATGTGAATTGATATAGG

CDKL5

FORWARD

CDKL5 EXON 3

GAGAAGCAATGTCAGTATAGCAG

CDKL5

REVERSE

CDKL5 EXON 3

CATGCCCACACGCAAAGACCAC

CDKL5

FORWARD

CDKL5 EXON 4

CAACTGGAATCCCCAGTCGGA

CDKL5

REVERSE

CDKL5 EXON 4

AGTGTCTGACCAGCTAGATCC

CDKL5

FORWARD

CDKL5 EXON 5

GAAGTACTCAAAGCAGAAGGTGA

CDKL5

REVERSE

CDKL5 EXON 5

TCGGGCAAATGTGCACATTGGC

CDKL5

FORWARD

CDKL5 EXON 6

GCTCTGTATTGGATGAATTATTCTAG

CDKL5

REVERSE

CDKL5 EXON 6

GACAGTAACATGTGAAATACTCTTAAC

CDKL5

FORWARD

CDKL5 EXON 7

GATGCTATTACAGTGATCTAACAG

CDKL5

REVERSE

CDKL5 EXON 7

TGTGACTCAAAAGAATGTTCCTC

CDKL5

FORWARD

CDKL5 EXON 8

GCCCATGCGAGAACAGTCATTAC

CDKL5

REVERSE

CDKL5 EXON 8

GCAAATGACAATAGAATCAGCAG

CDKL5

FORWARD

CDKL5 EXON 9

AGTTGCCAAAATAATCTCTTCCTT

CDKL5

REVERSE

CDKL5 EXON 9

GAACAATGACTCAAATACTGCAG

CDKL5

FORWARD

CDKL5 EXON 10

AACACTCACAAGCACGTGCA

CDKL5

REVERSE

CDKL5 EXON 10

TTATTTGCCATTCCACATCTCCT

CDKL5

FORWARD

CDKL5 EXON 11

CTTTGTAATGTTCTTAACGATC

CDKL5

REVERSE

CDKL5 EXON 11

CTAATTGCATCATTTAAGCAGCC

CDKL5

FORWARD

CDKL5 EXON 12.1

TTGTGTGTCAGCTATTGAGGG

CDKL5

REVERSE

CDKL5 EXON 12.1

GGTATGTTGTTGTTGGTGTGAGATC
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CDKL5

FORWARD

CDKL5 EXON 12.2

TGCACACCAAAACCTACCAAGC

CDKL5

REVERSE

CDKL5 EXON 12.2

GCTTTTGGCCTTGGTCCTGTAGGA

CDKL5

FORWARD

CDKL5 EXON 12.3

GAGTCGGCATAGCTATATTGACAC

CDKL5

REVERSE

CDKL5 EXON 12.3

GAATGGCTACTGTCCATGTGC

CDKL5

FORWARD

CDKL5 EXON 12.4

AACGCTGGACTCACGTCGAAC

CDKL5

REVERSE

CDKL5 EXON 12.4

CCACCAGATTCAGTCAAGGTG

CDKL5

FORWARD

CDKL5 EXON 13

CTGGTTATGGTCCTAGTTCTACC

CDKL5

REVERSE

CDKL5 EXON 13

GTGGGAGACTGGGTATTAATAC

CDKL5

FORWARD

CDKL5 EXON 14

AGGCTACAGTAAGCCATGA

CDKL5

REVERSE

CDKL5 EXON 14

GTGTAGGTGAGAAGGCCGCTG

CDKL5

FORWARD

CDKL5 EXON 15

GAAAAGTCCATCAGTGACTTAC

CDKL5

REVERSE

CDKL5 EXON 15

GGACACTAAAAAGCTCATCCAGA

CDKL5

FORWARD

CDKL5 EXON 16

GTTTGATTCTTCCCGGCTATAG

CDKL5

REVERSE

CDKL5 EXON 16

GGCTCTGTTGAGAGGATAGTTG

CDKL5

FORWARD

CDKL5 EXON 17

CTCCTCTTGGGTGTGGTTGC

CDKL5

REVERSE

CDKL5 EXON 17

GCTCAGCCTTACTGTAACATGG

CDKL5

FORWARD

CDKL5 EXON 18

TCTAACTTGAATCCTGTGTGC

CDKL5

REVERSE

CDKL5 EXON 18

CTGGTCACAGAGGACACATG

CDKL5

FORWARD

CDKL5 EXON 19

GTGGGCAGAAGTGGCCAATA

CDKL5

REVERSE

CDKL5 EXON 19

GTCTAGGGTCGTTATGGCAGC

CDKL5

FORWARD

CDKL5 EXON 20

ACCTTGGCTTCAGCTGGTGTC

CDKL5

REVERSE

CDKL5 EXON 20

GGGCAATTCCGAGGTACAGC

CDKL5

FORWARD

CDKL5 EXON 21

GCCAGAGTGCACCTGCTAGC

CDKL5

REVERSE

CDKL5 EXON 21

AAGGAAAACTCAACCTCAGCG

PDCD8

FORWARD

PDCD8 EXON 1

CGCAAATCCTCTCGCCGTG

PDCD8

REVERSE

PDCD8 EXON 1

AGGGTTCGGAGTCTGCCAAT
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PDCD8

FORWARD

PDCD8 EXON 2

TACTCTGTTTCCTTTTGTTTCTCTCTTGG

PDCD8

REVERSE

PDCD8 EXON 2

GCTCACCCACCCTACCCC

PDCD8

FORWARD

PDCD8 EXON 3

GCACACCCAGTATTTTTTATTTCTTA

PDCD8

REVERSE

PDCD8 EXON 3

CCATAAATCACAGCACCCAAAC

PDCD8

FORWARD

PDCD8 EXON 4

CTTGCTTTTCCTCTCCCATCA

PDCD8

REVERSE

PDCD8 EXON 4

CAATCAGTACCTTCAGACATAAAAAT

PDCD8

FORWARD

PDCD8 EXON 5

TGCTTTGACATTTGCCCCTTA

PDCD8

REVERSE

PDCD8 EXON 5

CCAAGCCATCCCTCCTAT

PDCD8

FORWARD

PDCD8 EXON 6

TTCTCCCTCTCTTCTCCATACA

PDCD8

REVERSE

PDCD8 EXON 6

CCCAGAAAGACACACTCAGC

PDCD8

FORWARD

PDCD8 EXON 7

GCTAATTCATCTCTACCTCTTTTGTGT

PDCD8

REVERSE

PDCD8 EXON 7

AGGCTGGACTCTAAAACTTGAATG

PDCD8

FORWARD

PDCD8 EXON 8

GGAGTATTGTTTGGGCTGGCT

PDCD8

REVERSE

PDCD8 EXON 8

CACAAGGAAAACACTAAAGCAGAC

PDCD8

FORWARD

PDCD8 EXON 9

GTATTATTATCCTATGCCCCTTTTG

PDCD8

REVERSE

PDCD8 EXON 9

ATCCTGCCAAACACATCTCTG

PDCD8

FORWARD

PDCD8 EXON 10

GATTGACTTTTGCTTCCTGCTGT

PDCD8

REVERSE

PDCD8 EXON 10

CAAAGGAAATAGAGTGGCAGCATA

PDCD8

FORWARD

PDCD8 EXON 11

TTTTACCGTGGAGGAGACCG

PDCD8

REVERSE

PDCD8 EXON 11

CTACTCTGGCTCTCATCATTCT

PDCD8

FORWARD

PDCD8 EXON 12

GATGGGGTGGTGGAGGCT

PDCD8

REVERSE

PDCD8 EXON 12

CCTCCAAACACTCTGACCCTA

PDCD8

FORWARD

PDCD8 EXON 13

GTGTTCATGTTATGTATTTGTTTCCAC

PDCD8

REVERSE

PDCD8 EXON 13

GCTCATAATAAAACCAAACCATAACTCT

PDCD8

FORWARD

PDCD8 EXON 14

ACACCCTCTTCTCTCTTCTTA

PDCD8

REVERSE

PDCD8 EXON 14

AAAGCACAACATGAAGAGAGG
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PDCD8

FORWARD

PDCD8 EXON 15

GAGAGGGCTGGTGAAGG

PDCD8

REVERSE

PDCD8 EXON 15

AGCCAAGTCCCAAGTGAAAAAGAAT

PDCD8

FORWARD

PDCD8 EXON 16

TCCCACAACTCCCTCCCAG

PDCD8

REVERSE

PDCD8 EXON 16

CCACCTTCACCCACCTGC

PDCD8

FORWARD

PDCD8 EXON 2 ALT

CTATTTTATTTTTGTATGTGTGTGTCTT

PDCD8

REVERSE

PDCD8 EXON 2 ALT

ACGCTGCTTTTCTACTTAC

MECP2

FORWARD

MECP2 EXON 4 5'

ATCCGCTCTGCCCTATCTCTGA

MECP2

REVERSE

MECP2 EXON 4 5

TTCAGTCCTTTCCCGCTCTTCTCA

MECP2

FORWARD

MECP2 EXON 4 MID

GCCACCACATCCACCCAG

MECP2

REVERSE

MECP2 EXON 4 MID

ATCCCTCTGGGCATCTTCTCCTCTT

MECP2

FORWARD

MECP2 EXON 4 3'

TGAGAAGAGCGGGAAAGGACTGA

MECP2

REVERSE

MECP2 EXON 4 3'

CCGAGCCCTACCCATAAGGAGAAG

MECP2

FORWARD

MECP2 EXON 3

CCTGCCTCTGCTCACTTGTT

MECP2

REVERSE

MECP2 EXON 3

GTTCCCCCCGACCCCACC

MECP2

FORWARD

MECP2 EXON 1

CCCGGCGTCGGCGGC

MECP2

REVERSE

MECP2 EXON 1

TCTCGGAGAGAGGGC

ATRX

FORWARD

XNP RT EXON 1

GGTACAGTGATTGTACAGCCAGA

ATRX

REVERSE

XNP RT EXON 1

CTTATTTTGCTGCAACAACTGTTC

ATRX

FORWARD

XNP RT EXON 2

CGTATTGCTGAGAGGGAGCG

ATRX

REVERSE

XNP RT EXON 2

CATTCCTTCCTTGAGCAAGATTTC

ATRX

FORWARD

XNP RT EXON 3

GCAACTGTGAAACGTCCTCAG

ATRX

REVERSE

XNP RT EXON 3

TTGTTAATGCTGTATAATCTTTCCTCTG

ATRX

FORWARD

XNP RT EXON 4

GATTCTACCATGGTAGATGTCAGAGTG

ATRX

REVERSE

XNP RT EXON 4

TGTCACTGCCACTTCCACTTG

ATRX

FORWARD

XNP RT EXON 5

GATTCTGATGAAACCTCCATGAG

ATRX

REVERSE

XNP RT EXON 5

CTTCTTCCTTGACTGTGCAGTAGTG
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ATRX

FORWARD

XNP RT EXON 6

GAATTAGCTAGTAGGGAGAAGACAGAAG

ATRX

REVERSE

XNP RT EXON 6

CTTTATGTATCTGAAGGAGCTCTGC

ATRX

FORWARD

XNP RT EXON 7

GAGCCAGACTTATTAGATGACCC

ATRX

REVERSE

XNP RT EXON 7

GTTCATAAGTATTCGCTGAACACAGC

ATRX

FORWARD

XNP RT EXON 8

GCCCAGCAATCACAGAAGC

ATRX

REVERSE

XNP RT EXON 8

TTACTTCTGCTTCTAAATTCAGGCC

ATRX

FORWARD

XNP RT EXON 9

GGATGAAAACAACCAATGGTATTG

ATRX

REVERSE

XNP RT EXON 9

GCTTTTGTTTCAAACTTAGCATCTATG

ATRX

FORWARD

XNP RT EXON 10

GGAAGAAGACTTAAATTCCGAGTTTC

ATRX

REVERSE

XNP RT EXON 10

GGGGAATTAGGAAGGGAAACAG

ATRX

FORWARD

XNP RT EXON 11

AGCAGTGGAACTGAACAAGAAGTG

ATRX

REVERSE

XNP RT EXON 11

ACTGTGACTCATCCTGCTCACC

ATRX

FORWARD

XNP RT EXON 12

CTGACAGTGCTATAGATAATCCTAAGC

ATRX

REVERSE

XNP RT EXON 12

GTGTCTTTATCAACTGTGCCTTCTG

ATRX

FORWARD

XNP RT EXON 13

CAAGGGCACAAAAATTTGAAGAC

ATRX

REVERSE

XNP RT EXON 13

TTACTTTTCTTTTCTCCATCAGTTGTTC

ATRX

FORWARD

XNP RT EXON 14

CAACAGTATGAATCTTCATCTGATGG

ATRX

REVERSE

XNP RT EXON 14

TGCTTCCTTTTAGTGCTTGTTCTTAG

ATRX

FORWARD

ATRX RT EXON 15

GTGCTGAGAAGTCAACAGGGAAAGGAGATAG

ATRX

REVERSE

ATRX RT EXON 15

ACATTGGCAAAATCCAGTATGTGAAGACAGC

ATRX

FORWARD

ATRX RT EXON 16

GCACTAAAAGGAAGCAAGCTGACATTACATC

ATRX

REVERSE

ATRX RT EXON 16

ACTTTATAGCTCCGCTGATTTTCTTCCAACTC

ATRX

FORWARD

ATRX RT EXON 17

GAAGAAGTTAGTGAATCCGAAGATGAACAGC

ATRX

REVERSE

ATRX RT EXON 17

ACATCCCACATAAACTGAACACCATCTACTTG

ATRX

FORWARD

ATRX RT EXON 18

GTAATCAACAGCTGGAGGACCTCATT

ATRX

REVERSE

ATRX RT EXON 18

ACGATTGGCATTTAAGGGGACCAAACT
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L1CAM

FORWARD

L1CAM exon 1

AACCGAGCCCGGGTGGCTGTGCTG

L1CAM

REVERSE

L1CAM exon 1

GGCCCAACATAGCGGCGAAGGTAG

L1CAM

FORWARD

L1CAM exon 11/12

GT GGT CCC AAG TCC TGC CCT GTC

L1CAM

REVERSE

L1CAM exon 11/12

C TCC CTC CCA GAG GCA CTG CCA G

L1CAM

FORWARD

L1CAM exon 13

GGT CTG GGC CTC TGG AGG AC

L1CAM

REVERSE

L1CAM exon 13

A CTT CCA GCT TTT CCC ACT CTG C

L1CAM

FORWARD

L1CAM exon 14/15

GA AGA GCC CAG ATG GCA GGA AAG

L1CAM

REVERSE

L1CAM exon 14/15

A GGG CTG GCA GAA GTG ACG GTG G

L1CAM

FORWARD

L1CAM exon 16

TC CCC CAA AGC CAC ATG CTG ATC

L1CAM

REVERSE

L1CAM exon 16

G GAG CCC CTT CCA GGT GGC ATG G

L1CAM

FORWARD

L1CAM exon 17

CC TCG TGG CTC TCC AAA AGA GGC

L1CAM

REVERSE

L1CAM exon 17

G GGG AGC AAC AGA CAC CCA GGT C

L1CAM

FORWARD

L1CAM exon 18

CG GGC CAA AGA ATG CTG GTG TTC

L1CAM

REVERSE

L1CAM exon 18

G GAA GCA GGC GAG CTC AAC CGT G

L1CAM

FORWARD

L1CAM exon 19

GG GTG AGA GCC TAT GGC TCT ATC

L1CAM

REVERSE

L1CAM exon 19

T CAC CAT CCT GTC GCT TTA CCT C

L1CAM

FORWARD

L1CAM exon 2

GG GCT GCA GGA GCT TAC TAT GTC

L1CAM

REVERSE

L1CAM exon 2

A GCA CAT GGT GCT CAG GGA GAG C

L1CAM

FORWARD

L1CAM exon 20

GT GCC TTC TGC CCC TGC GAG GTC

L1CAM

REVERSE

L1CAM exon 20

G CAG GTA GGT CCT CGC CCA GGT C

L1CAM

FORWARD

L1CAM exon 21/22

GG GCG AGG ACC TAC CTG CCA CTC

L1CAM

REVERSE

L1CAM exon 21/22

G GCA GGT CAT TCC TCC AGC TTA C

L1CAM

FORWARD

L1CAM exon 23/24

CA CTC TCC TCG TTC CCC TGC ATC

L1CAM

REVERSE

L1CAM exon 23/24

A TGC TTC CCT GGC AGG TGA TGG C

L1CAM

FORWARD

L1CAM exon 25

GG TTC TGG CTT GGG CGG CAG CAC

L1CAM

REVERSE

L1CAM exon 25

C TCC TCT CTG CCC TCG GCT CCA C
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L1CAM

FORWARD

L1CAM exon 26/27

TC AGG CTG GGG CGG GAG AAG AAG

L1CAM

REVERSE

L1CAM exon 26/27

C TAT AGG GAG ACC TTG CTG TTG G

L1CAM

FORWARD

L1CAM exon 28

TC GGC AGT GCT CTC ACT CGC AC

L1CAM

REVERSE

L1CAM exon 28

T CCC AAG GCC AGG GGC ACA GCA T

L1CAM

FORWARD

L1CAM exon 3

AG GCT ATG ACA CCA GCC AGG CAG

L1CAM

REVERSE

L1CAM exon 3

C TTC TGG GCT TAG AAG TTA GGC AG

L1CAM

FORWARD

L1CAM exon 4

CC GTT GGG TTC CAG GGC CTC AGG

L1CAM

REVERSE

L1CAM exon 4

C AAT CCC ACA CGA ACT CCG GGA C

L1CAM

FORWARD

L1CAM exon 5/6

AG GAG AGT GTC AGC CCG TCT GTC

L1CAM

REVERSE

L1CAM exon 5/6

A AGG AGT CAG GGA GAG AGT GCA G

L1CAM

FORWARD

L1CAM exon 7/8

GA GTC CCT CAG CCT TGC AAT TC

L1CAM

REVERSE

L1CAM exon 7/8

T GAC AGT GGG CAT CAC AGG CCA C

L1CAM

FORWARD

L1CAM exon 9/10

GC TGC TGG CTG CGG GCT CAG GGC

L1CAM

REVERSE

L1CAM exon 9/10

C AGT GGG TGC AGG GAC AGA CTG G

GDI1

FORWARD

EXON 1

CGACTGCTGCGGTGAAGGAG

GDI1

REVERSE

EXON 1

GGTCATGGCAACGAGCAGAGG

GDI1

FORWARD

EXON 5

CGATGAGAATGACCCCAAGACC

GDI1

REVERSE

EXON 5

GGAAATGGAAAGGGTGATAGGTGA
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APPENDIX E
Real Time PCR Primers
GENE

ORIENTATION

NAME

SEQUENCE 5' > 3'

XNP

FORWARD

NORTH PROBE #1

AGG TGG TGT GCG GAA GGT GG

XNP

REVERSE

NORTH PROBE #1

TTC CAC TGC TGC CAT CCC CTT G

XNP

FORWARD

NORTH PROBE #2

TTG CCT AAC ATG CAC AAA GC

XNP

REVERSE

NORTH PROBE #2

ATT GGC TAC GGA AAT TCA CC

XNP RT

FORWARD

RT EXP

ATGGAATGGATGAACAATGTAGGTGGTGT

XNP RT

REVERSE

RT EXP

CAGAAAGCATTATGGCAAAAGTCACAACAAATCA

18S RT

FORWARD

RT EXP

AGT CCC TGC CCT TTG TAC ACA

18S RT

REVERSE

RT EXP

GAT CCG AGG GCC TCA GTA AAC

MED12

FORWARD

MED12L RT-EXP

GAGATTGCCCAGCACCAGC

MED12

REVERSE

MED12L RT-EXP

CATATCCCAACTCGTCTTCCTCTTTC

MED12

FORWARD

MED12 RT-EXP

CTCCTCTCTCTTCAGCCAGTTC

MED12

REVERSE

MED12 RT-EXP

AATAAGGAAGAGCAAATGGAGAAAGCAC

FORWARD

ANDROGEN R-SEQ

AGTTAGGGCTGGGAAGGGTCT

REVERSE

ANDROGEN R-SEQ

GACACCGACACTGCCTTACAC

RAB33A

FORWARD

NORTHERN PROBE

CGAGGGCGAAGAAGATCAAGGT

RAB33A

REVERSE

NORTHERN PROBE

CCTTCCCCTGCTGCCTCTC

PDCD8

FORWARD

NORTHERN PROBE

AAAGCAACTGCACAAGACAACCCCAAA

PDCD8

REVERSE

NORTHERN PROBE

GAGAGGAGGTCGAATGGGTAAAGG

ANDROGEN
R
ANDROGEN
R

MCT8

FORWARD

MCT8 EXON 2

CCAGCAGTACCACCAGGCACTACA

MCT8

REVERSE

MCT8 EXON 2

CATGGCCACAGGGGATTCTGC

MCT8

FORWARD

MCT8 EXON 3

AAGGGCGGAGGAATGGAAGTCTCA

MCT8

REVERSE

MCT8 EXON 3

CCCACCCCCACCCTCTGGAATCTA
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FMR2

FORWARD

EXON 1

CCTGGCCGCTATGGATCTATTCG

FMR2

REVERSE

EXON 1

CAACACCTACCACTGCTGCTCCAA

FMR2

FORWARD

EXON 4

CTAATACACAGCAACAGAAAATCAAAACCT

FMR2

REVERSE

EXON 4

GGCTTGAGACTGGTCCTGTG
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APPENDIX F
RAB Associated Genes Regulated by MECP2
RAB
INTERACTING
FXR2
FMR1
FXR2
FXR1
LCMT1
FLJ32855
RTN4
ARL61P

MECP2 +

MECP2 -

RAB
INTERACTING
KCNRG
NDP52
TSC224
FBP1
PAICS
C10 ORF 62
GKAP1
CBS

ACTIVATED
UP REG
UP REG

SNAP23
AMOTL2

ACTIVATED

MGC2749
53 GENES TOTAL

MCRS1
LDOC1

UP REG
ACTIVATED

NIF3L1
COPS2

RBBP8
RBMX
MBIP
TRIM29
NONO
NCK2
SSSCA1
CYFIP2
ZBTB8
CRSP9
EFCBPZ
TNNT1
NT5C2
ZNF451
KIA1217
DPPA2
KR720
RP1A
HNRPC
LOC138046
TRAF2
PCBD1
APZM1
THAP1
PSME3
TRIM37
RTN3
KCTD4
RBPMS
RABAC1
AP1M1
FLJ1730

DOWN
REG

ACTIVATED

ACTIVATED
ACTIVATED

ACTIVATED

UP REG

NIF3L1
TRIP13
RABAC1
EAP30
DMRTB1
NOL3
S100A1
MGC2749
XTP3TPA
DCTD
WBSCR14
YWHAQ
CUTC
KRT15
TSC22D4
PCBD1
MAPRE2
KCTD17
DHPS
C10 ORF30
VIM
PRTFDC1
NIF3L1BP1
DIPA
FLJ10094
MAGEA11
TIFA
RPIA
GNMT
CPSF5
ZBED1
TRAF2
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MECP2 +

MECP2
-

ACTIVATED

12

ACTIVATED

UP REG

ACTIVATED
ACTIVATED

UP REG

1

DIPA

TRIM21

FTH1
RAB
INTERACTING

34 GENES TOTAL
RAB
INTERACTING

MECP2 +

MECP2 -

RAB3A

RAB27A

SYTL4

MLPH

RABAC1

MECP2 +

0
MECP2
-

SYTL4

CASK

UP REG

SYTL5

RAB31P

ACTIVATED

SYTL3

RAB1F

SYTL1

RAB3A

UP REG

RPH3AL

CHML

DOWN
REG

SYTL2

RAB31L1

MYO5A

SYTL5

ACTIVATED

STX1A

RABGGTB

COPS6

CHML

DKFZP564O0523

RPH3AL

RIF1

RPH3A

C14 ORF1

BSN

GDF9

DMXL2

EEF1A1

RIMS2

UNC13D

RIMS1
17
TOTAL

5

ACTIVATED

DOWN
REG

GZMB

GENES
3

0

MTRIP
RPH3AL

RAB1A
RABAC1
GOLGA2

ZBTB16

ACTIVATED

20 GENES TOTAL

3

2

0

0

RAB11B

ACTIVATED

VDP

RAB43

CHML

1 GENE TOTAL

MICAL1
GORASP2
GOLGA5

RAB17

ACTIVATED

TBC1D17

NUDT3

CDKN1A

CHMP6

RFK

RABAC1

SLC16A8

3 GENES TOTAL

ACTIVATED

1

0

0

0

RAB1F
CAPNS1

ACTIVATED

CREB1

ACTIVATED

RAB22A

FCN1
HIVEP1
16
GENES
TOTAL

RAB31

DOWN
REG
4

1 GENE TOTAL

1
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RAB
INTERACTING

MECP2 +

MECP2 -

RAB
INTERACTING

PAK1

WASF1

NCK2

PFN1

DLC1

CDC42

ARHGEF7

PSTPLP1

RAC1

SRGAP3

CDC2L2

ARHGEF2

LIMK1

DNMBP

PAK1LP1

6 GENES TOTAL

MECP2 +

MECP2
-

ACTIVATE

1

0

RHOJ
ARHGEF2
PLCG1

RAB33A

ARPC1B
BMX

RTN4

RAF1
AKT1

RTN3

UP REG

RABAC1

PPM1F

RAB3A

UP REG

CSNK2A2

4 GENES TOTAL

1

HGS
CDC42

ACTIVATE

NCK1

ACTIVATE
DOWN
REG

ARHGEF6
ERBB2
MYLK
CSNK2A1
ABL1
COL1A1
PXN
CDK5R1
27
GENES
TOTAL

3

1
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